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            Ixeris sonchifolia Hance is a small and bitter perennial herb widely 
distributed in the northeastern part of China. Its raw extract had recently been 
developed into an injectable formulation showing considerable therapeutic 
efficacy in stroke management. But the biological targets and the underlying 
chemical components remained mostly unknown. Accordingly, (1) the 
effectiveness of the herbal preparation may suffer from batch-to-batch 
variations since it is difficult to ensure the presence of similar amounts of 
active ingredients, and (2) some of the components present in the herbal 
formation may pose certain side effects that potentially limit the therapeutic 
benefits. This thesis aimed to isolate and identify constituents from Ixeris 
sonchifolia Hance that display anti-stroke activities and to elucidate the 
possible mechanism(s) through which the identified compound(s) exerted the 
neuroprotective effects.  
            To accomplish this objective, the aerial part of Ixeris sonchifolia 
Hance was extracted and the crude extract was partitioned into fractions. The 
fractions were then subjected to screening using both cell-based in vitro 
bioassays and biochemical reactions. The results had revealed that the ethyl 
acetate fraction, although failed to exhibit anticoagulant activities, dose-
dependently protected cells from H2O2-induced cytotoxicity, scavenged DPPH 
free radicals, induced ARE-dependent transcriptional activity and caused 
upregulation of Nrf2 protein levels.  
           The follow-up isolation work focused on the ethyl acetate fraction 
revealed the presence of two classes of compounds: flavonoids and 
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sesquiterpene lactones. In vitro bioassays conducted on the isolated flavonoids, 
which were identified to be Apigenin (1), Luteolin (2), Apigenin-7-O-β-
glucopyranoside (3), Luteolin-7-O-β-glucopyranoside (4), Luteolin-7-O-β-
glucruonopyranoside (5) and Luteolin-7-O-β-galacturonide (6) respectively, 
revealed that these compounds could protect cells from H2O2-induced 
cytotoxicity by scavenging free radical directly and inducing phase Ⅱ 
enzymes, suggesting that the purified flavonoid compounds might exert 
neuroprotective effects during the early response, characterized by excitotoxic 
damage and oxidative stress, to stroke occurrence. 
          Considering that the second wave of cell death after a stroke incident 
stems from the neuroinflammatory response, the anti-inflammatory effects of 
these isolated flavonoids on the LPS-stimulated cells were next determined. 
The results suggested that these flavonoid compounds might exert anti-
inflammatory activities by regulating cytokine secretion, inhibiting Cox-2 
expression, as well as reducing NO release and iNOS expression. 
            As validation, the potential anti-stroke effects of Luteolin, a 
representative of these isolated flavonoid compounds, were investigated using 
rats suffering from cerebral ischemia induced by MCA occlusion. The results 
revealed that while treatment with Luteolin failed to neither reduce MCAO-
induced mortality nor improve neurobehavioral recovery, it significantly 
reduced the infarct area, decreased the number of cells positively stained with 
anti-cleaved caspase-3 and anti-Cox-2 antibodies, suggesting that Luteolin 
might exert neuroprotective effects in an in vivo stroke model. 
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          In conclusion, extraction and isolation works focused on Ixeris 
sonchifolia Hance revealed the presence of two categories of compounds in 
the ethyl acetate fraction of its raw extract: flavonoids and sesquiterpene 
lactones. The isolated bioactive flavonoids were found to possess potential 
anti-stroke effects, which at least in part were attributed to their antioxidant 






































2.3.1.1 Anticoagulation activity of fractions 1 to 4 extracted from 
Ixeris sonchifolia Hance 
 
42 
3.3.1.1 13C-NMR spectral data for compounds 1 to 7  
 
65 
3.3.1.2 13C-NMR spectral data for compounds 8 to 13  
 
70 
3.3.2.1 Linear regression, r2 values, detection limits and quantity 
measurement of compounds 1 to 5 and 7 in fractions 1 to 4 
by HPLC analysis. 
 
73 
5.3.3.1 Effects of flavonoid compounds 1 to 5 on the mRNA 





   









1.2.1 The aerial part of Ixeris sonchifolia Hance 25 
2.3.2.1 Effects of fractions 1 to 4 isolated from Ixeris sonchifolia Hance 
extract on the viability of H2O2-exposed PC12 cells. 
 
43 
2.3.3.1 DPPH free radical scavenging activity of fractions 1 to 4 isolated 
from Ixeris sonchifolia Hance extract. 
 
45 
2.3.3.2 Effects of fractions 1 to 4 isolated from Ixeris sonchifolia Hance 
extract on ARE-dependent transcriptional activity.  
 
45 
2.3.3.3 Representative Western blot analysis of protein levels of 
transcription factor Nrf2 in SH-SY5Y cells treated with fractions 
1 to 4 isolated from Ixeris sonchifolia Hance extract.  
 
46 
2.3.3.4 Total cellular GSH levels in SH-SY5Y cells exposed to fractions 
1 to 4 isolated from Ixeris sonchifolia Hance extract.  
 
47 
2.4.1 The coagulation cascade under physiological conditions and 
experimental laboratory conditions.  
 
50 
2.4.2 Oxidative/electrophilic stress and Nrf2:Keap1 signaling pathway. 
 
52 
2.4.3 The glutathione system.  
 
54 
3.3.1.1 Chemical structures of compounds 1 to 7.  
 
64 
3.3.1.2 Chemical structure and important HMBC and NOESY 
correlations of compound 8.  
 
66 
3.3.1.3 Chemical structures of compound 9 and 10. 
 
68 
3.3.1.4  Chemical structures of compounds 11 to 13. 
 
71 
3.3.1.5  Chemical structures of compounds 14 to 18.  
 
71 
3.3.2.1 Representative HPLC profiles for purified compounds 1 to 5 and 
7 and fractions 1 to 4.  
 
74 
3.4.1 Structures of sesquiterpene lactones. 
 
75 








4.3.1.1 Effects of flavonoid compounds 1 to 5 on the viability of H2O2-
exposed SH-SY5Y cells.  
 
85 
4.3.1.2 Effect of 24 h-treatment with flavonoid compounds 1 to 5 on 
LDH release from H2O2-exposed SH-SY5Y cells. 
 
86 
4.3.1.3  Effect of 24 h-treatment with flavonoid compounds 1 to 5 on the 
subG0/G1 DNA content in H2O2-exposed SH-SY5Y cells.  
 
87 
4.3.2.1 DPPH free radical scavenging activity of flavonoid compounds 1 
to 5 isolated from Ixeris sonchifolia Hance extract.  
 
88 
4.3.2.2 Representative Western blot analysis of protein levels of 
transcription factor Nrf2 in SH-SY5Y cells treated with flavonoid 
compounds 1 to 5.  
 
89 
4.3.2.3 Effects of flavonoid compounds 1 to 5 isolated from Ixeris 




4.3.2.4  Representative Western blot analysis of protein levels of HO-1 
and NQO1 in SH-SY5Y cells treated with flavonoid compounds 
1 to 5.  
 
91 
4.3.2.5 Total cellular GSH levels in SH-SY5Y cells exposed to flavonoid 
compounds 1 to 5 for 24 h.  
 
92 
4.4.1 Chemical view on the oxidoreductive activation of quercetin and 
its possible reaction consequences.  
 
95 
5.3.1.1 Effects of flavonoid compounds 1 to 5 on the viability of RAW 
264.7 cells and BV-2 cells 
 
106 
5.3.2.1 Effects of flavonoid compounds 1 to 5 on NO production in LPS-
activated RAW 264.7 cells. 
 
107 
5.3.3.1 Effects of flavonoid compounds 1 to 5 on LPS-induced mRNA 
expression of cytokines in BV-2 cells. 
 
108 
5.3.4.1 Effects of flavonoid compounds 1 to 5 on the expression of Cox-2 
and cPLA2 in LPS-stimulated BV-2 cells. 
 
111 
5.3.5.1 Effects of flavonoid compounds 1 to 5 on the expression of iNOS 
in LPS-stimulated BV-2 cells. 
 
112 
5.4.1 The inflammatory cascade following a stroke event. 
 
115 
6.2.2.1 Schematic drawing of the suture placed into ECA and ICA of rat 





6.3.2.1 Analysis of the infarct area in rat brains by TTC staining. 
 
129 
6.3.3.1 Hematoxylin-Eosin staining of brain slices of rats subjected to 
MCA occlusion and reperfusion. 
 
130 
6.3.3.2 Cleaved caspase-3 immunohistochemical staining of brain tissue 
sections of rats subjected to MCA occlusion and reperfusion. 
 
131 
6.3.3.3 Cox-2 immunohistochemical staining of brain tissue sections of 
















AA  arachidonic acid 
ACA anterior cerebral artery 
AMPA   α-amino-3-hydroxy-5-methyl-4-isoxazole 
propionic acid 
AP-1 activator protein-1 
aPTT  activated partial thromboplastin time 
ARE  antioxidant-responsive element 
ASICs   acid-sensing ion channels 
ATP   adenosine triphosphate 
BBB  blood-brain barrier 
BCA  bicinchoninic acid 
bFGF  basic fibroblast growth factor 
BSA bovine serum albumin 
CCA common carotid artery 
cDNA cloning DNA 
Cox cyclooxygenase 
cPLA2 cytosolic phospholipase A2 
Da Daltons 
DAMPs  damage-asssociated molecular patterns 
DMEM Dulbecco’s modified Eagle’s medium 
DMSO dimethylsulphoxide 
DNA deoxyribonucleic acids 
dNTP  deoxyribonucleoside triphosphate 
DPPH 2,2-diphenyl-1-picrylhydrazyl 
DTNB 5,5'-dithiobis(2-nitrobenzoic acid) 
ECA external carotid artery 
ECM extracellular matrix 
EDTA ehylenediamine teraacetic acid 
eNOS  endothelial NOS 
EpRE electrophile-responsive element 
ESI electron spray ionization 
XV 
 
FBS foetal bovine serum 
GABA  γ-amino-butyric acid 
GADPH  glyceraldehyde-3-phosphate 
dehydrogenase 
GPx  glutathione peroxidase 
GR  glutathione reductase 
GSH   glutathione 
GSH-Px  glutathione peroxidase 
GSK-3β glycogen synthase kinase-3 beta 
GSSG glutathione, oxidised form/glutathione 
disulfide 
GST glutathione S-transferase 
GT γ-glutamyltranspeptidase 
H2O2 hydrogen peroxide 
HMGB-1  high mobility group box-1 
HPLC high performance liquid chromatography 
HRP horseradish peroxidase 
HS  heparan sulfate 
Hsp  heat-shock proteins 
ICA internal carotid artery 
IL-1 interleukin-1 
IL-10 interleukin-10 
IL-6  interleukin-6 
iNOS  inducible NOS 
IR infrared spectroscopy 
JNK  c-jun-N-terminal kinase 
Keap1 Kelch-like ECH-associated protein 1  
LDH lactate dehydrogenase 
Lox  lipoxygenase 
LPS  lipopolysaccharides 
m.p. melting point 
MAPK  mitogen-activated protein kinase 
MCA   middle cerebral artery 
XVI 
 
MCAO  middle cerebral artery occlusion 
MMPs matrix metalloproteinases 
mRNA messenger ribonucleic acid 
MS mass spectrometry 
MTT  3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenylterazolium bromide 
NADPH nicotinamide adenine dinucleotide 
phosphate reduced form 
n-BuOH/HOAc/H2O normal butyl alcohol/acetic acid/water 
NF-κB nuclear factor kappa-B 
NMDA  N-methyl-D-aspartate 
NMR nuclear magnetic resonance 
nNOS  neuronal NOS 
NO  nitric oxide 
NOS nitric oxide synthase  
Nrf2 Nuclear factor-erythroid 2 p45-related 
factor 2 
O2-. superoxide anion 
OH. hydroxyl radical  
PBS phosphate buffered saline 
PCA posterior cerebral artery 
PCR polymerase chain reaction 
PI propidium iodide 
PKC  protein kinase C 
PLA2  phospholipase A2 
PT prothrombin time 
RAGE receptor for advanced glycosylation end-
product 
Redox reduction/oxidantion 
RNA ribonucleic acid 
RNS reactive nitrogen species 
ROS reactive oxygen species 
Rt retention time 
XVII 
 
RT-PCR reverse transcription polymerase chain 
reaction 
S.D. standard deviation 
SCA superior cerebellar artery 
SDS sodium dodecyl sulphate/lauryl sulphate 
SOD  superoxide dismutase 
sPLA2  secreted phospholipase A2 
TAE tir-acetate-EDTA buffer 
TBS-T tris-buffed saline with 0.05% Tween 20 
TCM  Traditional Chinese Medicine 
TEMED N,N,N',N'-tetramethyleneethyldiamine 


















            Over 2,400 years ago, Hippocrates (460 to 370 BC) was first to 
describe the phenomenon of sudden paralysis, which is now known to be a 
consequence of stroke. Stroke, also known as cerebrovascular accident (CVA), 
is defined by WHO as a clinical syndrome characterized by “rapidly 
developing clinical signs of focal (or global) disturbance of cerebral function, 
with symptoms lasting 24 hours or longer or leading to death, and with no 
apparent cause other than a vascular one (1989; Sudlow et al., 1996; Kwan, 
2001; Warlow et al., 2003).” Based on WHO’s definition, stroke includes 
ischemic stroke, primary intracerebral haemorrhage, and subarachnoid 
haemorrhage, but excludes transient ischemic attacks (TIA, which last for less 
than 24 hours), subdural or extradural haemorrhage, and infarction or 
haemorrhage secondary to infection or malignancy. Among all stroke 
incidents, ischemic stroke, which may be due to thrombosis, embolism, or 
systemic hypoperfusion, accounts for the majority of incidence (about 80%), 
followed by primary intracerebral (about 10%), subarachnoid haemorrhage 
(about 5%) and uncertain type (about 5%).  
            When a stroke occurs, the perfusion-disturbed brain no longer receives 
adequate amounts of oxygen and glucose. This initiates the ischemic cascade 
and causes brain cells to die or be seriously damaged, impairing local brain 
function. Stroke is a medical emergency and can cause permanent neurologic 
damage or even death if not promptly diagnosed and treated. It is responsible 
for 10 - 12% of all deaths in industrialized countries and ranks the third 
leading cause (Kwan, 2001; Rosamond et al., 2007; Rosamond et al., 2008; 
Lloyd-Jones et al., 2009, 2009). Along with the emergence of aging 
populations in increasing number of countries, the occurrence of stroke and 
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the associated medical and social burdens are on the rise. The principles in 
stroke treatment involve the restoration of blood supply to the affected brain 
area in the shortest possible time from the onset of stroke, as well as to reduce 
ischemia-caused tissue damage. Unfortunately, despite decades of research, 
alteplase (a tissue plasminogen activator that catalyzes the conversion of 
plasminogen to plasmin) is still the only drug approved by FDA for stroke 
treatment. Therefore, finding new effective reagents efficient in stroke 
treatment and management has become crucial. 
            The following sections will give a short review on the physiopathology 
and epidemiology associated with stroke, followed by a summary of 
advancements in anti-stroke drug therapy. In addition, the application of 
Traditional Chinese Medicine (TCM) in stroke management will be discussed. 
Recently, the raw extract of Ixeris sonchifolia Hance was developed for use in 
the prevention and treatment of cardio- and cerebral-vascular diseases. As the 
main focus of this Ph.D study, the chemical constituents of Ixeris sonchifolia 




            The brain cells have a high demand for energy to maintain their 
physiological functions such as synthesis and transport of enzymes and 
neurotransmitters to the every end of their nerve branches, as well as 
production of bioelectric signals responsible for communication throughout 
the nervous system. Although the brain represents only 1/40 of the body 
weight, it receives 15% of the cardiac output, consumes 20% of total body 
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oxygen and utilizes 25% of total body glucose (Pierre et al., 2000). Therefore, 
it is especially vulnerable to energy supply failure. When a stroke occurs, the 
perfusion-disturbed brain no longer receives adequate amount of oxygen and 
glucose. Aerobic respiration in these areas fails and oxygen-deprived neurons 
become unable to generate sufficient adenosine triphosphate (ATP) to 
maintain energy dependent cellular ion homeostasis (Rashidian et al., 2007). 
High intracellular calcium levels increase cellular permeability and excitatory 
neurotransmitters (glutamate) release (Bouchelouche et al., 1989; Murphy et 
al., 1999; Fiskum, 2000). This in turn leads to over activation of glutamate-
gated channels such as N-methyl-D-aspartate (NMDA) and α-amino-3-
hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) channels. Excessive 
calcium influx is promoted, which triggers cell death by activating enzymes 
such as phospholipases and proteases that degrade membranes and proteins 
that are essential for cellular integrity (Lo et al., 2003). Furthermore, high 
levels of calcium, sodium and ADP in ischemic cells stimulate excessive 
mitochondrial oxygen radical production (Bouchelouche et al., 1989; Fiskum, 
2000). Upon reperfusion, enzymatic reactions such as cyclooxygenase-
dependent conversion of arachidonic acid (AA) to prostanoids and degradation 
of hypoxanthine will also lead to production of excessive oxygen radicals. The 
superoxide and hydroxyl radicals not only directly damage proteins, lipids and 
nucleic acids, but also cause mitochondrial membrane permealization that 
entails cell death (Kroemer et al., 2000). Thus, the early response to stroke is 
characterized by neuronal necrosis resulting from excitotoxic damage and 
oxidative damage.  
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            The second wave of cell death in response to stroke involves the 
neuroinflammatory response. The surrounding microglial cells  are activated 
and migrate to the injured site to remove cellular debris from the interstitial 
space (Lai et al., 2006). Activated astrocytes migrate to necrotic regions (a 
process known as “reactive astrogliosis”) where they upregulate expression of 
glial fibrillary acidic protein. At the same time, inflammatory cells within and 
around the injured site exhibit increased expression of proteoglycans, where in 
turn deposited in the extracellular space (Leonardo et al., 2008). Thus, a tissue 
barrier referred to as a “glial scar”, which comprises proteoglycans, and 
infiltrating astrocytes and microglial cells, is formed (Silver et al., 2004). 
Formation of the glial scar is believed to be an innate protective mechanism so 
as to isolate the injured cells from the surrounding tissue. However, as time 
progresses, the glial scar will prevent neuroplasticity and regeneration (Chew 
et al., 2006). The activated microglial cells release several pro-inflammatory 
cytokines such as TNF-α, IL-1β, IL-6, as well as other potential cytotoxic 
molecules including NO, ROS and prostanoids (Lucas et al., 2006). The 
astrocytes are also capable of secreting inflammatory factors such as cytokines, 
chemokines, and NO (Swanson et al., 2004). The released proinflammatory 
cytokines and chemokines will further enhance recruitment of microglial cells 
and macrophages to the injured site, leading to a vicious cycle of excessive 
inflammatory events that promote cell death (Alvarez-Diaz et al., 2007).  
            Excessive oxygen radical formation, protease activation and DNA 
damage also trigger apoptotic pathways to induce cell death (Budd et al., 2000; 
Yamashima, 2000; Salvesen, 2001). In the early stages of reperfusion, cysteine 
protease caspase 3 is cleaved and the active form in turn degrades numerous 
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substrate proteins, leading to cell demise (Namura et al., 1998). The stress-
activated protein kinase, c-jun-N-terminal kinase (JNK), phosphorylates Bax 
and enhances its mitochondrial translocation to augment pro-apoptotic caspase 
activation (Lo et al., 2003). The stress-activated protein kinase p38 also 
mediates neuronal death (Lee et al., 2003). Cytosolic Bid facilitates 
cytochrome c release and promotes apoptosome formation (Wei et al., 2001). 
In spinal cord ischemia, the formation of death-inducing signaling complex is 
involved in cell death (Qiu et al., 2002). The activation of acid-sensing ion 
channels (ASICs) by hydrogen ion, oxygen and glucose deprivation opens 
ASIC1a channels and provides a pathway for Ca2+ entry to exacerbate the 
injury (Simon, 2006). These apoptotic pathways crosstalk with one another, of 
which, numerous molecules serve as attractive targets in the management of 
stroke. 
            Within minutes from the stroke onset, while cells in the center (core) 
of the ischemic region undergo progressive death (Dirnagl et al., 1999), the 
penumbra, a large volume of brain tissue surrounding this core, suffers a mild 
damage due to a residual perfusion from the collateral blood vessels 
(Mergenthaler et al., 2004). These cells are viable, though functionally 
impaired; they can repolarize at the expense of further energy consumption 
and depolarize again in response to elevated levels of extracellular glutamate 
and potassium ions (Hossmann, 1996). Thus, the penumbra is the region 
responsive to therapeutic interventions, and its pathological revival, being 
associated with neurological improvement and recovery, forms the basis for 





            Ranked after coronary heart disease (CHD) and cancers of all types, 
stroke is the third leading cause of death worldwide, accounting for 10 - 12% 
of deaths. It is estimated that the annual incidence of stroke occurrence in the 
United States is 700,000 among all races; for every 45 seconds, a stroke 
incident occurs and for every 3 minutes, a death incident results from stroke 
(Sacco et al., 2001; Rosamond et al., 2007; Rosamond et al., 2008; Lloyd-
Jones et al., 2009, 2009). In the UK, about 130,000 people suffer a stroke each 
year; almost 40% of the survivors are disabled (Kwan, 2001). In India, the 
age-adjusted prevalence rate of stroke in 2006 was between 250 to 350 in 
100,000. Specifically, the age-adjusted annual incidence rate in the urban and 
rural community was 105 in 100,000 and 262 in 100,000 respectively 
(Banerjee et al., 2006). In China, stroke is the most frequent cause of death 
with an incidence of 219 in 100,000 people, which is more than 5-fold the 
incidence rate of myocardial infarction (Shi et al., 1989; Liu et al., 2007; Hu et 
al., 2008). 
            Strong geographic disparities in stroke incidence have been observed 
between countries or even in the same nations, with several countries of 
Eastern Europe clocking the highest rates. Upon normalization to the 
European population aged 45 to 84 years, it is reported that stroke incidence 
ranges from 240 in 100,000 people in Dijon, France  to about 600 in 100,000 
people in Novosibirsk, Russia, suggesting that environmental and genetic 
factors play important roles in determining stroke incidences (Warlow et al., 
2003; Donnan et al., 2008). In the United States, the incidence of stroke 
occurrence incidence is highest in the southeastern regions, commonly called 
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the “Stroke Belt”, and lowest in the southwestern regions (Donnan et al., 2008; 
Rosamond et al., 2008; Lloyd-Jones et al., 2009). In China, the stroke 
incidence and prevalence follows a north-south gradient, with stroke rates 
almost 3-fold higher in northern China cities, suggesting environmental or 
dietary factors play important roles, whereas difference in racial background is 
unlikely to account for this observed difference on the basis that 
approximately 94% of Chinese are of Han ancestry (Shi et al., 1989). 
Venketasubramanian et al compared the stroke prevalence among three Asian 
races in Singapore, the results, published in 2005, showed that Chinese had 
higher prevalence of stroke when compared to Indians and Malay 
Singaporeans, although the difference bore no statistical significance 
(Venketasubramanian N et al., 2005).    
            When considering the influence of gender on the epidemiology of 
stroke, a recent study by Appelros et al shows that a mismatch between the 
two genders exits. The incidence rate and prevalence is 33% and 41% higher 
respectively in males than in females. Among the female stroke patients, the 
first stroke occurs on average 4.3 years later than their male counterparts. In 
addition, while the incidence rates of brain infarction and intracerebral 
hemorrhage are higher among men, the rate of subarachnoidal hemorrhage is 
higher among women. Taken together, as women have longer life-span, the 
average age at which they suffer from stroke attacks is higher and thus the 
stroke is more severe, with a 1-month case fatality of 24.7% as compared to 
19.7% for men (Appelros et al., 2009).  
            Among all the risk factors for stroke, increased age is a 
noncontroversial predictor. Although stroke can occur at any age, including in 
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fetus, the incidence increases exponentially from 30 years of age with 95% of 
strokes occurring in people aged 45 and older, and two-thirds of stroke 
incidents occurring in those over the age of 65 (Rosamond et al., 2007; Hu et 
al., 2008; Rosamond et al., 2008; Lloyd-Jones et al., 2009). In addition to age, 
hypertension is another undisputable factor for high risk of stroke. Subjects 
with hypertension have approximately two times the lifetime risk of stroke 
than those with blood pressure less than 120/80 mm Hg (Seshadri et al., 2006). 
Other stroke risk factors include diabetes mellitus, smoking, previous stroke, 
heart disease, lack of exercise, low concentration of high-density lipoprotein 
and pregnancy.  Moderate alcohol intake has been reported to provide possible 
protection against ischemic stroke (Hajat et al., 2001; Thom et al., 2006; 
Rosamond et al., 2007; Rosamond et al., 2008; Lloyd-Jones et al., 2009).  
            The stroke incidence and mortality have been declining since the 1960s, 
with  a relative reduction of about 1% per year until the late 1960s, followed 
by a more steeper fall of as much as 5% per year (Bonita, 1992). Recently, the 
rate of this decline has decreased greatly (Feigin et al., 2003). This decline in 
incidence and mortality is likely related to the improved control of stroke risk 
factors such as high blood pressure and cigarette smoking in particular,  as 
well as an improvement in standards of living (Donnan et al., 2008). However, 
stroke occurrence and the number of stroke-related deaths have stably 
increased due to an increasingly aging population. If no more interventions are 
adopted, the number of global deaths is expected to rise to 6.5 million in 2015 
and to 7.8 million in 2030. The burden of stroke, especially in low-income and 
middle-income countries, will continue to rise in the near future (Strong et al., 
2007; Donnan et al., 2008). 
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1.1.3 Progress in stroke treatment 
            The principles underlying stroke therapy are to restore blood supply to 
the affected brain area as soon as possible, and to reduce ischemia-induced 
tissue damage. In order to resume blood supply, thrombolytic agents or 
surgical procedures are adopted to remove the thrombus formed in ischemic 
stroke (Fernandes et al., 2000). Anticoagulants and antiplatelet agents will be 
administrated to prevent the recurrence of clot. Carotid endarterectomy (a 
surgical procedure to correct stenosis in the common carotid artery by 
removing thrombus formed in the blood vessel) in patients with TIA or minor 
stroke is another effective prevention strategy (1991; 1996; 1998). While for 
haemorrhage stroke, surgical occlusion of ruptured blood vessel is necessary 
(van Gijn et al., 2007). In order to reduce tissue damage caused by ischemia, 
numerous neuroprotectants such as free radical scavengers, α-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and N-methyl-D-
aspartic acid (NMDA) receptor antagonists, matrix metalloproteinase (MMP) 
inhibitors and anti-inflammatory reagents, are under active investigation. This 
section will focus on discussing the progress of drug development in stroke 
treatment.   
 
1.1.3.1 Thrombolysis 
        Thrombolysis is the breakdown of blood clots and it may occur by 
pharmacological methods. By clearing the cross-linked fibrin mesh (the 
backbone of a clot) through enzyme-mediated proteolysis, blood flow in the 
occluded blood vessel can be restored.  Commonly studied thromolytic agents 
include alteplase (rtPA) (2009), streptokinase (Lopez-Saura, 2003), urokinase 
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(Shrivastava et al., 2007), reteplase (Khatri et al., 2008), tenecteplase (Burkart 
et al., 2003) and  desmoteplase (Hacke et al., 2009; Liebeskind, 2009; 
Paciaroni et al., 2009; Tebbe et al., 2009). Despite decades of research, 
alteplase is still the only FDA approved drug for acute ischemic stroke 
treatment (2009).  
            Tissue plasminogen activator (tPA) is a serine protease catalyzing the 
conversion of plasminogen to plasmin. The latter is the major enzyme 
responsible for clot breakdown. When administered within 3 hours of onset, 
tPA can significantly reduce the neurological damage and permanent disability 
of stroke (2009). Nevertheless, the stringent inclusion criteria requiring tPA 
administration with a 3-hour post-stroke window period and presentation of no 
apparent hemorrhagic complications, has limited tPA’s wide application for 
treatment among stroke patients. Although some clinical trials extend the 
therapy window to 6 hours, there is an observed net increase in deaths during 
the first 10 days due to occurrence of secondary cerebral haemorrhage (Hacke 
et al., 2008; Wahlgren et al., 2008; 2009; Bluhmki et al., 2009). tPA may also 
damage the basal lamina of the blood vessels, resulting in edema and 
disruption of the blood-brain barrier (BBB) (Lo et al., 2004). Furthermore, 
tPA’s short half-life of 5 to 10 min has restricted its action on subsequent and 
continued vessel occlusions caused by newly-formed thrombus (Gravanis et 
al., 2008).  
 
1.1.3.2 Anticoagulants and antiplatelet drugs 
            Anticoagulants are not able to re-canalize the occluded arteries, but 
they are useful in preventing progression of thrombosis and early recurrence 
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of embolic stroke. Intravenous administration of high doses of heparin (20,000 
U/24 h) followed by oral administration of an anticoagulant is well accepted in 
the treatment of ischemic stroke in patients with a cardiac source of embolism 
(1997). Low molecular weight heparin (Sandercock et al., 2008), aspirin 
(Warlow et al., 2003; Chairangsarit et al., 2005) and warfarin (Goldstein et al., 
2006; Genovesi et al., 2009; Singer et al., 2009) are other widely investigated 
potential anticoagulants.  
            As an essential part of secondary prevention of ischemic stroke, 
antiplatelet treatment enrolls three commonly used drugs with independent 
mechanism of action; (1) the irreversible cyclo-oxygenase (Cox) inhibitor 
aspirin (Warlow et al., 2003; Chairangsarit et al., 2005), (2) the indirect 
antagonist of the adenosine diphosphate (ADP) receptor  clopidogrel (Levine 
et al., 2003; Hassan et al., 2007; Belvis et al., 2008), and (3) the adenosine 
(possesses antiplatelet activities) uptake preventer dipyridamole (Goldstein et 
al., 2006; De Schryver et al., 2007; Sudlow, 2007; De Schryver et al., 2008).  
Among them, aspirin is the most widely studied antiplatelet drug, with daily 
dose of 75 – 150 mg. Higher doses have been found to exhibit no added 
effectiveness, and on the contrary, increase occurrence of adverse events 
(Collaboration, 2002). Clopidogrel is slightly more effective than aspirin alone, 
but it is not cost-effective and is used only as a substitute drug for patients 
intolerant to aspirin (Chen et al., 2009). Glycoprotein IIb/IIIa inhibitors, such 
as abciximab, exert antithrombotic effect through inhibition of GpIIb/IIIa 
receptors on the surface of the platelets, which in turn prevent platelet 
aggregation and thrombus formation (Mandava et al., 2005; Mandava et al., 




            As discussed in Section 1.1, in contrast to the cells in the core of the 
ischemic region that progress to irreversible death within minutes of the stroke 
onset, cells in the penumbra are viable although they are functionally impaired. 
They can repolarize at the expense of further energy consumption and 
depolarize again in response to elevated levels of extracellular glutamate and 
potassium ions. Upon therapeutic interventions, the penumbra’s pathological 
revival, being associated with neurological improvement and recovery, forms 
the basis for neuroprotective therapies (Fisher, 2004). Neuroprotectants refer 
to medications that reduce brain injury through their action on neuronal cells 
and tissues (Sacco et al., 2007). Numerous strategies and agents with 
neuroprotective potential are currently under investigation and development.  
Excitotoxicity  
            Excitotoxicity is the pathological process caused by overactivation of 
glutamate receptors such as the NMDA receptor and AMPA receptor. Binding 
of excitotoxins like NMDA and kainic acid, as well as pathologically elevated 
levels of glutamate released from dying cells to these receptors results in 
abnormal calcium ions influx into cells. This in turn activates phospholipases, 
endonucleases and proteases, which catalyze the damage to cell structures. As 
such, strategies that interfere with this process are expected to reduce the 
excitotoxicity damage.  
            The earlier trials of NMDA receptor antagonists such as selfotel (Davis 
et al., 1997), aptiganel hydrochloride (Albers et al., 2001) and dextrorphan 
(Albers et al., 1995) failed in part because of safety concern or poor 
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risk:benefit ratio. Two phase Ⅲ trials of eliprodil, a NMDA antagonist that 
binds to the polyamine modulatory site, were also stopped due to lack of clear 
beneficial effects (Devuyst et al., 1999, 2001). The AMPM receptor antagonist 
YM872 had exhibited neuroprotective properties in animal models of acute 
stroke but failed an interim futility analysis in phase Ⅱ trials (Kawasaki-
Yatsugi et al., 2000; Suzuki et al., 2003; Hara et al., 2006). The calcium 
channel blocker nimodipine, the most widely tested neuroprotector, 
demonstrated a significant improvement in functional outcome for those who 
received nimodipine within 12 hours of stroke onset (Mohr et al., 1994). 
However, an increased mortality, directly correlated with a fall in blood 
pressure, has cast safety concerns on its application (Wahlgren et al., 1994). 
Another NMDA receptor blocker, magnesium, also blocks voltage-gated 
calcium channels. Its low cost, ease of use, wide experience with low risk of 
adverse effects and ability to penetrate the blood-brain barrier qualities make it 
a good neuroprotectant candidate (Sacco et al., 2007).  However, a phase-Ⅲ 
trial conducted with magnesium given within 12 hours of ischemic stroke had 
disappointingly failed to demonstrate benefit (Muir et al., 2004). Attempts to 
reduce excitotoxicity by Gavestinel (GV150526), which acts at the glycine site 
of the NMDA receptor (Lees et al., 2000; Warach et al., 2006), and lubeluzole, 
which is a sodium channel blocker and reduces glutamate release from nerves 
(Ashton et al., 1997; Scheller et al., 1997; Gandolfo et al., 2002), have 
similarly been unsuccessful in definitive studies (Diener et al., 2000).   
            As γ -amino-butyric acid (GABA) is the major inhibitory 
neurotransmitter in the brain and can balance the excitatory effects of 
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glutamate, developing GABA agonists is another approach to reduce 
excitotoxicity. Results obtained from the Early GABA-Ergic Activation Study 
In Stroke trial (EGASIS) had favored diazepam treatment in various analysis 
(Lodder et al., 2006). In the Clomethiazole Acute Stroke Study (CLASS), 
clomethiazole showed no overall benefit on stroke patients, but there was a 
significant improvement in functional outcome in the subgroup with large or 
cortical strokes (Wahlgren et al., 1999; Wahlgren et al., 1999; Lyden et al., 
2002). Further data suggests that 5-clomethiazole is safe even in patients with 
haemorrhagic stroke (Devuyst et al., 2001). A combination of caffeine and 
ethanol-caffeinol has been found to be neuroprotective through effects on the 
adenosine and NMDA receptors and GABAergic systems. In addition, 
caffeinol alone or combined with intravenous tPA is well tolerated and can be 
administered safely (Aronowski et al., 2003; Piriyawat et al., 2003; Martin-
Schild et al., 2009). 
            Repinotan (BAYx3702), a serotonin agonist at the 5HT1A receptor 
(Berends et al., 2005; Lutsep, 2005), and ONO-2506, an agent that modulates 
the uptake capacity of glutamate transporters and expression of GABA 
receptors (de Paulis, 2003; Asano et al., 2005), had also failed in clinical trials 
despite their promise outcomes in previous animal models.     
Free radical scavengers 
            Mitochondria utilize the vast majority of O2 to generate energy in the 
form of ATP. During cellular respiration, 1 to 3% of total reduced O2 leaks to 
be consumed by the NAD(P)H oxidase complexes to form reactive oxygen 
species superoxide anion O2.-. The cellular enzymatic systems involved in O2.- 
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elimination include superoxide dismutase (SOD), which catalyzes the 
conversion of O2.-  to H2O2, and catalase, which in turn coverts H2O2 to H2O. 
Glutathione (GSH) and its affiliated enzymes, glutathione peroxidase (GPx) 
and glutathione reductase (GR), are also involved in the reduction of oxidative 
stress. Under normal physiological circumstances, the free radical production 
and elimination rates are almost equal to maintain a balanced redox potential. 
During cerebral ischemia, elevated intracellular Ca2+ activates phospholipase 
A2 (cPLA2), which releases arachidonic acid and thus initiates the formation of 
free radicals via the cyclo-oxygenase and lipoxygenase pathways (Handlogten 
et al., 2001). Increased level of free radicals disrupts redox homeostasis and 
cause damages to the cells through several mechanisms, including lipid 
peroxidation, tyrosine nitration, sulfhydryl oxidation, nitrosylation and DNA 
breakage. Anti-stroke strategies that involve inhibiting the production, 
increasing the removal or fostering the degradation of free radicals, have been 
developed to reduce damage processes induced by free radicals. Ebselen, a 
mimic of glutathione peroxidase, possesses glutathione peroxidase-like 
activity and can react with peroxynitrite. Treatment with ebselen had been 
previously found to delay ischemia-induced injury processes in experimental 
models when the animals were sacrificed between 4 - 24 h after ischemia, but 
not if the animals were sacrificed at a later time point (Lynch et al., 2004; 
Salom et al., 2004). Clinical trials have also suggested limited neuroprotective 
efficacy of Ebselen on stroke patients (Yamaguchi et al., 1998; Yamagata et 
al., 2008). Despite the benefit acquired from previous animal experiments, 
development of another free radical scavenger, Tirilazad, was also stopped 
because of safety concerns and limited efficacy on clinical trials (1994; Haley, 
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1998; Bath et al., 2001; Sena et al., 2007). Edaravone shows strong 
antioxidant actions by trapping hydroxyl radicals. In animal models, it can 
prevent brain edema after ischemia and reperfusion injury. Moreover, 
edaravone improves endothelial function in smokers through an increase in 
nitric oxide. The drug has been approved by the regulatory authority in Japan 
for the treatment of stroke patients. However, the development status of this 
compound outside Japan is still unclear (Toyoda et al., 2004; Kano et al., 2005; 
Imai et al., 2006; Kitagawa, 2006). Nitrone-derived free radical trapping 
agents, first developed as tools for studying free radical chemistry, have also 
been tested for their efficacies in ischemic injury. As the most widely studied 
free radical trapping agent, NXY-059 had been shown to improve functional 
outcomes in small trials conducted in both animals and humans. However, the 
results of this trial could not be replicated in the follow-up trial; its 
development has since been terminated by its drug company AstraZeneca and 
it seems likely that there will be no further clinical study on this compound 
(Marshall et al., 2001; Zhao et al., 2001; Lees et al., 2003; Green et al., 2005; 
Koziol et al., 2006; Lyden et al., 2007).  
Anti-inflammatory 
            The early response to stroke is characterized by excitotoxic damage 
and free radical attack, while the second wave of cell death comes from the 
neuroinflammatory response. Inflammatory processes are initiated by 
cytokines, adhesion molecules, prostanoid mediators of inflammation and 
nitric oxide (NO) and may progress for days and weeks. Inflammatory 
intervention serves an attractive therapeutic strategy in stroke treatment 
(Michael et al., 2004; Sacco et al., 2007). 
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            Cytokines have received most attention in relation to ischemic attack. 
However, the biological signaling pathways are extremely complicated and 
certain cytokines can have different effects depending on the context 
(Rothwell, 1997; Allan et al., 2001). Poly(ADP-ribose)polymerase inhibitor 
PJ34 brings about blockade of ischemia-induced increase of TNF-α in mice, 
with a sustained effect for up to 24 h (Haddad et al., 2006). Modulators that 
target adhesion molecules have been tested in human trials. Enlimomab, a 
murine antibody directed against intercellular adhesion molecule-1, was 
previously found to yield worse outcomes in human trials (2001; Furuya et al., 
2001). A subsequent study of the humanized antibody Hu23F2G directed 
against CD18 had been terminated in a previous study due to unfavorable 
interim results (Yenari et al., 1998; Becker, 2002; Sacco et al., 2007). Non 
antibody-based small molecule antagonists of cell adhesion are now emerging 
(Sacco et al., 2007). Immunosuppressive agent, Tacrolimus (FK506), has been 
shown to ameliorate the accumulation of cytochrome c in the cytosol and the 
increase of TUNEL-positive cells, as well as to limit attachment of 
granulocytes and platelets to blood vessels by inhibiting the expression of 
adhesion molecules (Furuichi et al., 2007; Maeda et al., 2009).  Nevertheless,  
corticosteroids, to date, have not been demonstrated to exert effective 
neuroprotection (Sacco et al., 2007). 
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Table 1.1.3.1 Summary of anti-stroke agents in preclinical studies and in clinical applications 
Objective Mechanism Anti-stroke agents in preclinical studies or in clinical use  
To restore the blood 
supply 
Thrombolysis alteplase (rtPA), urokinase, streptokinase, reteplase, tenecteplase, desmoteplase 
Anticoagulants heparin, warfarin 
Antiplatelet drugs 
Cyclo-oxygenase inhibitor: aspirin  
Indirect antagonist of the adenosine diphosphate receptor: clopidogrel 
Adenosine uptake preventer: dipyridamole 
Glycoprotein IIb/IIIa inhibitor: abciximab 
To reduce the 
ischemia-induced 
brain tissue damage 
Excitotoxicity antagonist 
NMDA receptor antagonist: selfotel, aptiganel hydrochloride, dextrorphan 
AMPM receptor antagonist: YM872, magnesium, gavestinel 
Calcium channel blocker: nimodipine 
Sodium channel blocker: lubeluzole 
GABA agonist: diazepam, clomethiazole   
Free radical scavengers ebselen, tirilazad, NXY-059, edaravone 
Anti-inflammatory agents 
 
Poly (ADP-ribose) polymerase inhibitor: PJ34 
Intercellular adhesion molecule-1 inhibitor: enlimomab, Hu23F2G 
Immuno-suppressive agent: tacrolimus (FK506) 




            Since multiple pathways are activated resulting in neuron injury 
following stroke occurrence, it is rational to develop “broad spectrum 
neuroprotective agents” which activate multiple pathways to achieve the best 
therapeutic outcome. Hydroxymethylglutaryl coenzyme A reductase inhibitors 
(statins) have gained increasing attention recently. The neuroprotective effects 
of statins are believed to be related to improved endothelial function, increased 
cerebral blood flow and reduced inflammation (2006; Amarenco et al., 2006; 
Sacco et al., 2007; Zhang et al., 2007; Zhang et al., 2009). Results from 
preclinical studies and phase І trial have demonstrated the potential 
neuroprotective effects of albumin mediated through mechanisms including 
haemodilution, binding to free fatty acid, inhibition of free radical production, 
inhibition of platelet activation and maintenance of microvascular patency 
(Ginsberg, 2003). Nootropic drugs, a class of memory enhancers that are 
purported to improve mental functions such as cognition, memory, 
intelligence, motivation, attention and concentration, are supposed to improve 
membrane bound cell functions, including ATP production, neurotransmission, 
and secondary messenger activity. In a phase Ⅲ trial, piracetam had been 
shown to improve the neurological scores of stroke patients, particularly in 
patients with moderate and severe degree damage (De Deyn et al., 1998).  
Growth factors, such as basic fibroblast growth factor (bFGF), insulin-like 
growth factor, brain-derived neurotrophic factor and osteogenic protein 1, 
have also been found to possess both acute phase effects and an action on 
recovery by reinforcing plasticity phenomena (Greenberg et al., 2006; Kalluri 
et al., 2008; Lanfranconi et al., 2009). Earlier observational studies had 
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suggested a protective effect of estrogens on cardiovascular risk among 
women who received postmenopausal hormone replacement therapy 
(Mendelsohn et al., 1999; Mendelsohn, 2002; Cho et al., 2003). However, 
there is now strong evidence that hormone replacement therapy increases the 
risk of stroke and venous thromboembolism. Thus, such treatments are not 
recommended in stroke treatmen (Beral et al., 2002). 
 1.1.3.4 Combination therapy 
            Ischemia in stroke leads to excitotoxic cell death, apoptosis, complex 
cascades of local inflammatory response, and remodeling of neuronal function 
(Chaudhuri, 2007). Since several pathways leading to cell death are activated 
in cerebral ischemia, in anti-stroke treatment, it is logical to combine a 
cocktail of drugs each targeting at distinct pathways. 
            In consideration that the platelet aggregation within the clot might 
resist the dissolution ability of fibrinolytic agents, glycoprotein IIb/IIIa 
inhibitors have been adopted in combination with tPA in the treatment of 
myocardial infarction (Ohman et al., 1997). To date, results from studies have 
demonstrated improved reperfusion without increasing bleeding rates. For 
instance, a study involving the combination use of intravenous abciximab 
followed by intra-arterial urokinase has found the recanalisation rate was 
increased by  2-fold as compared to the use of intra-arterial urokinase alone in 
stroke patients (Lee et al., 2002). In another study involving intravenous 
administration of tPA followed by argatroban, a direct thrombin inhibitor, the 
combination treatment has also resulted in improved recanalisation rates (Sugg 
et al., 2006). Although independent treatments may not necessarily yield 
additive results, combination therapies can render reduction in dosages for 
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each agent, thereby reducing the occurrence of adverse events (Lo et al., 2003). 
In the Emergency Management of Stroke Bridging Trial, intravenous 
administration of two-thirds dose of tPA, followed by intra-arterial 
administration of tPA had resulted in improvement in the recanalisation rates 
as compared to intra-arterial administration of tPA alone. Nevertheless, the 
risk of symptomatic intracerebral haemorrhage did not differ between these 
two groups (Swarnkar et al., 1999). The efficacy of aspirin in combination 
with clopidogrel in the secondary prevention of vascular events in patients 
with stroke or systemic arterial embolism is still currently under investigation 
(2008).  
            The combination of neuroprotective therapy with clot-lysing drugs 
reduces reperfusion injury and inhibits downstream targets in cell death 
cascades (Lo et al., 2003). Synergy is also observed between neuroprotectants 
(Schmid-Elsaesser et al., 1999; Lo et al., 2003). Co-administration of an 
NMDA receptor antagonist with GABA receptor agonists (Lyden et al., 2000), 
free radical scavengers (Barth et al., 1996), protein synthesis inhibitor 
cycloheximide (Du et al., 1996), caspase inhibitors (Ma et al., 1998) or growth 
factors such as bFGF (Barth et al., 1996), has demonstrated some success in 
animal models. In the combination treatments with caspase inhibitors, doses of 
bFGF or NMDA antagonists required for effective therapy are found to be 
reduced, and the therapeutic window extended (Ma et al., 1998; Ma et al., 
2001).  
            It can be anticipated that the combination approaches that encompass 
reperfusion, anti-inflammation, possibly neuroprotection, and reversal of 
excitotoxicity, is superior as compared to a single specific treatment. The main 
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challenge will be to find the right combination which is safe, efficacious, cost-
effective, and exerts its therapeutic effects on both a short-term and long-term 
basis (Chaudhuri, 2007). 
 
1.1.3.5 Traditional Chinese Medicine 
            Traditional Chinese Medicine (TCM) is a system of medical thought 
and practice that is distinctly different from Western Medicine. It postulates an 
unique and inextricable relationship between the human body and its 
environment. A disease state, where the body loses the ability to maintain 
normal physiological function, often ensues when this relationship is 
compromised. When disease occurs, Chinese medicine practitioners use herbal 
medicine derived from plant, animal and mineral sources to restore the 
compromised relationship in a sick individual. 
            The use of TCM in stroke therepy has a long history that can be dated 
back to as early as 2000 years ago. Scientific literature available in database 
contains a large body of articles devoted to the clinical evaluation of the use of 
TCM in stroke therapy (Gong et al., 1999, 2002; Mattson et al., 2002). 
Clinical data from these studies indicate that anti-stroke TCMs are effective 
and thus provide a basis for the pharmacological use of TCM in stroke 
management. However, as neither the biological targets nor the chemical 
compounds acting at these targets in most of the TCMs are known, it is 
challenging to ensure that a given herbal preparation used in a patient actually 
contains the active ingredient(s) underlying the purported therapeutic effect. 
Hence, evidence-based evaluation of the effectiveness of herbal anti-stroke 
medicines in practice is usually difficult. 
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            In an attempt to address some of these issues, a great deal of 
pharmacological research has been undertaken to review and establish reliable 
composite formulae of natural products in TCM such as “Hu Xin Dan”, 
“Puerarin injection” and “Shen Mai injection” (Wang et al., 1995; Lee et al., 
2004; Fattorusso et al., 2006; Ichikawa et al., 2006). In addition, research 
aimed at the characterization of molecular targets and effects of herbal 
medicine using either crude extracts of TCM natural products or isolated 
compounds possessing bioactivities, has also been conducted (Sucher, 2006). 
It is reasoned that the elucidation of molecular mechanisms underlying the 
anti-stroke effects of herbal anti-stroke medications, and the identification of 
chemical compounds responsible for these effects would be useful for the 
hypothesis-guided evaluation of their therapeutic efficacies. 
            In summary, the long history of use of anti-stroke TCM in China 
indicates that TCM preparations are to a certain extent effective in the 
management of stroke. There are now more than 100 traditional medicines for 
use in stroke therapy (Wu, 1989). Identification of molecular targets and 
subsequent identification of chemical compounds that bind to these targets in 
traditional Chinese stroke medicine therefore are pivotal in the discovery of 
natural products that may serve as leads for the development of safe and 
effective anti-stroke medications. 
 
1.2 Studies on Ixeris sonchifolia Hance 
            Ixeris sonchifolia Hance (Fig.1.2.1), which belongs to the Compositae 
family, is a small and bitter perennial herb widely distributed in the 
northeastern part of China (Feng et al., 2001; He et al., 2006; Na et al., 2007). 
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It is a well-known folk medicine and its whole plant has been used for many 
years in China to invigorate blood circulation, normalize menstruation and 
eliminate blood stasis to relieve pain (Feng et al., 2001; He et al., 2006; Na et 
al., 2007). Extensive phytochemical investigations on this herb have been 
carried out, and many components isolated from this plant exhibit significant 
bioactivities. Compounds isolated from Ixeris sonchifolia Hance can be 
classified into sesquiterpene lactones, triterpenes, steroids, phenylpropanoids, 
phenols, amino acids and fatty alcohols/acids.  
 
Fig.1.2.1 The aerial part of 
Ixeris sonchifolia Hance  
            In previous studies, the extract of Ixeris sonchifolia Hance was 
reported to be able to decrease apoptosis of cardiomyocytes in overtrained rats 
by regulating the expression of Bax and Bcl-2, decreasing Bax/Bcl-2 ratio 
(Rong et al., 2007). There are also studies reporting the use of Ixeris 
sonchifolia Hance extract in the preparation of medical agents for treating 
coronary heart diseases (Ma et al., 2009). In another study, cumulation 
administration of the water extract of Ixeris sonchifolia Hance was not 
observed to affect the vasomotion of aortic rings in basal tension, but the 
extract could induce a significant concentration-dependent relaxation of the 
intact endothelium rings preconstricted by phenylephrine (Lin et al., 2007). 
The relaxation was inhibited by preincubation with N-nitro-L-arginine methyl 
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ester, methylene blue and indomethacin. The bioactivities were therefore 
deduced to be mediated through the nitric oxide-guanylyl cyclase and 
cyclooxygenase pathway (Lin et al., 2007). Based on these preliminary results 
demonstrating potential therapeutic benefits of Ixeris sonchifolia Hance, 
development of this herb into a promising medicinal preparation for the 
prevention and treatment of cardio- and cerebral-vascular diseases is 
warranted.   
            Capitalizing on the unique properties of this herb, an injectible 
formulation containing a raw extract of Ixeris sonchifolia Hance (Diemailing 
Injection) was recently developed and launched by Liaoning Institute of 
Pharmaceutical Industry, China. The product is reported to have effects such 
as vascular smooth muscle relaxation, enhancement of cerebral blood flow, 
improvement of the activity of fibrinolytic enzyme activity and inhibition of 
thrombus formation. In an animal study involving anesthetized open-chest 
dogs, the Diemailing injection was found to decrease myocardial infarct size, 
activity of serum creatine kinase and lactate dehydrogenase, contents of serum 
free fatty acid and lipid peroxide, as well as increase the activity of serum 
SOD. In addition, myocardial blood flow was increased with an accompanying 
decrease in coronary vascular resistance (Wang et al., 2002). In another 
animal studies involving acute myocardial ischemic rats, the Diemailing 
Injection was also demonstrated to decrease the activities of serum creatine 
kinase and lactate dehydrogenase, as well as diminish the myocardial ischemia 
size and ST segment abnormalities in the electrocardiography (ECG) (Wang et 
al., 2006; Zhou et al., 2007).  
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            The therapeutic efficacy of Diemailing Injection in the management of 
stroke was investigated in clinical trials conducted by the Xiyuan Hospital of 
the Chinese Academy of Traditional Chinese Medicine, and five other hospital 
sites in China. In these studies, Diemailing Injection was shown to exhibit 
better therapeutic efficiency than the control medicine (standard stroke therapy 
proposal, 2000) in restoring stroke patients’ neural functions and recovery of 
daily vasomotor activities. Based on these favorable outcomes, the product has 
since been added onto to The National Basic Medical Insurance and Workman 
Compensation Insurance Pharmaceutical List.  
            Based on the findings of the conducted clinical trials, Diemailing 
Injection can be explored as an alternative treatment option in stroke 
management. Unfortunately, the biological targets and the chemical 
components underlying the activities of Ixeris sonchifolia Hance extract 
remains mostly unknown. Administration of a heterogenous herbal 
formulation does have its drawbacks. Firstly, the effectiveness of the herbal 
preparation may suffer from batch-to-batch variations since it is usually 
difficult to ensure the presence of similar amounts of active ingredients. 
Secondly, some of the components present in the herbal formation may pose 
certain side effects that potentially limit the therapeutic benefits.  For example, 
Zhang et al had previously reported the occurrence of asthma (Zhang, 2007) 
and Guan et al had reported the occurrence of lactation incidence during the 
treatment with Diemailing injection (Guan et al., 2004). Therefore, elucidation 
of molecular targets responsible for the effects of Ixeris sonchifolia Hance and 
the subsequent identification of the chemical compounds contributing to the 
observed molecular effects, will not only serve as surrogate markers in the 
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evaluation of the therapeutic efficacy of Ixeris sonchifolia Hance, but also 
provide a basis for development of a more defined anti-stroke product with 
assured therapeutic effects and controllable formulation quality. 
 
1.3 Rationale and aims 
            Based on the therapeutic outcomes of Diemailing Injection, which 
contains a raw extract of Ixeris sonchifolia Hance, it was hypothesized that the 
phytochemical constituents in this herb would possess anti-stroke potential 
with anticoagulation, antioxidant and anti-inflammatory activities. As such, 
the study aimed to elucidate the molecular targets responsible for the effects of 
Ixeris sonchifolia Hance, followed by the identification of components 
contributing to these molecular effects. The specific objectives of this Ph.D 
study were: 
            (1) To isolate and identify compounds with potential anti-stroke 
properties from Ixeris sonchifolia Hance through conducting bioassay-guided 
extraction, fractionation and purification experiments.  
            (2) To elucidate the molecular mechanism(s) underlying the potential 
anti-stroke properties of these compounds. Particularly, the potential 
antioxidant and anti-inflammatory activities of the compounds would be 
explored. 
            (3) To validate the anti-stroke activity of these compounds using well-
established animal stroke model.  
            To accomplish these objectives, crude extracts of Ixeris sonchifolia 
Hance would be subjected to screening using both cell-based and biochemical 
reactions in vitro bioassays. Extracts that display desirable bioactivity would 
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be subjected to further fractionation until finally pure bioactive compounds 
were obtained. The selection of assays to elucidate the molecular mechanism(s) 
of potential anti-stroke compounds would be based on the current 
understanding of the pathophysiology of neuronal injury during the 
reperfusion phase following an acute ischemic stroke attack. Currently, five 
key mechanisms with well-defined molecular targets are known to be involved 
in the cascade of events leading to neuronal injury and death in acute stroke. 
These mechanisms include (1) activation of receptors for excitatory amino 
acids, (2) calcium influx, (3) generation of free radicals, (4) programmed cell 
death, and (5) inflammation. It is plausible that Ixeris sonchifolia Hance may 
contain neuroprotective compounds with the ability to abate any of the five 
mechanisms. But to ensure the feasibility of the current proposal, efforts 
would be mainly directed towards the isolation of compounds that could 
exhibit either antioxidant, anti-apoptotic or anti-inflammatory activities. As 
Ixeris sonchifolia Hance is known for its fibrinolytic and thrombolytic activity, 
another objective of this thesis was to test if the potential anti-stroke effect of 
Ixeris sonchifolia Hance was partly attributed to the ability of its components 
to improve cerebral blood flow via their fibrinolytic and thrombolytic activity. 
Finally, candidate compounds identified above would be evaluated in a rat 
model of transient forebrain ischemia. This model, where occlusion of the 
middle cerebral artery is performed on the rats, closely resembles clinical 
stroke due to focal ischemic attacks and has been shown to be sensitive to 
treatment with neuroprotective compounds that function via a number of 
mechanisms. The results of investigations undertaken to achieve each aim 














Preparation and bioactivity screening of fractions from Ixeris 





            Ixeris sonchifolia Hance is a well-known folk medicine and its whole 
plant has been used for many years in China to invigorate blood circulation, 
normalize menstruation and eliminate blood stasis to relieve pain (Feng et al., 
2001; He et al., 2006; Na et al., 2007). Previous studies had also provided 
preliminary indication of the potential of developing Ixeris sonchifolia Hance 
into a medicinal preparation for the treatment of cerebro-vascular diseases. 
However, the chemical components accounting for the corresponding 
bioactivities have not been identified. This chapter would employ an approach 
involving extraction, fractionation and bioactivity screening on Ixeris 
sonchifolia Hance with the ultimate goal to isolate and identify the chemical 
components underlying the potential anti-stroke effects of this herb. Initiation 
of the isolation work involved preparation of an extract from the aerial part of 
Ixeris sonchifolia Hance and further partitioning of the extract into fractions 
according to their polarities. The fractions would be then subjected to 
screening using both cell-based in vitro bioassays and biochemical reactions. 
The selection of assays to screen the fractions was based on current 
understanding of the pathophysiology of neuronal injury during the 
reperfusion phase subsequent to acute ischemic stroke. In summary, the 
anticoagulation activities of the fractions, which would relate to the ability to 
prevent the progression of thrombosis and early recurrence of embolic stroke, 
and the antioxidant activities of the fractions, which would relate to the ability 
to reduce ischemia-caused tissue damage, were evaluated with in vitro 
bioassays. The cytoprotective effect of these fractions on H2O2-exposed cells 
was also evaluated using the MTT cell viability assay.  
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2.2 Materials and methods 
2.2.1 Preparation of Ixeris sonchifolia Hance extract 
2.2.1.1 Reagents and plant materials 
            The aerial part of Ixeris sonchifolia Hance was purchased from Beijing 
DDLD Medicinal Technology Development Co. Ltd (Beijing, China) in 
September 2006 and the identity was verified by Dr. Zhou Liang (Department 
of Pharmacy, National University of Singapore). The voucher specimen had 
been deposited in the laboratory of Dr. Chew Eng-Hui, Department of 
Pharmacy, National University of Singapore (No. 060902). All chemicals used 
in this section were purchased from Tedia Company Inc. (OH, USA) unless 
otherwise noted.   
 
2.2.1.2 Extraction procedures 
            The aerial part of Ixeris sonchifolia Hance (5 kg) was cut into small 
pieces (3 cm) and extracted three times with 95% C2H5OH at 60 °C for 3 h.  
The extract was evaporated to dryness under reduced pressure to yield a dried 
residue.  The dried crude extract (420 g) was dissolved in 800 ml of distilled 
water and subjected to liquid-liquid extraction with equal volumes of n-hexane, 
chloroform and ethyl acetate in a successive order.  In all, four extracts were 
obtained, namely n-hexane fraction (Fr. 1, 100 g), chloroform fraction (Fr. 2, 
80 g), ethyl acetate fraction (Fr. 3, 50 g) and water fraction (Fr. 4, 190 g). Each 
fraction was accurately weighed and dissolved in DMSO to constitute 20 
mg/ml stock solutions that were stored at -20 ℃. 
 




            The principles in stroke treatment involve the restoration of blood 
supply to the affected brain area in the shortest possible time from the onset of 
stroke, as well as to reduce ischemia-caused tissue damage. To identify the 
fraction(s) possessing significant bioactivities for potential stroke treatment, 
fractions 1 to 4 were assayed for their possible anticoagulation and antioxidant 
efficacies. The fraction(s) identified to exhibit the strongest bioactivities was 
then subjected to further fractionation and purification experiments, which 
would be the focus of discussion in Chapter 3. 
 
2.2.2.1 Anticoagulation activity assay 
            Considering that anticoagulant therapy showed significant clinical 
advantage in preventing progression of thrombosis and early recurrence of 
embolic stroke (see Section 1.1.3.2), and Diemailing Injection could inhibit 
thrombus formation (see Section 1.2), the anticoagulant effects of Fr. 1 to 4 
were tested by assaying the prothrombin time (PT) and activated partial 
thromboplastin time (aPTT) in vitro. PT is the time taken for plasma to clot 
after addition of tissue factor; it measures the coagulation efficacy of the 
extrinsic pathway. On the other hand, aPTT measures the efficacy of the 
intrinsic coagulation pathway (also known as the contact activation pathway). 
            Thromborel® S, Actin® FSL, Ci-Trol® coagulation Control Level 1 
and Calcium chloride solution were all obtained from Dade Behring (Marburg, 
Germany). Clotting time was detected with a Sysmex CA-500 Automated 
Blood Coagulation Analyzer (Sysmex Corporation, Japan). Briefly, once the 
coagulation cascade was initiated, the test tube was irradiated with light at 660 
nm and the change in scattered light due to turbidity change during conversion 
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of fibrinogen to fibrin was measured. The clotting time was defined as the 
time taken to reach 50% change in scattered light.  
            All procedures were carried out in accordance to the manufacturer’s 
protocols. Briefly, the lyophilized pooled human plasma (Ci-Trol® level 1) 
was freshly reconstituted with distilled water. Different concentrations of Fr. 1 
to 4 (50 µl) were then added to the reconstituted plasma (100 µl) to obtain the 
plasma mixture. PBS and Heparin (Mayne Pharma Pty Ltd, Australia) were 
added to the reconstituted plasma to serve as blank control and positive control 
respectively. For determination of PT, to initiate the coagulation process, 100 
µl of thromboplastin (Thromborel® S) was added to 50 µl of the plasma 
mixture, which had already been incubated at 37 ℃ for 180 s. The reaction 
system was monitored with the Automated Blood Coagulation Analyzer for 
120 s. For determination of aPTT, 50 µl of plasma mixture was incubated at 
37 ℃ for 60 s before the addition of 50 µl of soy and rabbit brain phosphatides 
(Actin® FSL). The mixture was incubated at 37 ℃ for another 180 s, after 
which 50 µl of calcium chloride solution supplied within the assay kits was 
added to initiate the coagulation cascade and the reaction system was 
monitored for 190 s (Lau et al., 2009).  
 
2.2.2.2 In vitro MTT cell viability assay 
            PC12 rat pheochromocytoma cells were obtained from Dr. Liou Yih 
Cherng (Department of Biological Sciences, National University of Singapore) 
and grown in RPMI 1640 medium (Gibco, NY, USA) supplemented with 10% 
horse serum (Hyclone, UT, USA) and 5% bovine serum (Hyclone, UT, USA), 
at 37 ℃ in a humidified 5% CO2 atmosphere. 
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            Cells were harvested from maintenance cultures when they reach 70 - 
80% confluence. By gently syringing the cell suspension 3 to 4 times through 
a 23 G needle, a single cell suspension was obtained. Cell counts were 
obtained using a haemocytometer. The cell suspension was diluted 
appropriately to achieve the desired cell density in 100 µl of culture medium 
for inoculation into each well of a 96-well plate. The seeding cell density for 
PC12 cells was 5000 cells/well. In order to minimize medium evaporation 
from the plate, wells in the 2 peripheral lanes were left cell-free (blank wells) 
and filled with 200 µl of medium. The plates were then incubated for 
approximately 48 h at 37 ℃ to allow cell attachment. Serial drug dilutions of 
the fractions 1 to 4 DMSO stock solutions were prepared in medium 
immediately before each assay, of which an aliquot of 100 µl was added into 
each well to achieve final concentration of 1 µM, 10 µM, 20 µM, 50 µM and 
100 µM (n = 8). To the control wells, 100 µl of medium was added. Previous 
assays had been carried out to verify that cell viability was not affected by the 
amount of DMSO added into the drug treated wells. To produce oxidative 
stress, H2O2, freshly prepared from 30% stock solution with PBS, was 
introduced (final concentration 150 µM) 30 min after the drug treatment. The 
drug treated plates were incubated for another 12 h at 37 ℃, after which 10 µl 
of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl (MTT; purchased from Sigma-
Aldrich Pte Ltd, MO, USA) solution (5 mg/ml in PBS) was added into each 
well. Following MTT addition, the plates were reincubated for 4 h at 37℃ to 
allow metabolic conversion of MTT by dehydrogenases in viable cells to 
insoluble formazan crystals. The medium and any unconverted MTT was 
aspirated, 150 µl of DMSO:glycine buffer (pH 10.5, 4:1) was added to each 
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well and the plates were shaken to ensure complete formazan solubilization. 
Absorbance was then read at 550 nm on an Infinite® M200 PRO (Tecan 
Group Ltd, Switzerland) plate reader and data was automatically transferred to 
a computer, where the absorbance readings (corrected to background 
absorbance in blank wells) were displayed. The intensity of absorbance was 
directly proportional to cell viability. The assay for each fraction treatment 
was performed at least three times and the mean absorbance value at each drug 
concentration was recorded for plotting the dose-response graph (Hong et al., 
2004; Sun et al., 2005; Liu et al., 2007).  
 
2.2.2.3 Evaluation of antioxidant activities of fractions 1 to 4 
            Redox homeostasis is critical for cell survival and growth, and under 
normal physiologic conditions, this is achieved by a number of cellular 
antioxidant systems including the two major thiol redox systems: the 
glutathione and thioredoxin systems (Bjornstedt et al., 1994; Mulder et al., 
1997; Dixon et al., 1998; Casagrande et al., 2002; Holmgren et al., 2005; 
Koharyova et al., 2008). During cerebral ischemia, elevated intracellular Ca2+ 
activates a series of reaction pathways and initiates the formation of free 
radicals. The increase in free radical levels disrupts the redox homeostasis and 
cause cellular damage through lipid peroxidation, tyrosine nitration, sulfhydryl 
oxidation and nitrosylation, as well as DNA strand breakage. Strategies to re-
establish redox homeostasis by inhibiting the production, increasing the 
removal or fostering the degradation of free radicals, have been investigated to 
reduce free radical-induced damage processes in stroke. This chapter had 
adopted two approaches to assess the antioxidant activities of Fr. 1 to 4: (1) 
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direct measurement of free radical scavenging activities and (2) detection of 
the induction on cellular antioxidant enzymes and molecules. 
 
2.2.2.3a Determination of free radical scavenging activity 
            To measure the direct free radical scavenging activity, Fr. 1 to 4 were 
dissolved in 100 µl acetonitrile and added to an equal volume of acetonitrile 
solution containing 100 µM 2,2-diphenyl-1-picrylhydrazyl (DPPH; purchased 
from Sigma-Aldrich Pte Ltd, USA). The mixture were agitated vigorously and 
then kept in the dark at room temperature for 30 min. Absorbance (A) of 
residual DPPH was read at 516 nm and compared to a positive control solution 
of DPPH with Trolox (Sigma-Aldrich Pte Ltd, USA) and a solution containing 
only DPPH (Ono et al., 2008; Sugiyama et al., 2009). The DPPH free radical 
scavenging rate was calculated using the following formula: Scavenging Rate 
= (Abs DPPH-only solution – Abs compound-treated DPPH solution) / Abs DPPH-only solution 
×100% (Awika et al., 2003; Chung et al., 2007; Obied et al., 2007). 
  
2.2.2.3b Determination of inducibility of cellular antioxidant enzymes and 
molecules 
 
ARE-dependent luciferase reporter assay 
            Human-derived SH-SY5Y neuroblastoma cells (CRL-2266) were 
purchased from American Type Culture Collection (Rockville, MD, USA) and 
cultured at 37 ℃, 5% CO2 in Dulbecco’s Modified Eagle’s Medium/Nutrient 
Mixture F-12 Ham (1:1) culture medium supplemented with 10 % fetal bovine 
serum (Hyclone, UT, USA), 100 µg/ml streptomycin, 100 U/ml penicillin G 
and 1.5 g/L sodium bicarbonate. Cells were seeded in 12-well culture plates 
and at approximately 60% confluency, they were cotransfected with 1.0 μg 
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pGL3-ARE plasmid (gift from Professor Alan Porter, IMCB, Singapore) and 
0.05 μg pRL-CMV plasmid (Promega, Madison, WI) per well for 24 h. After 
which the cells were treated with different concentrations of Fr. 1 to 4, as well 
as 10 µM sulforaphane (used as a positive control in this study) for 10 h. 
Firefly and renilla luciferase activities were assayed using the Dual 
Luciferase® Assay System (Promega, Madison, WI) and results were 
expressed as firefly luciferase activity normalized to renilla luciferase activity. 
Each drug treatment was carried out in duplicates and means from three 
independent experiments (± SEM) were obtained. Statistical significance 
between treatment control groups were analyzed using Student’s t - test. 
 
Western blot analysis of cellular Nrf2 levels 
            Drug treatment    SH-SY5Y cells were seeded in 6-well culture plates 
and allowed to grow to 60 - 70% confluency before addition of Fr. 1 to 4 at 10 
and 50 µg/ml for 8, 12 and 24 h. Cell treatment with 10 µM sulforaphane 
(used as a positive control in this study), as well as 25 µM MG-132 (a 
proteasome inhibitor that causes accumulation of Nrf2 through preventing its 
degradation) was also carried out.  
            Preparation of cell lysates    Following desired treatment, medium 
containing detached cells was collected. Attached cells were collected using a 
cell scraper. Both attached and floating cells were pooled and pelleted by 
centrifugation (1,200 rpm, 4 ℃, 5 min). The pellet was washed twice with 
cold PBS, and resuspended in an appropriate volume (0.1 - 0.5 ml, depending 
on size of cell pellet) of ice-cold lysis buffer (Cell Signaling Technology Inc., 
MA, USA) containing freshly added protease inhibitors. The lysis buffer was 
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composed of 20 mM Tris-HCl (PH 7.5), 150 mM NaCl, 1 mM Na2EDTA, 1 
mM EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM beta-
glycerophosphate, 1 mM Na3VO4 and 1 µg/ml leupeptin. The protease 
inhibitors added were 1 mM phenylmethylsulfonyl fluoride, 10 µg/ml 
aprotinin and 5 µg/ml pepstatin A. After brief sonication on ice, cell lysates 
were centrifuged at 14,000 × g for 15 min at 4 ℃ to remove cell debris. The 
supernatant was collected and protein content was quantified using a Pierce® 
BCA Protien Assay Kit (Pierce, Rockford, IL) according to the manufacturer’s 
instruction. This protein assay was conducted on a 96-well plate by adding 
200 µl of BCA reaction solution to each well containing 20 µl of protein 
samples or different concentration of BSA. After incubation of the plate in 
37 ℃ for 30 min, absorbance values at 562 nm were measured using an 
Infinite® M200 PRO (Tecan Group Ltd, Switzerland) microplate reader. 
Protein concentration of cell lysates was calculated against BSA standard 
calibration curve. 
            Western blot analysis    Protein mixture in cell lysates was separated 
using SDS-PAGE based on their molecular size. Resolving gel (10%; solution 
formula for two gels: 9.6 ml distilled water, 5 ml 40% acrylamide, 5 ml 1.5 M 
Tris pH 8.8, 200 µl 10% SDS, 200 µl 10% ammonium persulfate and 8 µl 
TEMED) and stacking gel (5%; solution formula for two gels: 7.25 ml 
distilled water, 1.25 ml 40% acrylamide, 1.25 ml 1 M Tris pH 6.3, 100 µl 10% 
SDS, 100 µl 10% ammonium persulfate and 8 µl TEMED) were used for the 
separation process. A 10- or 15-well comb was used to create wells for sample 
loading. Cell lysates containing equal amount of proteins were diluted with 1:1 
laemmli sample buffer [62.5 mM Tris HCl (pH 6.8), 2% SDS, 25% glycerol, 
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0.01% (w/v) bromophenol blue, 5% 2-mercaptoethanol] and boiled at 100 ℃ 
for 10 min. The samples were then loaded into wells in the stacking gel. The 
proteins were separated by 10% resolving gel under constant current of 40 mA 
using running buffer containing 25 mM Tris, 192 mM glycine and 0.1% SDS. 
            After separation of proteins by SDS-PAGE, the proteins were 
transferred to a nitrocellulose membrane (Bio-Rad Laboratories, CA, USA) 
under constant voltage of 25 V at 4 ℃ for overnight using transfer buffer 
containing 25 mM Tris, 192 mM glycine, 0.1% SDS and 20% methanol. The 
transblotted membrane was blocked with 5% (w/v) non-fat milk in TBS-T 
(113 mM NaCl, 25 mM Tris HCl with 0.05% Tween 20) at room temperature 
for 1 h, and then incubated with the primary antibodies anti-Nrf2 (Santa Cruz 
Biotechnology Inc., CA, USA) and anti-β-actin (Santa Cruz Biotechnology 
Inc., CA, USA) for 2 h at room temperature. After washing the membrane 
with TBS-T for three times, appropriate secondary antibody (anti-rabbit IgG 
HRP-linked antibody, purchased from Cell Signaling Technology Inc., MA, 
USA) was added on to the membrane to incubate at room temperature for 1 h. 
Prior to antibody visualization using the enhanced chemiluminescence system, 
the membrane was rinsed in TBS-T for three times to remove excess 
secondary antibody. The antibody/protein complexes were visualized using 
the enhanced chemiluminescence system (Perkin-Elmer, MA, USA). 
 GSH measurement 
            SH-SY5Y cells were seeded onto 60 mm diameter plates at a density 
of 5 × 104 cells/plate and allowed to grow to 60 - 70% confluency before 
addition of Fr. 1 to 4 at 10 and 50 µg/ml. Each treatment was performed in 
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duplicates (2 plates of cells for each treatment). After 24 h of treatment, 
detached cells floating in medium were then collected and the attached cells 
trypsinized. Attached and floating cells were pooled, pelleted by 
centrifugation (1,200 rpm, 4 ℃, 5 min), washed once in ice-cold PBS and the 
obtained cell pellet was frozen at -20 ℃. Cell pellets from one of the duplicate 
samples (per treatment) were thawed. To each pellet, 1 ml of 3% w/v 5-
sulfosalicylic acid was added to extract GSH. The mixture was centrifuged to 
remove precipitated proteins, total GSH content was determined by the 
enzymatic method of Tietze with modification (Tietze, 1969; Chew et al., 
2006). Briefly, total GSH content was assayed by measuring the change in 
absorbance at 412 nm over 6 min in a 96-well plate containing 0.1 M sodium 
phosphate, 5 mM EDTA buffer (pH 7.5), 0.12 mM 5,5’-dithio-bis(2-
nitrobenzoic acid), 0.2 IU yeast GSH reductase (Sigma-Aldrich Pte Ltd, USA), 
0.04 mM NADPH, and 20 µl of sample in a final volume of 200 µl. GSH 
values were calculated from a standard curve that was generated for each 
experiment using known amounts of GSH (1×10-5-5×10-7 M). Total GSH 
levels were then normalized to total protein content that was determined from 
the cell lysates prepared from the remaining duplicate sample using a 
bicinchoninic acid (BCA) protein assay kit according to the manufacturer’s 
instructions. 
 
2.2.3 Statistical analysis  
            All data were expressed as means ± S.D. (or means ± SEM) and 
Student’s t - test was used for comparison between treatment groups. 




2.3.1 Possible anti-coagulation activities of fractions 1 to 4 isolated from 
Ixeris sonchifolia Hance extract 
 
            As shown in Table 2.3.1.1, results revealed that Heparin (1 U/ml), used 
in this study as a positive control, could markedly prolong both PT and aPTT 
to > 120 and > 190 s respectively. As compared to untreated control, while Fr. 
1 at 100 µg/ml could prolong PT marginally, none of the other fractions 
showed significant effects, indicating that at least in this in vitro 
anticoagulation activity assay employed, the fractions isolated from Ixeris 
sonchifolia Hance extract were found not to possess significant anticoagulant 
activities.  
Table 2.3.1.1 Anticoagulation activity of the fractions 1 to 4 extracted from 
Ixeris sonchifolia Hance 
 Prothrombin Time (s)  Activated Partial Thromboplastin 
Time (s) 
10 µg/ml 50 µg /ml 100 µg /ml 10 µg /ml 50 µg /ml 100 µg /ml 
Unteated 
Control 
 15.7 ± 0.3   39.5  ± 0.9  
Heparin     
(1 U/ml) 
 >120**   >190**  
Fr. 1 15.9 ± 0.2 15.9 ± 0.2 16.2 ± 0.1* 39.2 ± 0.4 40.7 ± 0.5 40.6 ± 1.8 
Fr. 2 15.5 ± 0.2 15.0 ± 0.2 14.8 ± 0 37.8 ± 3.6 41.3 ± 1.4 40.1 ± 0.6 
Fr. 3 15.2 ± 0.2 15.2 ± 0.2 15.2 ± 0.2 39.9 ± 1.5 40.7 ± 1.1 40.6 ± 1.0 
Fr. 4 16.0 ± 0.3 15.8 ± 0.2 16.0 ± 0.3 39.7 ± 0.5 40.0 ± 0.7 39.8 ± 0.5 
 
* p < 0.05 versus untreated control group; ** p < 0.01 versus untreated control 
group 
 
2.3.2 Effects of fractions 1 to 4 isolated from Ixeris sonchifolia Hance 




            The fractions isolated from Ixeris sonchifolia Hance extract were 
evaluated for their possible cytoprotective effects against cells exposed to 
oxidative stress. MTT cell viability assays were carried out where PC12 cells  
 
 
Fig 2.3.2.1 Effects of fractions 1 to 4 isolated from Ixeris sonchifolia Hance 
extract on the viability of H2O2-exposed PC12 cells. Cells were pre-treated 
with different concentrations of fractions 1 to 4 for 30 min, followed by H2O2 
addition to a final concentration of 150 µM. Cell viability was determined 
using MTT assay after a 12 h-treatment. ## p < 0.01 versus control group; ** 
p < 0.01 versus H2O2 group. 
 
pretreated with different concentrations of Fr. 1 to 4 for 30 min were treated 
with 150 µM H2O2 for another 12 h. As shown in Fig 2.3.2.1, cell viability 
was significantly decreased to around 70% after a 12 h exposure to H2O2. Pre-
treatment of cells with the different fractions obtained from Ixeris sonchifolia 
Hance extract yielded varied results; H2O2-induced cytotoxic effect was 
significantly attenuated in cells that were pre-exposed to Fr. 1 and 3 at 
concentrations more than 20 µg/ml, whereas cells pre-treated with Fr. 2 and 4 
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suffered an accentuated cytotoxic effect. Of note, the cytoprotective effects of 
Fr. 1 and particularly Fr. 3 were dose-dependent, suggesting that these 
fractions contained components capable of scavenging the cytotoxic effect of 
H2O2. Based on the results obtained from this preliminary screening assay, Fr. 
1 and 3 could be selected for further isolation and purification work to identify 
the components accountable for the possible cytoprotective effect.   
 
2.3.3 Evaluation of antioxidant activities of fractions 1 to 4 isolated from 
Ixeris sonchifolia Hance extract 
 
            As preliminary results presented in Section 2.3.2 were suggestive of 
possible antioxidant activities of the fractions isolated from the Ixeris 
sonchifolia Hance extract, the free radical scavenging activity of these 
fractions were determined in an in vitro assay using DPPH as substrate. As 
shown in Fig 2.3.3.1, while the low concentrations (10 - 100 µg/ml) of Fr. 1, 2 
and 4 exhibited little activity, a high concentration (1 mg/ml) of all fractions 
could scavenge DPPH free radical effectively. Among the fractions, it was 
observed that Fr. 3 possessed the most promising and effective free radical 
scavenging activity; elimination of 90% of DPPH free radical could be 






Fig 2.3.3.1 DPPH free radical scavenging activity of fractions 1 to 4 isolated 
from Ixeris sonchifolia Hance extract. The DPPH scavenging rate for each 
sample was calculated as percentage of (Abs DPPH-only solution – Abs compound-treated 
DPPH solution)/ Abs DPPH-only solution. Trolox at the concentration of 100 µM was 
used as positive control. * p < 0.05, **p < 0.01 versus solution containing only 
DPPH. 
 
             
 
Fig 2.3.3.2 Effects of fractions 1 to 4 isolated from Ixeris sonchifolia Hance 
extract on ARE-dependent transcriptional activity. SH-SY5Y cells 
cotransfected with pGL3-ARE and pRL-CMV were treated with fractions 1 to 
4 or 10 µM sulforaphane (SF) for 10 h. Ratios of firefly luciferase activities 
normalized to renilla luciferase activities were determined. * p < 0.05, ** p< 















Fig 2.3.3.3 Representative Western blot analysis of protein levels of 
transcription factor Nrf2 in SH-SY5Y cells treated with fractions 1 to 4 
isolated from Ixeris sonchifolia Hance extract. Cells were treated with 
indicated concentrations of fractions 1 to 4 and 10 µM of sulforaphane for 8, 
12 and 24 h and whole cell lysates were collected for SDS-PAGE and Western 
blot analysis of Nrf2 protein levels. β-actin immunodetection was carried out 
to verify equal protein loading. The use of proteasome inhibitor MG-132 
served the purpose of prevention Nrf2 degradation so as to aid in locating the 
Nrf2 protein band on the Western blot films. 
 
            To further assess the antioxidant activities of Fr. 1 to 4, their ability to 
induce ARE-dependent transcriptional activity was determined. Results 
revealed that as compared to DMSO control, Fr. 1 to 3 brought about an 
induction in ARE-dependent transcriptional activity in a dose-dependent 
manner. In particular, Fr. 3 registered the greatest fold of induction that was 
comparable to that of positive control sulforaphane (SF) (Fig 2.3.3.2). In view 
that the upregulation of ARE-dependent transcriptional activity could be due 
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to an enhancement in the activity of the transcription factor Nrf2, the effects of 
Fr. 1 to 4 on the cellular levels of Nrf2 protein were next determined. As 
depicted in the representative Western blot in Fig 2.3.3.3, all fractions 1 to 4 at 
a low concentration of 10 µg/ml were found to increase Nrf2 protein levels at 
a time point of 8 h. Among the fractions, Fr. 3 displayed remarkably and 
sustainable Nrf2 induction at all time points (8, 12 and 24 h) and at both 
concentrations of 10 and 50 µg/ml. Nrf2 induction was not maintained for Fr. 
1, 2 and 4 at later time points of 12 and 24 h. 
                     
 
Fig 2.3.3.4 Total cellular GSH levels in SH-SY5Y cells exposed to fractions 1 
to 4 isolated from Ixeris sonchifolia Hance extract. Cells were treated with 10 
and 50 µg/ml of fractions 1 to 4 and whole cell lysates were collected for GSH 
measurement after 24 h treatment. Each data were obtained from the average 
of three independent experiments. ** p < 0.01 versus DMSO control 
 
            GSH is an abundant thiol redox molecular whose levels could be 
elevated in times of oxidative stress in order to restore redox homeostasis. 
Measurement of total GSH content in SH-SY5Y cells treated with 10 and 50 
µg/ml Fr. 1 to 4 for 24 h was conducted, and it was found that among the 
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fractions tested, only Fr. 3 at 50 µg/ml was able to result in a significant 
increase in total GSH content (Fig 2.3.3.4). The other fractions, on the 
contrary, showed little effects. 
 
2.4 Discussion and conclusions  
            In this chapter, the aerial part of Ixeris sonchifolia Hance was extracted 
by 95% ethanol and the crude extract was partitioned into four fractions (Fr. 1 
to 4) according to their polarity. The fractions were then subjected to 
screening using both cell-based in vitro bioassays and biochemical reactions. 
The screening assays were selected based on current understanding of the 
pathophysiology of neuronal injury during the reperfusion phase subsequent to 
acute ischemic stroke.  
            The principles in stroke treatment involve the restoration of blood 
supply to the affected brain area in the shortest possible time from the onset of 
stroke, as well as to reduce ischemia-caused tissue damage. In order to restore 
the blood supply, thrombolytic reagents or surgical intervention are adopted to 
remove the thrombus in ischemic stroke (Fernandes et al., 2000). 
Anticoagulants and antiplatelet agents will be administrated to prevent the 
progression of thrombosis and early recurrence of embolic stroke. Coagulation 
is a complex process with several coagulation factors activated one after the 
other, and at last resulting in the formation of blood clots (Fig 2.4.1). The clots 
block the injured vessel until it heals. Of the anticoagulants, warfarin affects 
the vitamin K-dependent clotting factors (II, VII, IX, X) (Salte et al., 1991), 
whereas heparin increases the action of antithrombin on thrombin and Factor 
Xa. In this chapter, the anticoagulant effects of Fr. 1 to 4 were tested by 
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assaying the prothrombin time (PT) and activated partial thromboplastin time 
(aPTT) in vitro. PT is the time it takes for plasma to clot after addition of 
tissue factor. It assessed Factors VII, X, V, II and fibrinogen that are involved 
in the extrinsic pathway. On the other hand, aPTT assesses factors that take 
part in the intrinsic pathway: XII, XI, IX, VIII, X, V, II.  Results obtained 
from the in vitro anticoagulation activity assay had revealed that fractions 1 to 
4 isolated from Ixeris sonchifolia Hance extract possess negligible 
anticoagulant activities. However, significant differences exist between the 
physiological cascade and the in vitro experimental set-up. For instance, under 
physiological conditions, the speed of the extrinsic pathway is greatly affected 
by levels of Factor VII, which has a short half-life and its synthesis is 
dependent on Vitamin K. Therefore, the deficiencies in vitamin K, poor factor 
VII synthesis or increased consumption may prolong the PT in the 
physiological cascade (Godsafe et al., 1992). However, under experimental 
laboratory conditions, interfering factors that do not exert direct and 
immediate inhibitory effects on clotting factors would probably failed to yield 
a similar inhibitory outcome. Therefore, possibilities that fractions 1 to 4 
isolated from Ixeris sonchifolia Hance might exert anti-coagulation activity in 
an in vivo setting could not be excluded. 
            It was further found that Fr. 1 and 3 at concentrations more than 20 
µg/ml could bring about a reduction in H2O2-induced cytotoxic effect on PC12 
cells (refer to Fig 2.3.2.1). PC12 is a cell line derived from 
pheochromocytoma of the rat adrenal medulla. It responds reversibly to nerve 
growth factor by induction of the neuronal phenotype, which makes it useful 
as a cell model for screening of neuroprotectants. The cytoprotective effects of 
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Fr. 1 and particularly Fr. 3 were dose-dependent, suggesting that these 






























































Fig 2.4.1 The coagulation cascade under physiological conditions (A), and 
experimental laboratory conditions (B). Solid arrows indicate activation of a 
coagulation factor by the factor above it in the cascade; dotted arrows indicate 
activation of factors by thrombin. 
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             Free radical insult accounts for the early response following a stroke 
episode and strategies to inhibit the production, increase the removal or foster 
the degradation of free radicals have been investigated to reduce these 
detrimental processes. Medicines under investigation such as Tirilazad, 
Edaravone and NXY-059 are all free radical trapping reagents and most of 
them register significant efficiency in pre-clinical experiments. In the DPPH 
free radical scavenging assay, it was observed that among the four fractions, 
Fr. 3 exhibited the most efficient free radical scavenging effect, thus indicating 
that this fraction contained components that indeed possessed direct free 
radical scavenging activity. 
            Another strategy to protect cells against oxidative stress is to stimulate 
the production of cellular antioxidant enzymes and molecules. The Keap1-
Nrf2-ARE pathway is presumably the most important modulator to coordinate 
the phase II response. Under basal conditions, the actin-associated and 
cysteine-rich Kelch-like ECH-associated protein 1 (Keap1) serves as an 
adaptor to link Nrf2 to the ubiquitin E3 ligase Cul3-Rbx1 complex that 
ubiquitinates Nrf2 and leads to proteasomal degradation of Nrf2. When 
oxidative/electrophilic stress is introduced, modification of critical cysteine 
residues in Keap1 causes Keap1 to lose the ability to negatively regulated Nrf2.       
Accumulation of Nrf2 therefore results, which upon translocation into the 
nucleus, Nrf2 binding to the antioxidant response element (ARE), the 
promoter region of a battery of genes encoding Phase Ⅱ enzymes, leads to 
induction of expression of these cytoprotective enzymes. As a delayed 
response to oxidative/electrophilic stress, Glycogen synthase kinase-3 beta 


















































Fig 2.4.2 Oxidative/electrophilic stress and Nrf2:Keap1 signaling pathway.  
Under basal conditions, Keap1 (INrf2) serves as an adaptor to link Nrf2 to the 
ubiquitin ligase Cul3-Rbx1 complex and leads to proteasomal degradation of 
Nrf2. When oxidative/electrophilic stress is introduced, modification of 
critical cysteine residues in Keap1 causes Keap1 to lose the ability to 
negatively regulated Nrf2. Accumulation of Nrf2 therefore results, which upon 
translocation into the nucleus, Nrf2 binding to the antioxidant response 
element (ARE), leads to induction of expression of phase enzymes. As a Ⅱ
delayed response to oxidative/electrophilic stress, GSK-3β is activated and 
phosphorylates Fyn. The following nuclear translocation of phosphorylated 
Fyn phosphorylates Tyr568 in Nrf2, which results in nuclear exporting and 
degradation of Nrf2. Nrf2 is also degraded by prothymosin-α-mediated 
nuclear translocation of INrf2. Nrf2 degradation both in the cytosolic and 
nuclear compartments thus rapidly returns Nrf2 to normal levels. Adapted 
from Zhang, Li et al and Kaspar et al’s publications (Zhang, 2006; Kaspar et 
al., 2009; Li et al., 2009).   
 
 
translocation of phosphorylated Fyn. Phosphorylated Fyn in turn 
phosphorylates Tyr568 in Nrf2, which results in nuclear exporting and 
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degradation of Nrf2. Nrf2 is also degraded by prothymosin-α-mediated 
nuclear translocation of INrf2. Nrf2 degradation both in the cytosolic and 
nuclear compartments thus rapidly returns Nrf2 to normal levels (Fig 2.4.2) 
(Zhang, 2006; Li et al., 2009).  A broad spectrum of electrophiles has been 
found to inhibit Keap1-mediated Nrf2 degradation. In this chapter, the 
inducibility of cellular antioxidant enzymes and molecules was determined. 
Among the fractions evaluated, Fr. 3 was found to induce markedly ARE-
dependent transcriptional activity. Consistent with these results, Fr. 3 brought 
about accumulation of Nrf2 protein whereas the other fractions failed to 
display significant induction of Nrf2 levels.   
            Redox homeostasis is achieved by a number of antioxidant systems 
including the two major thiol redox systems: glutathione and thioredoxin 
systems (Bjornstedt et al., 1994; Holmgren et al., 2005; Koharyova et al., 
2008).  The thioredoxin system comprises thioredoxin (Trx), thioredoxin 
reductase (TrxR), and NADPH. TrxR catalyzes the NADPH-dependent 
reduction of the active-site disulfide of oxidized Trx. The glutathione system 
consists of reduced glutathione (GSH), oxidized glutathione (GSSG), 
peroxidase (GSH-Px) and glutathione reductase (GR). The thiol group in the 
cysteine residue within a GSH molecule is able to donate a reducing 
equivalent (H+ + e-) to ROS. In donating an electron, glutathione readily reacts 
with another reactive glutathione to form glutathione disulfide (GSSG). The 
NADPH-dependent enzyme glutathione reductase reduces GSSG to GSH (Fig 
2.4.3). The ratio of GSSG-to-GSH is considered indicative of the redox status 
(Bjornstedt et al., 1994; Holmgren et al., 2005; Koharyova et al., 2008). 
Measurement of intracellular total GSH content in SH-SY5Y cells treated with 
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Fr. 1 to 4 had revealed that only Fr. 3 at 50 µg/ml caused an increase in total 
GSH content, while the other fractions showed little effects. This suggested 
that Fr. 3 contained components capable of inducing production of GSH.  
 
 
Fig 2.4.3 The glutathione system. The Grx system consists of Grx, GSH and 
NADPH-dependent-GSH-reductase. Grxs are able to catalyse reactions not 
only via a dithiol mechanism, but also via a monothiol mechanism, which is 
required for the reduction of protein GSH-mixed disulphides. Both these 
oxidized forms can be catalytically reduced back to GSH by the NADPH-
dependent glutathione reductase.  
 
  
            In conclusion, while the ethyl acetate fraction (Fr. 3) isolated from 
Iexris sonchifolia Hance extract was found not to possess anticoagulant 
activities, it dose-dependently protected cells from H2O2-induced cytotoxicity, 
scavenged DPPH free radicals, induced ARE-dependent transcriptional 
activity and caused upregulation of Nrf2 protein levels. Based on these 
findings indicating the potential neuroprotective properties of Fr. 3, further 
fractionation and purification experiments were performed (to be highlighted 
in Chapter 3) with the ultimate goal of identifying the underlying components 














Isolation and characterization of components from ethyl 
acetate fraction of Ixeris sonchifolia Hance 
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3.1 Introduction  
            In the previous chapter, ethyl acetate fraction (Fr. 3) isolated from 
Ixeris sonchifolia Hance extract had been proven to protect cells from H2O2-
induced cytotoxicity dose-dependently, scavenged DPPH free radicals, 
induced ARE-dependent transcriptional activity and caused upregulation of 
Nrf2 protein levels, indicating the potential neuroprotective properties of Fr. 3. 
In this chapter, further fractionation and purification experiments was 
performed by repeated chromatography with the ultimate goal of identifying 
the underlying components that could play key roles in the prevention and 
treatment of ischemia-related diseases. The quantities of the isolated flavonoid 
compounds, which were identified by spectral analysis and postulated to be 
the underlying components exerting cytoprotective effects, was quantitatively 
determined with an Agilent 1100 series HPLC system. 
 
3.2 Materials and methods 
3.2.1 Isolation of the fractions from Ixeris Sonchifolia Hance extract 
3.2.1.1 Materials and general analytical procedures 
            All chemicals were purchased from Tedia Company Inc. (OH, USA) 
unless otherwise stated.  The deuteriated solvents for NMR analysis, pyridine-
d5 and dimethyl sulfoxide-d6, were purchased from Sigma-Aldrich Inc. (MO, 
USA).  The sorbents for chromatographic isolation, such as silica gel 60 (40 - 
63 μm) and precoated silica gel 60 TLC plates were purchased from Merck 
KGaA (Darmstadt, Germany).  Sephadex LH-20 was obtained from 
Pharmacia (Uppsala, Sweden) and Chromolith® SemiPrep 100-10 mm RP-18 
endcapped column was purchased from Merck KGaA. 
57 
 
            Melting points were determined in Pyrex capillaries using a 
Gallenkamp Griffin MPA350.BM2.5 melting point apparatus. IR spectra were 
recorded on the Perkin-Elmer 983G spectrometer. 1H and 13C NMR spectra 
were obtained using a Bruker ACF300 spectrometer (Karlsruhe, Germany) 
operating at 300 MHz and 75 MHz respectively. Mass spectra and ESI-TOF-
MS analysis was performed on a QTrap® 2000 ESI mass spectrometer 
(Applied Biosystems Inc., USA) and a Waters Q-TOF premierTM mass 
spectrometer respectively. Data were acquired in continuum mode until 
acceptable averaged data were obtained.  
 
3.2.1.2 Isolation procedures 
            Fr. 3, the ethyl acetate fraction isolated from Ixeris sonchifolia Hance 
extract (as discussed in Chapter 2) was further separated by a sephadex LH-20 
column using CHCl3/MeOH in a 1:1 volume ratio as the mobile phase. Nine 
fractions (Fr. 3.1 - 3.9) were obtained. Fr. 3.2 was separated by silica gel 
column chromatography with solvents of increasing polarity (CHCl3/MeOH, 
95:5 → 85:15 → 80:20, with methanol added over a 1% gradient) to yield four 
fractions (Fr. 3.2.1 - 3.2.4).  Fr. 3.2.3 was subjected to further separation with 
semi-preparative reversed phase HPLC using H2O/MeOH [flow rate: 4ml/min, 
H2O:MeOH 88:12 (0 min)→ 40:60 (25 min)] as eluting solvent to yield 
compound 13 (Rt = 10.6 min, 10 mg) and compound 11 (Rt = 14.0 min, 25 mg). 
Fr. 3.3 was separated by reverse-phase silica gel column chromatography with 
a mobile phase system of H2O/MeOH (90:10→10:90) to afford six fractions 
(Fr. 3.3.1 - 3.3.6). Fr. 3.3.3 and 3.3.5 were further separated by reverse-phase 
silica gel column chromatography to yield compound 2 (88 mg) and 1 (116 
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mg) respectively. Fr. 3.4 was separated using the same semi-preparative 
HPLC system applied to Fr. 3.2 to yield compound 8 (Rt = 9.8 min, 5 mg). 
Similarly, separation of Fr. 3.5 isolated compound 9 (Rt = 12.8 min, 12 mg) 
and 12 (Rt = 14.2 min, 10 mg) and Fr. 3.6 yielded compound 10 (Rt = 15.1 min, 
12 mg). The waste elution solvents of Fr. 3.4 to 3.6 were pooled and 
concentrated. The residue was subjected to silica gel column chromatography 
with CHCl3/MeOH (70:30→25:75) as elution system to afford compound 14 
(29 mg). When separated with the preparative HPLC system using 
H2O/MeOH  [flow rate: 4ml/min, H2O:MeOH 90:10 (0 min)→ 72:28 (20 min)] 
as mobile phase, Fr. 3.7 yielded compound 5 (Rt = 4.9 min, 22 mg), 4 (Rt = 
12.6 min, 33 mg) and 3 (Rt = 15.5 min, 20 mg), and Fr. 3.8 yielded compound 
6 (Rt = 4.9 min, 4 mg).  
            In addition, Fr. 2, the chloroform fraction isolated from Ixeris 
sonchifolia Hance extract, was further separated on a silica gel column with 
Hexane/EtOAc (85:15→10:90) as elution system to yield compound 15 (8 mg) 
and 18 (19 mg). Fr. 4, the water fraction, was separated on a reverse-phase 
silica gel column with H2O/MeOH (90:10→30:70) as elution system to yield 
compound 7 (28 mg), 16 (6 mg) and 17 (4 mg). 
 
3.2.1.3 Reactions 
        Molisch’s reaction  Samples were dissolved in 0.5 ml ethanol, and 1 ml 
α-naphthol (10%) dissolved in ethanol was added. After mixing, 0.5 ml 
concentrated sulfuric acid was slowly added down the sides of the sloping test-
tube, without mixing, to form a bottom layer. The appearance of a purple ring 
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at the interface between the acid and test layers was referred as positive result 
of the Molisch’s reaction. 
        Acid hydrolysis   Samples were refluxed with 2 M HCl for 2 h.  After 
cooling to room temperature, the reaction mixture was neutralized with 
AgNO3 and centrifuged.  The supernatant was evaporated to dryness on a 
water bath and subjected to TLC analysis on precoated silica gel 60 TLC 
plates with a elution system of n-BuOH/HOAc/H2O (4:1:5 v/v/v). An 
authentic sample of glucose was adopted for comparison. 
 
3.2.2 Quantitative HPLC analysis of compounds 1 to 5 and 7 in fractions 1 
to 4 isolated from Ixeris sonchifolia Hance extract 
 
3.2.2.1 HPLC system and mobile phase 
        An Agilent 1100 series HPLC system consisting of autosampler, 
quartpump, on-line degasser and DAD-detector (Palo Alto, USA) was adopted 
to assay the contents of the compounds that had been identified as flavonoids 
in the fractions. The separations were performed on a Waters XBridgeTM C18 
3.5 μm 150 × 4.6 mm column with solvent A (H2O + 0.8% Acetic Acid): 
solvent B (Methanol + 0.8% Acetic Acid) as mobile phase. The gradient 
elution was set at a flow rate of 1 ml/min. The injection volume and column 
temperature was set at 5 µl and 36 ℃ respectively. The detector wavelength 
was 350 nm with 410 nm as reference. The optimized linear gradient elution 
conditions were: 26% to 40% to 95% B over 28 min (0→18 min→28 min), 
then followed by an isocratic hold at 95% B for another 10 min. At 38 min, B 
was returned to 26% in 2 min and the column was equilibrated for 10 min 
before the next injection. The total run time was 50 min. The HP ChemStation 
Software was used for data analysis. 
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3.2.2.2 Sample preparations 
            The purified compounds 1 to 5 and 7 were accurately weighed and 
dissolved in DMSO to constitute 20 mM stock solutions. Fr. 1 to 4 obtained 
from Ixeris sonchifolia Hance extract were dissolved in DMSO to make stock 
solution of 20 mg/ml. All samples were filtered with a 0.22 µm nylon 
membrane filter before being loaded into the HPLC system. 
 
3.2.2.3 Calibration graphs 
            Standard curve for each flavonoid was obtained over a range of eight 
different concentrations (0.5, 1, 10, 50, 100, 250, 500 and 1000 µM) diluted 
from stock solution. Calibration curves (y = ax + b) were represented by 
plotting peak area (y) of the compounds versus the concentrations (x) of the 
calibration standards. 
 
3.2.2.4 Quality control 
            Following 72 h post-preparation of samples, the stability profiles of 
compounds 1 to 5 and 7 in DMSO were investigated in one sample run in the 
autosampler at room temperature. The intra-day precision was calculated on a 
six-time continuous injection of standard solutions with a 4 h interval; the 
inter-day precision was calculated on a four-time continuous injection of the 
same solutions with a 24 h interval. The recovery rates for each compound in 
Fr. 1 to 4 were calculated based on the addition of three different 






3.3.1 Characterization of purified compounds isolated from Ixeris 
sonchifolia Hance 
 
            Two main categories of compounds were isolated from the ethyl 
acetate fraction (Fr.3) of Ixeris sonchifolia Hance extract: flavonoids and 
sesquiterpene lactones. The isolated flavonoids were identified to be Apigenin 
(1), Luteolin (2), Apigenin-7-O-β-glucopyranoside (3), Luteolin-7-O-β-
glucopyranoside (4), Luteolin-7-O-β-glucruonopyranoside (5) and Luteolin-7-
O-β-galacturonide (6). The identified sesquiterpene lactones included 11,13α-
Dihydroixerinoside (8), Ixerinoside (9), 3-Hydroxydehydroleucodin (10), 
Ixerin Z (11), 11,13α-Dihydroixerin Z (12) and Ixerin Z1 (13). In addition to 
these two categories of compounds, Oleanolic Acid (14), a triterpenoid, was 
also isolated from this fraction.  
            Compounds 15 and 18, which were isolated from the chloroform 
fraction (Fr. 2), were elucidated as β-sitosterol and Ceryl Alcohol respectively. 
In addition to the six flavonoids isolated from the ethyl acetate fraction (Fr.3), 
one more flavonoid glycoside, Luteolin-7-O-gentibioside (7), together with 
two phenols, Vanillin (16) and Protocatechuic aldehyde (17), were obtained 
from the water fraction (Fr.4). 
 
Compound 1 Apigenin 
            Pale yellow powder, positive Mg-HCl reaction; mp. > 300℃ ; UV 
(MeOH) λmax: 260 nm, 360 nm; 1H NMR (300 MHz, DMSO-d6): δ 6.20 (1H, 
d, J = 2.0 Hz, H-8), δ 6.49 (1H, d, J = 2.0 Hz, H-6),  δ 6.77 (1H, s, H-3),  δ 
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6.94 (2H, d, J = 9.0 Hz, H-3', 5'),  δ 7.92 (2H, d, J = 9.0 Hz, H-2', 6'); 13C 
NMR (75 MHz, DMSO-d6) (Table 3.3.1.1); negative ESI-MS: m/z 269 [M-H]-. 
 
Compound 2 Luteolin 
            Yellow powder, positive Mg-HCl reaction; mp. > 300℃; UV (MeOH) 
λmax: 260 nm, 370 nm; 1H NMR (300 MHz, DMSO-d6): δ 6.13 (1H, d, J = 2.0 
Hz, H-6), δ 6.39 (1H, d, J = 2.0 Hz, H-8),  δ 6.62 (1H, s, H-3),  δ 6.86 (1H, d, 
J = 9.0 Hz, H-5'),  δ 7.38 (1H, br s, H-2'), δ 7.41 (1H, br d, H-6'); 13C NMR 
(75 MHz, DMSO-d6) (Table 3.3.1.1); negative ESI-MS: m/z 285 [M-H]-. 
 
Compound 3 Apigenin-7-O-β-glucopyranoside 
          Pale yellow powder, positive Mg-HCl reaction, positive Molisch’s 
reaction; 1H NMR (300 MHz, DMSO-d6): δ 5.07 (1H, d, J = 7.5 Hz, H-1''), δ 
6.45 (1H, d, J = 2.0 Hz, H-6),  δ 6.83 (1H, d, J = 2.0 Hz, H-8),  δ 6.87 (1H, s, 
H-3),  δ 6.94 (2H, d, J = 8.5 Hz, H-3', 5'), δ 7.96 (2H, d, J = 8.5 Hz, H-2', 6'); 
13C NMR (75 MHz, DMSO-d6) (Table 3.3.1.1); negative ESI-MS: m/z 431 
[M-H]-, 269 [M-162-H]-. 
 
Compound 4 Luteolin-7-O-β-glucopyranoside 
            Yellow powder, positive Mg-HCl reaction, positive Molisch’s reaction; 
1H NMR (300 MHz, DMSO-d6): δ 5.09 (1H, d, J = 7.5 Hz, H-1''), δ 6.45 (1H, 
d, J = 2.0 Hz, H-6),  δ 6.76 (1H, s, H-3),  δ 6.79 (1H, d, J = 2.0 Hz, H-8),  δ 
6.91 (1H, d, J = 9.0 Hz, H-5'), δ 7.43 (1H, br s, H-2'), δ 7.47 (1H, d, J = 2 Hz, 
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H-6'); 13C NMR (75 MHz, DMSO-d6) (Table 3.3.1.1); negative ESI-MS: m/z 
447 [M-H]-, 285 [M-162-H]-. 
 
Compound 5 Luteolin-7-O-β-glucruonopyranoside 
            Yellow amorphous powder, positive Mg-HCl reaction, positive 
Molisch’s reaction; 1H NMR (300 MHz, DMSO-d6): δ 5.29 (1H, d, J = 6.0 Hz, 
H-1''), δ 6.48 (1H, br s, H-6),  δ 6.76 (1H, s, H-3),  δ 6.83 (1H, br s, H-8),  δ 
6.91 (1H, d, J = 8.0 Hz, H-5'), δ 7.44 (1H,br s, H-2'), δ 7.47 (1H, br s, H-6'), δ 
13.01 (-OH); 13C NMR (75 MHz, DMSO-d6) (Table 3.3.1.1); negative ESI-
MS: m/z 461 [M-H]-, 285 [M-176-H]-. 
 
Compound 6 Luteolin-7-O-β-galacturonide 
            Yellow powder, positive Mg-HCl reaction, positive Molisch’s reaction; 
1H NMR (300 MHz, DMSO-d6): δ 5.11 (1H, d, J = 6.0 Hz, H-1''), δ 6.80 (1H, 
d, J = 2.0 Hz,  H-6),  δ 6.69 (1H, s, H-3),  δ 6.85 (1H, d, J = 2.0 Hz, H-8),  δ 
6.86 (1H, d, J = 8.0 Hz, H-5'), δ 7.37 (1H, dd, J = 2.0, 2.0 Hz, H-6'), δ 7.43 
(1H, J = 2.0, H-2'); 13C NMR (75 MHz, DMSO-d6) (Table 3.3.1.1); negative 
ESI-MS: m/z 475[M+CH3OH-H2O-H]-, 461 [M-H]-, 285 [M-176-H]-. 
 
Compound 7 Luteolin-7-O-gentibioside 
            Yellow amorphous powder, positive Mg-HCl reaction, positive 
Molisch’s reaction; 1H NMR (300 MHz, DMSO-d6): δ 5.11 (1H, d, J = 7.0 Hz, 
H-1''), δ 6.53 (1H, br s, H-6),  δ 6.75 (1H, br s, H-8),  δ 6.83 (1H, s, H-3), δ 
6.94 (1H, d, J = 8.5 Hz, H-5'), δ 7.48 (1H, br s, H-6'); 13C NMR (75 MHz, 
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Fig 3.3.1.1 Chemical structures of compounds 1 to 7. Compounds 1 to 7 were 
identified as Apigenin (1), Luteolin (2), Apigenin-7-O-β-glucopyranoside (3), 
Luteolin-7-O-β-glucopyranoside (4), Luteolin-7-O-β-glucuronopyranoside (5), 





Table 3.3.1.1 13C-NMR spectral data for compounds 1 to 7 which were 
identified as Apigenin (1), Luteolin (2), Apigenin-7-O-β-glucopyranoside (3), 
Luteolin-7-O-β-glucopyranoside (4), Luteolin-7-O-β-glucruonopyranoside (5), 
Luteolin-7-O-β-galacturonide (6) and Luteolin-7-O-gentibioside (7) 
respectively. (75 MHz; compounds 1 to 7 in DMSO-d6; δ  in ppm). 
Position 1 2 3 4 5 6 7  
2 164.1 165.9 164.2 164.7 164.6 164.4 164.6 
3 102.8 102.4 103.0 103.4 103.1 102.7 103.1 
4 181.7 181.3 181.9 182.1 181.9 181.7 181.9 
5 161.4 157.3 161.3 157.1 161.2 160.9 157.0 
6 98.8 99.2 99.8 99.7 99.4 99.4 99.6 
7 163.7 163.6 162.9 163.1 162.5 162.8 162.9 
8 93.9 94.0 94.7 94.9 94.6 94.4 94.8 
9 157.2 161.3 156.8 161.3 157.0 156.8 161.2 
10 103.6 102.9 105.2 105.5 105.5 105.1 105.4 
1′ 121.1 120.8 120.9 121.6 121.3 120.9 121.4 
2′ 128.4 112.9 128.5 113.8 113.7 113.4 113.7 
3′ 115.9 145.9 115.9 145.9 145.8 145.9 145.8 
4′ 161.1 150.5 161.0 150.1 150.0 150.2 150.0 
5′ 115.9 115.9 115.9 116.2 116.5 116.0 116.1 
6′ 128.4 118.8 128.5 119.4 119.1 118.8 119.2 7-Glc II
1′′ - - 99.4 100.1 99.2 99.3 99.8 103.5
2′′ - - 73.0 73.3 71.3 73.9 73.5 73.1
3′′ - - 77.1 76.6 72.8 72.8 77.0 76.3
4′′ - - 69.4 69.7 75.7 71.8 70.1 68.6
5′′ - - 76.3 77.4 75.4 76.2 76.8 75.4




Compound 8 11, 13-Dihydroixerinoside 
            White amorphous powder; positive Molisch’s reaction; mp: 187 - 
189 ℃; UV (MeOH) λmax: 226 nm; IR (KBr) νmax: 3400 (OH), 1760, 1678, 
1640 cm-1; 1H NMR (300 MHz, Pyridine-d5) δ 0.67 (3H, d, J = 6.0 Hz, H-14), 
1.25 ( 3H, d, J = 6.0 Hz, H-13), 2.11 (3H, s, H-15), 2.41 (1H, m, H-10), 3.62 
(1H, overlapped with H-6′, H-9), 4.96 (1H, d, J = 6.0 Hz, H-1′),  6.07 (1H, s, 
H-3); 13C NMR (75 MHz, Pyridine-d5) (Table 3.3.1.2); negative ESI-MS: m/z 



































Fig 3.3.1.2 Chemical structure (A) and important HMBC (B) and NOESY (C) 
correlations of compound 8 which was elucidated as 11,13-dihydroixerinoside. 
 
            The molecular formula for compound 8 was deduced as C21H30O9 on 
the basis of its ESI-TOF-MS ([M-H]－, m/z 425.1812) in tandem with the 13C 
and 1H NMR spectra.  IR spectrum of compound 8 revealed absorption bands 
of a hydroxyl group (υOH 3400 cm-1), a γ-lactone group (υC=O 1760 cm-1), and 
an α,β-unsaturated five member ring carbonyl moiety (υC=O 1678, υC=C 1640 
cm-1).  On acid hydrolysis, 8 gave glucose that was identified by comparison 
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with authentic glucose samples on co-TLC and by 13C NMR signals [δ 103.9 
(C-1′), 75.1 (C-2′), 79.7 (C-3′), 71.6 (C-4′), 79.0 (C-5′) and 63.1 (C-6′)].  The 
13C NMR spectrum displayed signals of an α,β-unsaturated ketone at δ 210.8 
(C-2), 132.3 (C-3), and 179.9 (C-4).  Furthermore, the 13C NMR spectrum 
revealed a lactone carbonyl at δ 178.3 (C-12), and two carbons bearing oxygen 
at δ 81.6 (C-6) and 79.7 (C-9).  The 1H NMR spectrum displayed the 
characteristic signals of three methyl groups at δ 0.67 (3H, d, J = 6.0 Hz, H-
14), 1.22 (3H, d, J = 6.0 Hz, H-13), and 2.11 (3H, s, H-15), of which the latter 
clearly depicted a vinyl methyl group.  The spectrum also revealed an 
anomeric proton of a sugar moiety at δ 4.96 (1H, d, J = 6.0 Hz, H-1′), whose 
coupling constant affirmed the presence of a β-glycosidic linkage.  The 
linkage position of the sugar moiety to the aglycone was determined and 
confirmed by HMBC experiment (Fig 3.3.1.2B).  The 1H NMR spectral data 
of 8 and 9 showed close similarities, suggesting similarities between the 
configurations at the C-5, C-6, C-7 and C-9 positions for the two compounds.  
However, 1H NMR spectrum of compound 8 revealed a methyl proton (CH3-
13) at δ 1.22 (3H, d, J = 6.0 Hz, H-13) that was missing in compound 9.  In 
contrast, the methylene proton of a terminal olefinic double bond at δ 5.38 and 
6.22 (each 1H, d, J = 3.0 Hz) in the spectrum of compound 9 was clearly 
missing in the spectrum of compound 8.  In addition, the 13C NMR signal of 
C-13 showed a significant upfield shift from δ 119.3 (compound 9) to 12.8 
(compound 8).  These shifts could be explained by a hydrogenation at C-13 of 
the α-methylene-γ-lactone unit in compound 9.  The stereochemistry of the 
aglycone part was determined by NOESY experiments (Fig 3.3.1.2C).  Based 
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on these spectral analyses, the structure of 8 was elucidated to be 11,13-
dihydroixerinoside. 
 
Compound 9 Ixerinoside 
            Yellow amorphous powder, 1H NMR (300 MHz, Pyr-d5) δ 0.66 (3H, d, 
J = 6.0 Hz, H-14), δ 2.14 (3H, s, H-15), δ 2.46 (1H, s, H-10), δ 3.65 (1H, 
overlapped with H-6′, H-9), δ 5.01 (1H, d, J = 9.0 Hz, H-1′), δ 6.09 (1H, s, H-
3), δ 5.38, 6.22 (e.a. 1H, d, J = 3.0 Hz, H-13); 13C NMR (75 MHz, Pyr-d5) 




























9 10  
Fig 3.3.1.3 Chemical structures of compound 9 and 10 which were identified 
as Ixerinoside and 3-Hydroxydehydroleucodin respectively. 
 
Compound 10 3-Hydroxydehydroleucodin 
            Yellow amorphous powder,  1H NMR (300 MHz, DMSO-d6) δ 2.03 
(3H, s, H-14), δ 2.50 (3H, s, H-15), δ 3.05 (1H, m, H-7), δ 3.50 (1H, d, J = 
10.0 Hz, H-5), δ 3.58 (1H, t, J = 10.0 Hz, H-6), δ 5.58, 6.00 ( e.a. 1H, d, J = 
3.0 Hz, H-13); 13C NMR (75 MHz, DMSO-d6) (Table 3.3.1.2); negative ESI-




Compound 11 Ixerin Z 
            Amorphous powder, 1H NMR (300 MHz, Pyr-d5) δ 2.47 (3H, s, H-14), 
δ 2.35 (3H, s, H-15), δ 2.75 (1H, br. t, J =12.0 Hz, H-7), δ 1.89 (1H, br. d, J = 
12.0 Hz, H-9), δ 2.10 (1H, m, H-9), δ 3.23 (1H, d, J = 9.0 Hz, H-5), δ 3.18 
(1H, dd, J = 9.0, 12.0 Hz, H-6), δ 1.06 (1H, dd, J = 12.0, 8.0 Hz, H-8), δ 2.31 
(1H, overlapped, H-8), δ 6.33 (1H, d, J = 6.0 Hz, H-1′), δ 5.38, 6.18 ( e.a. 1H, 
d, J = 3.0 Hz, H-13); 13C NMR (75 MHz, Pyr-d5) (Table 3.3.1.2); negative 
ESI-MS: m/z 421 [M-H]-. 
 
Compound 12 11,13α-Dihydroixerin Z 
            Amorphous powder, 1H NMR (300 MHz, Pyr-d5) δ 1.17 ( 3H, d, J = 
9.0 Hz, H-13), δ 2.45 (3H, s, H-14), δ 2.32 (3H, s, H-15), δ 3.15 (1H, m, H-5), 
δ 3.24 (1H, m, H-6), δ 6.35 (1H, d, J = 9.0 Hz, H-1′); 13C NMR (75 MHz, Pyr-
d5) (Table 3.3.1.2); negative ESI-MS: m/z 423 [M-H]-. 
 
Compound 13 Ixerin Z1 
            Amorphous powder, 1H NMR (300 MHz, Pyr-d5) δ 2.47 (3H, s, H-14), 
δ 2.33 (3H, s, H-15), δ 2.77 (1H, br. s, H-7), δ 3.28 (1H, H-5, overlapped with 
H-6), δ 3.30 (1H, H-6), δ 6.17 (1H, d, J = 6.0 Hz, H-1′), δ 5.36, 6.18 ( e.a. 1H, 
d, J = 3.0 Hz, H-13), δ 3.70 (2H, s, H-2″), δ 7.32 (2H, d, J = 8.0 Hz, H-4″, 8″), 
δ 7.13 (2H, d, J = 8.0 Hz, H-5″, 7″); 13C NMR (75 MHz, Pyr-d5) (Table 




Table 3.3.1.2 13C-NMR spectral data for compounds 8 to 13 which were 
elucidated as 11,13-dihydroixerinoside (8), Ixerinoside (9), 3-
Hydroxydehydro-leucodin (10), Ixerin Z (11), 11,13α-Dihydroixerin Z (12) 
and Ixerin Z1 (13) respectively. (75 MHz; compounds 8, 9, 11, 12 and 13 in 
C5D5N and compound 10 in DMSO-d6; δ  in ppm). 
Position 8 9 10 11 12 13 a) 
1 47.5 47.4 153.2 153.1 153.3 152.6 
2 210.8 210.8 188.8 189.0 189.2 188.6 
3 132.2 132.5 152.1 153.7 153.8 153.2 
4 179.9 179.7 135.1 146.0 146.7 146.5 
5 53.2 53.0 51.2 52.4 47.6 46.5 
6 81.6 81.8 85.8 85.1 84.9 84.6 
7 44.2 41.0 46.7 47.9 55.6 51.9 
8 30.2 29.9 23.7 24.1 25.7 23.6 
9 79.7 80.1 36.1 36.9 37.3 36.4 
10 40.0 40.2 128.8 129.0 129.6 129.1 
11 41.1 139.8 139.0 139.5 41.0 139.1 
12 178.3 169.8 169.0 169.1 177.5 168.7 
13 12.8 119.3 118.2 118.0 12.3 117.5 
14 13.7 13.6 21.3 21.7 21.6 21.2 
15 18.6 18.8 13.9 14.9 15.0 14.5 
1′ 103.9 104.6  101.7 101.8 101.4 
2′ 75.1 75.1  75.4 75.5 74.8 
3′ 79.7 79.1  78.3 78.4 77.6 
4′ 71.6 71.7  71.1 71.2 70.7 
5′ 79.0 78.4  78.7 78.8 75.1 
6′ 63.1 63.2  62.3 62.4 64.2 
 
a) p-Hydroxyphenylacetyl resonances of 13 at δC 171.6 (C-1′′), 39.8 (C-2′′), 
124.6 (C-3′′), 130.5 (C-4′′, 8′′), 115.7 (C-5′′, 7′′), and 157.4 (C-6′′). 





















11  R=H         
12  R=H 11,13-2H






Fig 3.3.1.4 Chemical structures of compounds 11 to 13 which were identified 
as Ixerin Z (11), 11,13α-Dihydroixerin Z (12) and Ixerin Z1 (13) respectively. 
 
            The remaining compounds 14 to 18 were identified as Oleanolic Acid, 
β-sitosterol, Vanillin, Protocatechuic aldehyde and Ceryl Alcohol respectively. 
As they were prototypical compounds commonly found in natural products, 















Fig 3.3.1.5 Chemical structures of compounds 14 to 18 which were identified 
as Oleanolic Acid (14), β-sitosterol (15), Vanillin (16), Protocatechuic 
aldehyde (17) and Ceryl Alcohol (18) respectively. 
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3.3.2 Quantitative HPLC analysis of compounds 1 to 5 and 7 in fractions 1 
to 4 isolated from Ixeris sonchifolia Hance extract 
            The retention times for compounds 1 to 5 and 7 were 26.13, 25.20, 
22.07, 17.69, 17.06 and 13.34 min respectively. Typical chromatograms are 
presented in Fig 3.3.2.1A. These profiles showed that no interferences existed 
under the conditions adopted for HPLC analysis. The linear relationship, 
correlation coefficients r2 and limits of detection were listed in Table 3.3.2.1. 
The regression equations for calibration curves at the range of 0.5-1000 µM 
display a good linearity with the r2 values ranging from 0.9998 to 0.9999. The 
stock solutions of compounds 1 to 5 and 7 were found to be stable for at least 
72 h under room temperature. The precision of the method was evaluated by 
the inter- and intra-day assays at three different concentrations of these 
compounds. The repeatability for inter-day and intra-day was 0.45 - 2.97% 
R.S.D. The accuracy of the method, which was studied by calculating the 
mean recovery rate of the compounds by adding standards to the fractions had 
also met the acceptable criteria. Contents of compounds 1 to 5 and 7 in Fr. 1 to 
4 are displayed in Table 3.3.2.1. While none or minor of compounds 1 to 5 
and 7 were detected in Fr. 1 and 2, all of them presented  in Fr. 3 with 
compound 1 and 7 registering the highest (3.7%, w/w) and the lowest (0.37%, 
w/w) content respectively. High quantity of compound 7 (0.45%, w/w) was 






Table 3.3.2.1 Linear regression, r2 values, detection limits and quantity measurement of compounds 1 to 5 and 7 in fractions 1 to 4  
by HPLC analysis.  
 





















y = 5.0159x 
+ 0.9429 
y = 4.827x 
- 2.5915 
y = 5.6499x 
- 6.1079 
y = 3.8521x 
+ 9.0277 
y = 4.6622x 
- 12.614 
y = 3.0819x 
+ 0.1152 
r2 0.9999 0.9998 0.9999 0.9999 0.9999 0.9998 




































Fr. 1 (w/w, %) - - - - - - 
Fr. 2 (w/w, %) 0.018 ± 0.001 0.014 ± 0.005 - - - - 
Fr. 3 (w/w, %) 3.679 ± 0.045 0.675 ± 0.008 0.732 ± 0.011 0.794 ± 0.014 0.448 ± 0.006 0.369 ± 0.002 









Fig 3.3.2.1 Representative HPLC profiles for purified compounds 1 to 5 and 7 
(A) and fractions 1 to 4 (B-E). The separations and analysis were performed 
on an Agilent 1100 series HPLC system with solvent A (H2O + 0.8% Acetic 
Acid): solvent B (Methanol + 0.8% Acetic Acid) as mobile phase. The 
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gradient elution was set at a flow rate of 1 ml/min and the optimized linear 
gradient elution conditions were: 26% to 40% to 95% B over 28 min (0→18 
min→28 min), then followed by an isocratic hold at 95% B for another 10 min. 
At 38 min, B was returned to 26% in 2 min and the column was equilibrated 
for 10 min before the next injection. The injection volume and column 
temperature was set at 5 µl and 36  respectively. The detector wavelength 
was 350 nm with 410 nm as reference.  
 
3.4 Discussion and conclusions 
            In this chapter, isolation work focused on the ethyl acetate fraction (Fr. 
3) of Ixeris sonchifolia Hance had revealed the presence of two classes of 
compounds: flavonoids and sesquiterpene lactones. Sesquiterpene lactones are 
a class of terpenes with a molecular formula C15H24 that comprises three 
isoprene units. They can be classified into six categories based on their 
skeletal structure: Guaianolides, Germacranolides, Heliangolides, 
Pseudoguaianolides, Hypocretenolides and Eudesmanolides (Fig 3.4.1). All 
the sesquiterpene lactones isolated from the ethyl acetate fraction of Ixeris 


















Fig 3.4.1 Structures of sesquiterpene lactones. A and B: Guaianolides; C: 
Germacranolides; D: Heliangolides; E: Pseudoguaianolides; F: 
Hypocretenolides; G: Eudesmanolides. 
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            Flavonoids are a class of plant secondary metabolites and can be 
classified into flavonoids, isoflavonoids and neoflavonoids (Fig 3.4.2). Based 
on the presence of a 3-hydroxyl or/and 2,3-dihydro substitution, flavonoids are 
subdivided into four subgroups, namely flavone, flavonol, flavanone and 
flavanonol (Fig 3.4.3). The six flavonoids (Apigenin, Luteolin, Apigenin-7-O-
β-glucopyranoside, Luteolin-7-O-β-glucopyranoside, Luteolin-7-O-β-
glucruonopyranoside and Luteolin-7-O-β-galacturonide) isolated from Fr. 3, as 
well as the flavonoid glycoside (Luteolin-7-O-gentibioside) isolated from Fr. 4, 





O A B C  
Fig 3.4.2 Skeletal structures of flavonoids (A), isoflavonoids (B) and 













         R             
A        H               
B       OH              
C        H       2, 3-dihydro 
D       OH     2,3-dihydro  
Fig 3.4.3 Skeletal structures of subgroups of flavonoids. (A) flavones; (B) 
flavonol; (C) flavanone and (D) flavanonol 
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            Pharmacological studies on sesquiterpene lactones have recently 
demonstrated variety of biological activities such as cytotoxicity (Kim et al., 
2007; Suzuki et al., 2007; Tabopda et al., 2007; Yang et al., 2007; Yang et al., 
2007), antimalarial (Bischoff et al., 2004; Pedersen et al., 2009), antibacterial 
(Theodori et al., 2006) and herbicidal (Macias et al., 2000) effects. If 
overdosed, sesquiterpene lactones can cause allergic reactions and toxicities 
(Stampf et al., 1978). On the contrary, flavonoids are found ubiquitously in 
plants and among the most common group of polyphenolic compounds in the 
diet of humans and animals. Biological studies on this category of compounds 
revealed health-modulating effects, such as anti-allergic (Muthian et al., 2004), 
anti-inflammatory (Kao et al., 2005; Lim et al., 2006; Zhou et al., 2009), anti-
microbial (Cushnie et al., 2005; Alvarez et al., 2008; Pistelli et al., 2009) and 
anti-cancer (Choi et al., 2009; Guo et al., 2009; Jung et al., 2009; Rajkapoor et 
al., 2009) activities. In addition, bioflavonoids, such as rutin, has been found 
to exhibit potential vasoprotective proprieties and significantly reduce the 
myocardial antioxidant status and infarct size on MI/R rats (Ali et al., 2009). 
Studies on the cytoprotective effects of compounds 1 to 5 on H2O2-exposed 
SH-SY5Y cells also revealed that the H2O2-induced cytotoxicity could be 
significantly attenuated by the isolated flavonoid compounds (the research 
focus of Chapter 4). To move the project forward, the next chapters would 
focus on studying the potential protective effects of these isolated flavonoid 
compounds on oxidative injury and inflammatory reactions, which are the two 













Cytoprotective effects of flavonoid compounds isolated from 
ethyl acetate fraction of Ixeris sonchifolia Hance extract 
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4.1 Introduction  
             As discussed in Chapter 3, isolation work performed on the ethyl 
acetate fraction (Fr. 3) from Ixeris sonchifolia Hance extract had resulted in 
the identification of two classes of compounds, flavonoids and sesquiterpene 
lactones, to be present in the fraction. Flavonoids belong to a class of plant 
secondary metabolites and are among the most common group of polyphenolic 
compounds present in human diet. Biological studies conducted on this 
category of compounds have revealed their beneficial effects on cardio- and 
cerebral-vascular related diseases (Ali et al., 2009). This chapter would 
investigate the cytoprotective effects of these isolated flavonoids on H2O2-
exposed SH-SY5Y cells with the final goal to find chemical basis for potential 
stroke therapy effects of Ixeris sonchifolia Hance. Cell viabilities would be 
evaluated by MTT assay, LDH release and flow cytometery. The capacities to 
scavenge free radicals directly, as well as to induce phase Ⅱdetoxifying 
enzymes, would also be measured to see whether these anti-oxidant abilities 
contribute to their cytoprotective effects. Overall 6 flavonoids had been 
isolated from the ethyl acetate fraction of Ixeris sonchifolia Hance extract, 
which were Apigenin (1), Luteolin (2), Apigenin-7-O-β-glucopyranoside (3), 
Luteolin-7-O-β-glucopyranoside (4), Luteolin-7-O-β-glucruonopyranoside (5) 
and Luteolin-7-O-β-galacturonide (6), respectively. For lack of enough 
flavonoid 6, the bioactivity assays would be performed on flavonoids 1 to 5 
only.  
 
4.2 Materials and methods 
4.2.1 Preparation of stock solutions of flavonoid compounds 
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            Purified compounds 1 to 5 were accurately weighed and dissolved in 
DMSO to constitute 20 µM stock solutions that were stored at -20 ℃ before 
use. 
 
4.2.2 In vitro MTT cell viability assay 
            See Section 2.2.2.2 for experimental procedures.  
 
4.2.3 Determination of LDH leakage 
            SH-SY5Y cells were seeded into 6-well culture plates at a density of 1 
× 105 cells per well. The plates were then incubated for approximately 48 h at 
37  to allow cell attachment and exponential cell growth. When cells 
reached 60 – 70% confluency, compounds 1 to 5 diluted from DMSO stock 
solutions were added to attain a final concentration of 20 µM. Cells were also 
treated with 200 µM Vitamin E (served as positive control; Sigma-Aldrich Pte 
Ltd, MO, USA). To produce oxidative stress, H2O2, freshly prepared from 
30 % stock solution with PBS, was introduced (final concentration 200 µM) 
30 min following drug treatment. The cells were incubated for another 24 h at 
37 ℃, after which the culture medium was gently collected and centrifuged 
(4,000 g, 5 min, 4 ) to obtain the cell-free supernatant for measurement of 
lactate adhydrogenase (LDH) levels. The release of LDH, an in vitro marker 
for cellular toxicity, was determined using an assay kit (Nanjing Jiancheng 
Bioengineering Institute, China) according to the manufacturer’s protocol. 
 
4.2.4 Flow cytometric analysis of cell death 
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            SH-SY5Y cells were seeded into 6-well plates at a density of 1 × 105 
cells per well. Upon cell attachment and exponential cell growth to 60 – 70% 
confluency, the cells were treated with compounds 1 to 5 for 24 h at indicated 
concentrations. Attached and detached cells were then pooled together and 
centrifuged at 1,200 rpm, 4 ℃ for 5 min to obtain cell pellet. After washing 
twice with ice-cold PBS, the cell pellets were fixed with 1 ml of 70% ice-cold 
ethanol for a minimum of 4 h at 4 ℃. The fixed cells were washed with ice-
cold PBS, and resuspended in 100 µl of PBS containing 100 μg/ml 
ribonuclease A (Sigma-Aldrich Pte Ltd, MO, USA). Finally, 400 µl of 
propidium iodide (PI, 50 μg/ml, purchased from Sigma-Aldrich Pte Ltd, USA) 
was added and the cell samples were left in darkness at room temperature for 
30 min. The tubes were shaken occasionally to maintain the cells in 
suspension (Zhao et al., 2010). PI-stained cells were then analyzed by a BD 
FACSCalibur™ flow cytometer (BD Biosciences, CA, USA). Cell death was 
measured as the percentage of cell population with a sub-G0/G1 DNA content 
in the PI intensity-area histogram plot. 
 
4.2.5 Determination of free radical scavenging activity 
            See Section 2.2.2.3a for experimental procedures. 
 
4.2.6 ARE-dependent luciferase reporter assay 
            See Section 2.2.2.3b for experimental procedures. Briefly, SH-SY5Y 
cells contransfected with pGL3-ARE and pRL-CMV plasmids were treated 
with 5, 10 and 20 µM of compounds 1 to 5, as well as 10 µM of sulforaphane 
(used as a positive control in this assay) for 14 h before firefly and renilla 
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luciferase activities were assayed using the Dual Luciferase® Assaay System 
(Promega, WI, USA). 
 
Western blot analysis 
            See Section 2.2.2.3b for experimental procedures. Briefly, SH-SY5Y 
cells were treated with 5 and 20 µM of compounds 1 to 5 for 12 h and 24 h, 
and the collected cell lysates were subjected to SDS-PAGE. Antibodies 
against HO-1 (Stressgen Biotechnologies Corporation, CA, USA), Nrf2, 
NQO1 and β-actin (Santa Cruz Biotechnology Inc., CA, USA) were used to 
probe for the cellular levels of the respective proteins. 
 
GSH measurement 
            See Section 2.2.2.3b for experimental procedures. 
 
4.2.7 Statistical analysis  
            Data were expressed as means ± S.D. (or means ± SEM) and the 
Student’s t - test was used for comparison between treatment groups. 
Difference was considered significant at p < 0.05. 
 
4.3 Results 
4.3.1 Effects of flavonoid compounds 1 to 5 on the viability of H2O2-
exposed SH-SY5Y cells 
 
            MTT cell viability assays were carried out where SH-SY5Y cells were 
exposed to a range of concentrations of H2O2 (50 - 500 µM) for 24 h. As 
shown in Fig 4.3.1.1A, 24 h exposure of 150 - 500 µM of H2O2 dose-
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dependently caused a decrease in cell viability. Cell viability was reduced to 
around 70% and 20% after a 24 h-exposure to 200 and 500 µM H2O2 
respectively. When the cells were treated with 30 µM of the purified flavonoid 
compounds 1 to 5 alone, viability remained largely unaffected (Fig 4.3.1.1B). 
In contrast, pre-treatment of the cells with different concentrations of 1 to 5 
before H2O2 challenge brought about varied results. It was observed that in a 
dose-dependent manner, pre-treatment with compounds 2, 4 and 5 between 2 
to 25 µM for durations 12 to 72 h resulted in significant attenuation of H2O2-
induced cytotoxicity (Fig 4.3.1.1C-F). However, these flavonoids at higher 
concentrations, particularly at 100 µM, displayed a marked reduction in 
cytoprotective abilities (Fig 4.3.1.1C-F). Compound 3 at all doses failed to 
display impressive cytoprotective effects as compared to 2, 4 and 5. 
Interestingly, among the isolated flavonoids, combined addition of compound 
1 apigenin and H2O2 produced obvious cytotoxicity instead of cytoprotective 
actions; cell viability had dropped to less than 20% of the viability of 
untreated control cells upon cell exposure to 100 µM compound 1 and 200 µM 












Fig 4.3.1.1 Effects of flavonoid compounds 1 to 5 on the viability of H2O2-
exposed SH-SY5Y cells. (A) Effects of different concentrations of H2O2 on 
cell viability. Cell viability was assessed using MTT assay following 24 h-
exposure to H2O2. (B) Effect of 24 h-treatment with flavonoid compounds 1 to 
5 (30 µM) on cell viability. (C-F) Effects of co-administration of flavonoid 
compounds 1 to 5 and H2O2 on SH-SY5Y cells. Cells were pre-treated with 
different concentrations of flavonoid compounds 1 to 5 for 30 min, followed 
by H2O2 addition to a final concentration of 200 µM. Cell viability was 
determined at time points 12 h (C), 24 h (D), 48 h (E) and 72 h (F). # p < 0.05, 






Fig 4.3.1.2 Effect of 24 h-treatment with flavonoid compounds 1 to 5 on LDH 
release from H2O2-exposed SH-SY5Y cells. Cells were pre-treated with 30 
µM flavonoid compounds 1 to 5 for 30 min, followed by H2O2 addition to a 
final concentration of 200 µM. LDH levels in the culture medium were 
quantified after a 24 h-treatment. # p < 0.05, ## p < 0.01 versus untreated 
control; * p < 0.05 versus H2O2 group.         
 
            To further investigate the possible protective effect of flavonoid 
compounds 1 to 5 against H2O2-induced toxicity on SH-SY5Y cells, the 
release of lactate dehydrogenase into the culture medium, an in vitro marker 
for cellular toxicity, was measured. As depicted in Fig 4.3.1.2, 24 h exposure 
of 200 µM of H2O2 resulted in an increase in LDH release from SH-SY5Y 
cells into the culture medium. While pre-treatment of the cells with 30 µM of 
compound 1 before H2O2 challenge exacerbated the H2O2-induced cytotoxicity, 
pre-treatment of the cells with compounds 2, 4, 5 at 30 µM and vitamin E (Vit. 
E) at 200 µM brought about moderate attenuation in the H2O2-induced LDH 
release, with compound 4 showing the greatest cytoprotective effect. The 
activities of LDH released from the compounds 4 and Vit. E pre-treated cells 
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were reduced to a low level that was comparable to that of DMSO control 
(compared with DMSO control, p > 0.05).   
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Fig 4.3.1.3 Effect of 24 h-treatment with flavonoid compounds 1 to 5 on the 
subG0/G1 DNA content in H2O2-exposed SH-SY5Y cells. Untreated and 
treated cells were harvested and labeled with PI, and analyzed by flow 
cytometry. Representative flow cytometric histograms of untreated cells (A) 
and cells exposed to 200 µM H2O2 for 24 h (B) showed an accumulation of 
subG0/G1 DNA content in the H2O2-treated cells. (C) Cells were treated with 
30 µM of flavonoid compounds 1 to 5 for 30 min prior to 24 h exposure of 
H2O2 (200 µM) and percentage of cells with subG0/G1 DNA content was 
analyzed by flow cytometry. ## p < 0.01 versus untreated control; * p < 0.05, 




            Furthermore, flow cytometry analysis of PI-stained SH-SY5Y cells 
treated or untreated with compounds 1 to 5 (30 µM) and H2O2 (200 µM) 
revealed that compounds 2, 4 and 5 brought about a statistically significant 
reduction in the population of cells with subG0/G1 DNA content (Fig 4.3.1.3). 
As detection of subG0/G1 DNA content was indicative of cell death, these 
findings, in agreement with results obtained from the MTT and LDH release 
assay, suggested that the isolated flavonoids, in particular compounds 2, 4 and 
5, exerted a cytoprotective effect.  
 
4.3.2 Antioxidant activities of flavonoid compounds 1 to 5 isolated from 




Fig 4.3.2.1 DPPH free radical scavenging activity of flavonoid compounds 1 
to 5 isolated from Ixeris sonchifolia Hance extract. The DPPH scavenging rate 
for each sample was calculated as percentage of (Abs DPPH-only solution – Abs 
compound-treated DPPH solution) / Abs DPPH-only solution. * p < 0.05, **p < 0.01 versus 
solution containing only DPPH. 
 
            In the in vitro free radical scavenging assay, while flavonoids 1 and 3 
exhibited little activity, flavonoid compounds 2, 4 and 5, even at a 
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concentration of 10 µM, were found to scavenge DPPH free radical effectively 
(p < 0.01). Compounds 2 and 4 from 25 to 100 µM, as well as compound 5 
between 50 to 100 µM displayed antioxidant capacity comparable to that of 










Fig 4.3.2.2 Representative Western blot analysis of protein levels of 
transcription factor Nrf2 in SH-SY5Y cells treated with flavonoid compounds 
1 to 5. Cells were treated with 5 and 20 µM of compounds 1 to 5 for 12 and 24 
h and whole cell lysates were collected for SDS-PAGE and Western blot 
analysis of Nrf2 protein levels. β-actin immunodetection was carried out to 
verify equal protein loading. 
             
            The antioxidant activity of a compound could be a result of the 
compound’s direct and indirect effect. While the free radical scavenging 
activity would be a measure of the compound’s direct antioxidant effect, the 
compound might exert indirect antioxidant activity by inducing the expression 
of antioxidant and cytoprotective enzymes through upregulation of Nrf2-
mediated ARE-dependent transactivation. To determine whether the isolated 
flavonoid compounds 1 to 5 possessed the latter biological effect, protein 
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levels of transcription factor Nrf2 in lysates of SH-SY5Y cells treated with 
compounds 1 to 5 were analyzed by Western blotting. As depicted in the 
representative Western blot in Fig 4.3.2.2, all flavonoid compounds 1 to 5, at 
concentrations of 5 and 20 µM were found to upregulate Nrf2 protein levels at 
both time points (12 and 24 h). The use of proteasome inhibitor MG-132 
served the purpose of prevention Nrf2 degradation so as to aid in locating the 
Nrf2 protein band on the Western blot films.  
 
 
Fig 4.3.2.3 Effects of flavonoid compounds 1 to 5 isolated from Ixeris 
sonchifolia Hance extract on ARE-dependent transcriptional activity. SH-
SY5Y cells cotransfected with pGL3-ARE and pRL-CMV were treated with 
compounds 1 to 5 or 10 µM solforaphane (SF) for 14 h. Ratios of firefly 
luciferase activities normalized to renilla luciferase activities were determined.  
* p < 0.05, ** p < 0.01 versus DMSO control group. 
 
          The effects of these compounds on ARE-dependent transcriptional 
activity were next determined. Results revealed that in agreement with the 
observed enhanced accumulation of Nrf2 (Fig 4.3.2.2), compounds 1 to 5 at 5 
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and 10 µM brought about an upregulation in ARE-dependent transcriptional 
activity, with compound 2 registering the greatest fold of induction of around 
5-fold at 10 µM (Fig 4.3.2.3). Nevertheless, this induction was not comparable 
to that brought about by 10 µM sulforaphane (~ 9-fold). Notably, it was also 
observed that the addition of these isolated compounds at a higher 
concentration of 20 µM generally failed to elevate significantly ARE-
dependent transcriptional activity (Fig 4.3.2.3).             
24  h








Fig 4.3.2.4 Representative Western blot analysis of protein levels of HO-1 and 
NQO1 in SH-SY5Y cells treated with flavonoid compounds 1 to 5. Cells were 
treated with 5 and 20 µM of compounds 1 to 5 for 12 and 24 h and whole cell 
lysates were collected for SDS-PAGE and Western blot analysis of HO-1 and 
NQO1 protein levels. β-actin immunodetection was carried out to verify equal 
protein loading. 
 
            Finally, the expression levels of HO-1 and NQO1, which were 
cytoprotective enzymes whose expression were under the transcriptional 
activity of Nrf2, were determined. As shown in Fig 4.3.2.4, the protein level of 
HO-1 was increased within 12 h of treatment, while NQO1 level was only 
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increased marginally. The obtained results, taken together, therefore suggested 
that the isolated flavonoids from Ixeris sonchifolia Hance extract, particularly 
compound 2 luteolin, when used at low concentration of 10 µM, exhibited 
potential cytoprotective effect through its free radical scavenging activity and 
induction of ARE-dependent transcriptional activity. 
             
 
Fig 4.3.2.5 Total cellular GSH levels in SH-SY5Y cells exposed to flavonoid 
compounds 1 to 5 for 24 h. Cells were treated with 5 and 20 µM of 
compounds 1 to 5 and whole cell lysates were collected for GSH measurement 
after 24 h treatment. * p < 0.05, ** p < 0.01 versus DMSO control 
 
            The effects of flavonoids 1 to 5 on the cellular total GSH content in 
SH-SY5Y cells were also measured. As shown in Fig 4.3.2.5, treatment of 
SH-SY5Y cells with 5 µM of compounds 2, 4 and 5 for 24 h caused a slight 
increase in total GSH levels, with only compound 2 registering a statistically 
significant elevation as compared to that of DMSO control. At higher 
concentration of 20 µM, compounds 1 to 4 surprisingly caused a decline in 
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total GSH content (Fig 4.3.2.5). In particular, compounds 1 and 2 at 20 µM 
had significantly resulted in depletion of GSH by almost 50% of that in the 
DMSO control cells. 
 
4.4 Discussion and conclusions 
            Flavonoids are naturally occurring polyphenolic compounds found 
ubiquitously in vegetables, herbs, nuts and teas. Together with other dietary 
reducing agents, such as vitamin C, vitamin E and carotenoids, flavonoids 
protect the body's tissues against oxidative stress and associated pathologies 
(Jan et al., 2010). The in vitro antioxidant activities offer biological 
foundations for flavonoids’ health-modulating effects, such as anti-allergic, 
anti-inflammatory, anti-microbial and anti-cancer activities (Muthian et al., 
2004; Cushnie et al., 2005; Kao et al., 2005; Lim et al., 2006; Alvarez et al., 
2008; Pistelli et al., 2009; Zhou et al., 2009). In this chapter, the antioxidant 
activities of flavonoid compounds 1 to 5 were assayed by the in vitro DPPH 
free radical scavenging assay. The results revealed that while compounds 1 
and 3 exhibited negligible activity, compounds 2, 4 and 5 at low concentration 
of 10 µM were able to scavenge DPPH free radical effectively. 
            In addition to the direct free radical scavenging activities, the other 
important mechanism contributing to the protective effects of flavonoids is the  
capacity to induce detoxifying enzymes, such as glutathione S-transferases 
(GST), UDP-glucuronosyltransferases (UGTs), γ-glutamylcysteine synthetase 
(γ-GCS), NAD(P)H-quinone oxidoreductase 1 (NQO1) and heme oxygenase-1 
(HO-1) (Lee et al., 2005). These enzymes play a pivotal role in maintaining 
the redox homeostasis. The expression of these phase II detoxifying enzymes 
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is mediated by the antioxidant-responsive element (ARE), also known as 
electrophile-responsive element (EpRE) (Moinova et al., 1998). In this chapter, 
it was found that 12 h and 24 h treatment with 5 and 20 µM of flavonoid 
compounds 1 to 5 could upregulate Nrf2 levels in SH-SY5Y cells. The cellular 
levels of phase II enzymes HO-1 and NQO1 were also elevated, although the 
increase for NQO1 was only marginal. ARE-dependent luciferase reporter 
assays conducted on contransfected SH-SY5Y cells exposed to low doses (5 
and 10 µM) of compounds 1 to 5 had revealed a dose-dependent enhancement 
in ARE-dependent transcriptional activity, with compound 2 luteolin 
displaying the greatest fold of induction at 10 µM. However, when a higher 
concentration (20 µM) was used for all compounds, although Nrf2 protein 
levels remained elevated, the upregulation in ARE-dependent transcriptional 
activity was drastically reduced. The extract mechanism accounting for this 
decline in ARE transcriptional activity induction was not well clarified. 
Flavonoids have been demonstrated to behave as both antioxidant and 
prooxidant agents depending on the concentrations used and the free radical 
source (Liu et al., 2010). Therefore, it was postulated that at high 
concentrations of 20 µM, the predominated prooxidant action of flavonoids 
caused depletion of cellular GSH, as evident from the obtained results that 
GSH content had markedly decreased (Fig 4.3.2.5). 
            Under basal conditions, Keap1 serves as an adaptor to link Nrf2 to the 
ubiquitin E3 ligase Cul3-Rbx1 complex that ubiquitinate and degrade Nrf2 
(Kaspar et al.). When a cell encounters oxidative/electrophilic stress, Keap1 
loses the ability to negatively regulate Nrf2 such that Nrf2 accumulation leads 
to increased ARE activation to transcribe and translate a myriad of genes 
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encoding phase II enzymes (see Section 2.4). Accumulation of Nrf2 was 
proposed to be due to either a direct interaction of the drug inducer with 
Keap1 that weakened the Nrf2-Keap1 interaction or by protein kinase C 
(PKC)-mediated phosphorylation of Nrf2. The study by Lee-Hilz et al using 
EpRE-LUX cells had revealed that PKC was not involved in flavonoids 
induction of ARE-mediated gene transcription (Lee-Hilz et al., 2006). As such, 
the direct oxidant reaction with the Keap1-Nrf2 complex was proposed to be 
the mechanism underlying flavonoids’ action. The dimeric Keap1 protein 
contains multiple cysteine residues in each monomer which would likely offer 






































Fig 4.4.1 Chemical view on the oxidoreductive activation of quercetin and its 
possible reaction consequences. Quercetin is oxidized by the classic 
peroxidase mechanism to form a free radical intermediate, o-semiquinone. The 
reaction would be followed by radical-radical comproportionation reaction to 




 by which flavonoids would oxidatively interact with Keap1 is currently not 
clearly elucidated. It was proposed that electrophilic flavonoid metabolites 
could be the interacting species with Keap1’s cysteine. Metodiewa et al 
proposed the formation of free radical intermediate, o-semiquinone, during 
quercetin oxidative by the classic peroxidase mechanism (Fig 4.4.1) 
(Metodiewa D et al., 1999). The reaction would be followed by radical-radical 
comproportionation reaction to give o-quinone and parent molecule. The 
prooxidant reactive metabolites would possess electrophilic properties to 
oxidize the cysteine residues in Keap1 protein.   
            The prooxidant effects of flavonoids cause cell damage by lipid 
peroxidation, tyrosine nitration, sulfhydryl oxidation and nitrosylation and 
DNA breakage, while the anti-oxidant activities of these compounds would 
neutralize these harmful effects and restore redox homeostasis. The biological 
activities of flavonoids on cells should be the combination effects of their anti-
/prooxidant property. As demonstrated in the performed experiments, the 
H2O2-induced cytotoxicity on SH-SY5Y cells was attenuated when the cells 
were pre-treated with compounds 2, 4 and 5. The protective effect was in a 
dose-dependent manner from 2 µM to 25 µM. But when the dose exceeded 50 
µM, the cytoprotective effects decreased drastically. When analyzing the 
protective effects of compounds 1 to 5 on H2O2-induced cell death by flow 
cytometry, the results were in concert with that determined by MTT and LDH 
release assay. It could be deduced from the results that the anti-oxidant effects 
took priority over the prooxidant effects when the flavonoids were in low 
concentrations, which could reduce the H2O2-induced cytotoxicity by 
scavenging free radical directly and inducing the expression of detoxifying 
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enzymes. But when the concentration was allowed to exceed a “threshold”, the 
induced detoxifying enzymes could no longer scavenge efficiently the free 
radicals produced by the flavonoids. In doing so, flavonoids’ prooxidant 
effects took priority over the anti-oxidant effects and thus reacted with the 
antioxidant molecule GSH to produce reduced cytoprotective effects.  
            In conclusion, flavonoids 1 to 5 were found to protect cells from H2O2-
induced cytotoxiciy by scavenging free radical directly and inducing phase Ⅱ
detoxifying enzymes, suggesting that these compounds might exert 
neuroprotective effects during the early response to stroke occurrence. Since 
the second wave of cell death after stroke stems from the neuroinflammatory 
response, the next chapter will be focused on investigating whether these 
isolated flavonoid compounds would be able to exert any anti-inflammatory 












Anti-inflammatory effects of flavonoid compounds isolated 






            While the early response to stroke is characterized by excitotoxic 
damage and oxidative damage, the second wave of cell death after stroke 
stems from the neuroinflammatory response. An inflammatory reaction 
characterized by leukocyte influx into the cerebral parenchyma and activation 
of endogenous microglia occurs following ischemic stroke and hemorrhage 
stroke (Hallenbeck, 1996; Becker, 1998; Zheng et al., 2004), and leads to 
inflammatory injury to the neural tissues. The activated inflammatory cells 
release a variety of agents including cytokines, matrix metalloproteinases 
(MMPs), nitric oxide (NO) and reactive oxygen species (ROS). These 
substances may trigger more cell damage as well as disruption of the blood-
brain barrier (BBB) and extracellular matrix (ECM) (Danton et al., 2003). As 
a consequence of BBB disruption, which permits serum elements and blood to 
enter the brain (Rosenberg, 1999), secondary neural damage develops through 
activation of microglia and brain infiltration of peripheral leukocytes that 
produce cascades of inflammatory events leading to exacerbation of the 
inflammatory damage (Dirnagl et al., 1999). Blockade of various aspects of 
the inflammatory cascades has been shown to ameliorate injury resulting from 
experimental stroke (Han et al., 2003). This chapter was focused on 
investigating whether the isolated flavonoid compounds from Ixeris 
sonchifolia Hance extract could exert potential anti-inflammatory activities on 
the lipopolysaccharides (LPS)-stimulated cells. 
 
5.2 Materials and methods 
5.2.1 Preparation of stock solutions of flavonoid compounds 
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            See Section 4.2.1 for preparation of DMSO stock solutions of 
flavonoid compounds 1 to 5, namely Apigenin (1), Luteolin (2), Apigenin-7-
O-β-glucopyranoside (3), Luteolin-7-O-β-glucopyranoside (4) and Luteolin-7-
O-β-glucruonopyranoside (5) respectively. 
 
5.2.2 Cell culture and treatment 
            Mouse macrophage cell line RAW 264.7 (TIB-71) was purchased from 
the American Type Culture Collection (Rockville, MD, USA) and grown in 
Dulbecco’s Modified Eagle’s Medium (DMEM; purchased from Sigma-
Aldrich Pte Ltd, MO, USA) supplemented with 10% fetal bovine serum 
(Hyclone, UT, USA), 3.7 g/L sodium bicarbonate, 100 µg/ml streptomycin 
and 100 U/ml penicillin G. The cells were incubated at 37 °C in a 5 % CO2 
humidified environment.  
            BV-2 cells, a murine microglial cell line, were obtained from Dr. Dong 
Yiyu (Department of Anatomy, National University of Singapore) and 
cultured in DMEM supplemented with 10% fetal bovine serum, at 37 °C in a 
humidified 5% CO2 atmosphere. When BV-2 cells reached 70 - 80% 
confluence in the maintenance cultures, they were trypsinized by 0.25% 
trypsin-EDTA to obtain a single cell suspension. The cell suspension was 
diluted appropriately to achieve the desired cell density in 2 ml of culture 
medium for inoculation into each well of a 6-well plate (20,000 cells/well). 




            Usually, the culture medium was changed to fresh serum-free medium 
(for RAW 264.7 cells) or fresh medium with 2% FBS (for BV-2 cells) before 
any treatment to reduce the serum effect. In all experiments, cells were pre-
treated with flavonoids 1 to 5 for 30 min before the addition of 
lipopolysaccharides (LPS; purchased from Sigma-Aldrich Pte Ltd, MO, USA).  
 
5.2.3 In vitro MTT cell viability assay 
            See Section 2.2.2.2 for experimental procedures. The macrophage 
RAW 264.7 cells and microglial BV-2 cells (5 × 103 cells) were seeded in 96-
well plates and incubated for 24 h. After replacing the culture medium with 
serum free medium (for RAW 264.7 cells) or DMEM containing 2% fetal 
bovine serum (for BV-2 cells), various concentrations of flavonoid compounds 
1 to 5, freshly prepared by diluting DMSO stock solutions in each assay, were 
then added to the wells (final concentrations 2, 5, 10 and 20 µM). The plates 
were incubated for another 24 h at 37 ℃, after which 10 µl of MTT solution (5 
mg/ml in PBS) was added into each well to evaluate the effect of compounds 
on cell viability. 
 
5.2.4 Measurement of nitric oxide release 
            The production of nitric oxide (NO) was measured by the 
accumulation of nitrite in culture media. Briefly, RAW 264.7 cells were 
seeded and cultured in 24-well plates till 80% confluence. Culture medium 
was replaced by serum-free and phenol red-free DMEM before addition of 1, 
102 
 
5 or 10 µM of flavonoid compounds 1 to 5. Following 30 min of flavonoids 
addition, 1 µg/ml LPS was added and the cells were further incubated for 24 h. 
The medium was gently collected and centrifuged (4,000 g, 5 min, 4 ℃), after 
which 100 μl of the cleared medium was added to an equal volume of Greiss 
reagent (1% sulfanilamide, 0.1% naphthylethylenediamine dihydrochloride, 
and 2.5% phosphoric acid) (Fluka BioChemika, Switzerland). The mixture 
was agitated and kept in darkness at room temperature for 15 min. The 
absorbance was read at 540 nm using a plate reader. Absorbance readings of a 
range of known nitrite concentrations derived from sodium nitrite (Sigma-
Aldrich Pte Ltd, MO, USA) were predetermined to obtain a standard plot, 
from which the nitrite concentrations detected in the collected medium 
samples were determined and expressed in micromoles per liter (Madrigal-
Carballo et al., 2009; Sae-wong et al., 2009; Yoo et al., 2009).  
 
5.2.5 RNA extraction and reverse transcription-polymerase chain 
reaction 
            After BV-2 cells were pre-treated with 2 and 10 µM of flavonoid 
compounds 1 to 5 for 30 min, LPS dissolved in PBS was introduced (final 
concentration 1 µg/ml). The drug treated plates were incubated for another 4 h 
at 37 ℃, after which total RNA from each sample was isolated using an 
RNeasy® Mini Kit (Qiagen, Hilden, Germany). Following the manufacturer’s 
instructions, cells were scraped in lysis buffer provided in this kit, and 
homogenized with a QIAshredder® homogenizer. Ethanol (70%) was mixed 
with the homogenized lysate, and the mixture was applied on a RNeasy spin 
column to remove ethanol. After washing the RNeasy spin column with wash 
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buffers, RNA was finally eluted in RNase-free water. The concentration of 
extracted RNA was determined by measurement of absorbance at 260 nm on 
an UV spectrophotometer (Ultro Spec 2100 Pro UV/visible spectrophotometer, 
Amersham Biosciences, Sweden). 
            Single-stranded cDNA was synthesized from 2 µg of RNA by reverse 
transcription using a RevertAidTM First Strand cDNA Synthesis Kit 
(Fermentas, MD, USA). An appropriate volume containing 2 µg of total RNA 
was mixed with 1 µl Oligo18 primer and made up finally to 12 µl with 
nuclease-free water. The mixture was incubated in 70 ℃  for 5 min, and 
subsequently mixed with reaction buffer, RiboLockTM Ribonuclease inhibitor 
and deoxyribonucleoside triphosphate (dNTP) for 5 min at 37 ℃. 
RevertAidTM M-MuLV Reverse Transcriptase was next added to the above 
mixture and incubated at 42 ℃ for 60 min for reverse transcription to occur. 
The reverse transcription was stopped by heating at 70 ℃ for 10 min. The 
resulting cDNA was stored at -20 ℃ until use.  
            Fragments specific to genes to be examined were amplified in reaction 
solution (20 µl) containing 2 µl of generated cDNA, 2 µl of dNTP, 0.2 µl of 
Taq DNA Polymerase (New England BioLabs® Inc., UK) and 1 µl of each 
specific sense and anti-sense primers (5 nM). PCR was run for 26 cycles of 
94 ℃ for 15 sec (denaturation), 55 ℃ for 15 sec (annealing) and 72 ℃ for 30 
sec (extension). The nucleotide sequences of the PCR primers were 5’- GGA 
GAG ACT ATC AAG ATA GTG ATC - 3’ (forward) and 5’- ATG GTC 
AGT AGA CTT TTA CAG CTC - 3’ (reverse) for Cyclooxygenase-2 (Cox-2, 
861 bp), 5’- TTG ACC TCA GCG CTG AGT TG- 3’ (forward) and 5’- CCT 
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GTA GCC CAC GTC GTA GC - 3’ (reverse) for tumor necrosis factor (TNF-
α, 374 bp), 5’- GTG TTC CAC CAG GAG ATG TTG - 3’ (forward) and 5’- 
CTC CTG CCC ACT GAG TTC GTC - 3’ (reverse) for inducible nitric oxide 
synthase (iNOS, 576 bp), 5’- CAG GAT GAG GAC ATG AGC ACC- 3’ 
(forward) and 5’- CTC TGC AGA  CTC AAA CTC CAC- 3’ (reverse) for 
interleukin-1 beta (IL-1β, 447 bp), 5’- GTA CTC CAG AAG ACC AGA GG - 
3’ (forward) and 5’- TGC TGG TGA CAA CCA CGG CC - 3’ (reverse) for 
interleukin-6 (IL-6, 308 bp), and 5’- CAC TGC TAT GCT GCC TGC TC - 3’ 
(forward) and 5’- TCT TCA CCT GCT CCA CTG CC - 3’ (reverse) for 
interleukin-10 (IL-10, 417 bp). Samples of each single-stranded cDNA were 
also treated with primers that amplify a 452 bp fragment of the 
glyceraldehyde-3-phosphate dehydrogenase (GADPH) house keeping gene 
[5’- GGT GCT GAG TAT GTC GTG GA - 3’ (forward), 5’- GAC ACA TTG 
GGG GTA GGA AC - 3’ (reverse)] to allow for quantitative comparison of 
loading.  The PCR products were subjected to electrophoresis on 1.2% agarose 
gels containing ethidium bromide and images were captured under UV light in 
a Bio-Rad ChemiDoc imaging system (Bio-Rad Laboratories, CA, USA). 
 
5.2.6 Western blot analysis 
            See Section 2.2.2.3b for experimental procedures. Briefly, BV-2 cells 
in DMEM containing 2% FBS were pre-treated with 1, 5 and 10 µM flavonoid 
compounds 1 to 5 for 30 min before the addition of 1 µg/ml LPS. The cells 
were cultured for another 24 h at 37 ℃, then lysed and collected for SDS-
PAGE. Protein levels in cell lysates were determined using specific antibodies 
against Cox-2 (Santa Cruz Biotechnology Inc., CA, USA), cPLA2 (Cell 
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Signaling Technology Inc., MA, USA), iNOS (Santa Cruz Biotechnology Inc., 
CA, USA) and β-actin (Santa Cruz Biotechnology Inc., CA Biotechnology 
Inc., USA). 
 
5.2.7 Statistical analysis 
            Numerical data were presented as means ± S.D. of different 
determinations. Statistical comparisons between groups were performed using 
the Student’s t - test. Values of p < 0.05 were considered statistical significant. 
 
5.3 Results 
5.3.1 Effects of flavonoid compounds 1 to 5 on the viability of RAW 264.7 
cells and BV-2 cells 
             
            MTT cell viability assays were carried out where RAW 264.7 and BV-
2 cells were exposed to a range of concentrations of flavonoid compounds 1 to 
5 (2 - 20 µM) for 24 h. As shown in Fig 5.3.1.1, viabilities of RAW 264.7 
cells and BV-2 cells remained unaffected upon treatment with the flavonoid 
compounds across all tested concentrations. 
 
5.3.2 Effects of flavonoid compounds 1 to 5 on nitric oxide production in 
LPS-activated RAW 264.7 cells. 
 
            To determine the effects of flavonoid compounds 1 to 5 on NO 
production, RAW 264.7 cells were pretreated with compounds 1 to 5 (1, 5 and 
10 µM) for 30 min before the addition of LPS (1 µg/ml). The cells were 







                                          
 
Fig 5.3.1.1 Effects of flavonoid compounds 1 to 5 on the viability of RAW 
264.7 cells and BV-2 cells. (A) RAW 264.7 cells cultured in serum free 
medium were treated with 1, 5, 10 and 20 µM of flavonoid compounds 1 to 5 
for 24 h at 37 ℃, after which 10 µl of MTT solution (5 mg/ml in PBS) was 
added to evaluate cell viabilities. (B) BV-2 cells were cultured in medium 
containing 2% fetal bovine serum. Effects of flavonoids on the cell viability 
were assessed using MTT assay following 24 h treatment with 1, 5, 10 and 20 





mesured. As shown in Fig 5.3.2.1, the concentration of NO released into the 
culture medium was significantly enhanced when the cells were treated with 1 
µg/ml of LPS, whereas pre-treatment with compounds 1 to 5 caused a 
reduction in NO release in a dose-dependent manner. Among all the 
flavonoids, compound 1 apigenin displayed the greatest reduction in NO 
release, where a dose of 10 µM was observed to reduce NO release by more 
than 50% of that released by LPS-stimulated RAW 264.7 cells. 
 
 
Fig 5.3.2.1 Effects of flavonoid compounds 1 to 5 on NO production in LPS-
activated RAW 264.7 cells. RAW 264.7 cells were pretreated with 1, 5 and 10 
µM of flavonoid compounds 1 to 5 for 30 min before addition of LPS (1 
µg/ml). Following 24 h of LPS treatment, nitrite levels in the culture medium 
were determined by Griess reaction. # p < 0.01 versus DMSO control; * p < 
0.01 versus LPS alone.  
 
5.3.3 Effects of flavonoid compounds 1 to 5 on LPS-induced mRNA 




            The effects of flavonoid compounds 1 to 5 on mRNA expression of 
pro-inflammatory cytokines TNF-α, IL-1β, IL-6 and IL-10 in LPS-activated 
BV-2 cells were next determined (Fig 5.3.3.1). The results revealed that there 
was a basal expression of TNF-α, IL-1β, IL-6 and IL-10 mRNA in the 
untreated cells. When the BV-2 cells were stimulated by 1 µg/ml of LPS for   
4 h, while the mRNA level of IL-1β was moderately increased, TNF-α and IL-
6 mRNA levels remained largely unaffected. On the contrary, mRNA 
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Fig 5.3.3.1 Effects of flavonoid compounds 1 to 5 on LPS-induced mRNA 
expression of cytokines in BV-2 cells. BV-2 cells were cultured in DMEM 
medium containing 10% fetal bovine serum at 37 ℃ for 24 h to allow cell 
attachment, after which the culture medium was replaced with low-serum 
DMEM containing 2% fetal bovine serum. Flavonoid compounds 1 to 5 were 
introduced at indicated concentrations 30 min before LPS (1 µg/ml) 
stimulation. The cells were cultured for another 4 h for collection of total RNA. 
The mRNA levels of TNF-α, IL-1β, IL-6 and IL-10 were determined by RT-
PCR. A house keeping gene GADPH was also amplified to allow for 




            Pre-treatment of the cells with 2 and 10 µM of flavonoid compounds 1 
to 5 yielded varied results. The enhanced IL-1β mRNA levels in the cells were 
suppressed upon treatment with the higher concentration of compounds 1 to 4 
(10 µM), whereas a low concentration of these compounds at 2 µM exerted no 
effect. Interestingly, compound 5 failed to suppress IL-1β induction at both 
concentrations. TNF-α expression was not induced by LPS and it was found 
that this basal expression was generally not suppressed by the compounds at 
both concentrations, except for compound 2 luteolin at 10 µM. Similarly, cells 
pre-treated with 10 µM of compounds 1, 2 and 3 also produced less IL-6 
mRNA than the DMSO control group. On the contrary, 2 µM of compounds 1, 
2 and 5 promoted the expression of IL-6 mRNA to a higher level than the 
untreated and LPS-stimulated cells. The LPS-inhibited mRNA expression of 
IL-10 was restored by pre-treatment of the cells with 2 µM of compounds 1, 2 
and 3. Compound 2 at concentration of 10 µM and compound 5 at 2 µM also 
attenuated the inhibition effects of LPS, but the mRNA expression was not 
restored to the normal level.  
 
Table 5.3.3.1 Effects of flavonoid compounds 1 to 5 on the mRNA expression 













2 10  2 10  2 10  2 10  2 10 (µM) 
IL-1β ↑ − ↓  − ↓  − ↓  − ↓  − −  
TNF-α − − −  − ↓  − −  − −  − −  
IL-6 − ↑ ↓  ↑ ↓  − ↓  − −  ↑ −  
IL-10 ↓ ↑ −  ↑ ↑  ↑ −  − −  ↑ −  




5.3.4 Effects of flavonoid compounds 1 to 5 on the expression of Cox-2 
and cPLA2 in LPS-stimulated BV-2 cells 
 
            The effects of flavonoid compounds 1 to 5 on the expression of Cox-2 
and cPLA2 in LPS-stimulated BV-2 cells were next investigated. As shown in 
Fig 5.3.3.1A, treatment with 1 µg/ml of LPS moderately elevated the 
expression of Cox-2 mRNA. It could be observed that while compound 1 at 10 
µM and compounds 2 to 5 at 2 and 10 µM display no inhibitory effects on 
LPS-induced Cox-2 expression, lower concentration of compound 1 apigenin 
(2 µM) caused a reduction in the induced levels (Fig 5.3.4.1A). In agreement 
with the RT-PCR results, Western blot analysis of Cox-2 protein levels 
revealed that compound 1 brought about a reduction in the induced expression 
of the Cox-2 enzyme in a dose-dependent manner, although the protein 
expression was not reduced to the normal level. In addition to compound 1, 
compound 3 also showed considerable bioactivity in reducing the expression 
of the Cox-2 enzyme in a dose-dependent manner. Results from Western blot 
analysis of cPLA2 suggested that the protein level of cPLA2 in BV-2 cells was 
regulated neither by the LPS stimulation nor by pretreatment with the 













Fig 5.3.4.1 Effects of flavonoid compounds 1 to 5 on the expression of Cox-2 
and cPLA2 in LPS-stimulated BV-2 cells. BV-2 cells were cultured in DMEM 
medium containing 10% fetal bovine serum at 37 ℃ for 24 h to allow cell 
attachment, after which the culture medium was replaced with low-serum 
DMEM containing 2% fetal bovine serum. Different concentrations of 
flavonoid compounds 1 to 5 were introduced 30 min before LPS (1 µg/ml) 
stimulation. The cells were cultured for another 4 h or 24 h for collection of 
total RNA and whole cell lysates respectively.  The mRNA levels of Cox-2 
were determined by RT-PCR. A house keeping gene GADPH was also 
amplified to allow for quantitative comparison of loading (A). The whole cell 
lystaes were collected for SDS-PAGE and Western blot analysis of Cox-2 and 
cPLA2 protein levels. β-actin immunodetection was carried out to verify equal 
protein loading (B). Results are representative of three independent 
experiments. 
 
5.3.5 Effects of flavonoid compounds 1 to 5 on the expression of inducible 
nitric oxide synthase (iNOS) in LPS-stimulated BV-2 cells 
 
            The effects of flavonoid compounds 1 to 5 on iNOS expression in 
LPS-activated BV-2 cells were also investigated. Firstly, RT-PCR was 
performed to determine mRNA expression levels in the flavonoids-treated 
BV-2 cells. The results revealed that treatment with LPS (1 µg/ml) for 4 h 






Fig 5.3.5.1 Effects of flavonoid compounds 1 to 5 on the expression of iNOS 
in LPS-stimulated BV-2 cells. BV-2 cells were cultured in DMEM medium 
containing 10% fetal bovine serum at 37 ℃ for 24 h to allow cell attachment, 
after which the culture medium was replaced with low-serum DMEM 
containing 2% fetal bovine serum. Different concentrations of flavonoid 
compounds 1 to 5 were introduced 30 min before LPS (1 µg/ml) stimulation. 
The cells were cultured for another 4 h or 24 h for collection of total RNA and 
whole cell lysates respectively.  The mRNA levels of iNOS were determined 
by RT-PCR. A house keeping gene GADPH was also amplified to allow 
quantitative comparison of loading (A). The whole cell lysates were collected 
for SDS-PAGE and Western blot analysis of iNOS protein levels. β-actin 
immunodetection was carried out to verify equal protein loading (B). Results 
are representative of three independent experiments. 
           
While the enhanced iNOS mRNA expression remained largely unaffected 
when the cells were pre-treated with 2 µM of compounds 2 to 5, compounds 1 
to 5 suppressed the expression at a higher concentration of 10 µM, with 
compound 1 registering the greatest activity (Fig 5.3.5.1A). Pretreatment of 
the cells with 10 µM of compound 1 30 min before LPS stimulation 
effectively suppressed the mRNA level of iNOS to a level comparable to that 
of DMSO control. Western blot analysis was also performed to determine the 
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effects of flavonoid compounds 1 to 5 on iNOS protein levels. Consistent with 
the RT-PCR results, LPS-induced enhanced expression of iNOS protein level 
was attenuated by pre-treatment of the cells with higher concentration (10 µM) 
of compounds 1 to 5 (Fig 5.3.5.1B). Among the compounds, compounds 1, 3, 
4 and 5 (5 and 10 µM) produced a strong suppressive effect such that the 
iNOS protein levels were reduced to levels lower than that of DMSO control 
(Fig 5.3.5.1B). 
 
5.4 Discussion and conclusions 
            Following an episode of stroke that results in a state of oxygen-glucose 
deprivation, ROS, activated  proteases as well as complements and factors 
subsequently released from necrotic cells rapidly lead to a robust 
inflammatory reaction characterized by leukocyte influx into the cerebral 
parenchyma and microglia activation (Hallenbeck, 1996; Becker, 1998; Zheng 
et al., 2004). The activated microglial cells produce more cytokines that cause 
upregulated production of adhesion molecules in the cerebral vasculature, 
which in turn mediate adhesion of circulating leukocytes to the vascular 
endothelia and infiltration into the brain parenchyma. Once gaining entry into 
the brain, the activated leukocytes and microglia produce a variety of 
inflammatory mediators such as inducible nitric oxide synthase (iNOS) 
(Yamagata et al., 2008) that generates nitric oxide (NO), matrix 
metalloproteinases (MMPs), cytokines and more ROS. The vicious cycles of 
inflammatory responses will lead to brain edema, hemorrhage and ultimately, 
cell death. Notably, the microvascular injury provides a positive feedback loop 
which will amplify the inflammatory cascade (Fig 5.4.1).   
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            Several so-called damage-asssociated molecular patterns (DAMPs) 
such as heat-shock proteins (Hsp), heparan sulfate (HS) that are released 
during the early onset of cerebral ischemia bind to Toll-like receptors (TLRs) 
and subsequently activate the nuclear factor kappa-B (NF-κB) and mitogen-
activated protein kinase (MAPK) pathways in various brain cell types. 
Synthesis and secretion of proinflammatory cytokines and chemokines, as well 
as expression of leucocyte adhesion molecules therefore set in (Kleinig et al., 
2009). LPS, employed in the experiments described in this chapter, had been 
reported to induce inflammatory reaction via binding to TLR-4 and activating 
the NF-κB signaling pathway (Beutler, 2000; Triantafilou et al., 2005). 
Through binding to high mobility group box-1 (HMGB-1) protein, receptor 
for advanced glycosylation end-product (RAGE) has also been found to 
potently up-regulate NFκB signaling pathway (Qiu et al., 2008). CD36 may 
also serve as “danger sensors” responding to early post-stroke formation of 
oxidized low-density lipoproteins and diacylglycerides; it forms signaling 
complexes with TLRs to activate NFκB, MAPK and AP-1 signaling pathways 
to play a deleterious role in ischemic stroke (Cho et al., 2005; Bjorkbacka, 
2006). The major proinflammatory cytokine pro-IL-1β is inactive unless it is 
cleaved by the so-called “inflammasome”, a protein assembly incorporating 
caspase-1 (Ogura et al., 2006). While the TLRs sense predominantly 
extracellular DAMPs, upstream components of the inflammasome sense 






Fig 5.4.1 The inflammatory cascade following a stroke event. Initiation of the 
inflammatory cascade by a variety of factors leads to systemic inflammation 
or activation of cellular proinflammatory pathways in a typical cell (neuron, 
astrocyte, endothelial cell, etc.). Chemokines and cytokines are consequently 
secreted, microglial cells activated and endothelial adhesion molecules 
expressed. These initiators lead to microglial activation which produces more 
cytokines causing upregulation of adhesion molecules in the cerebral 
vasculature. Adhesion molecules mediate adhesion of circulating leukocytes to 
vascular endothelia and infiltration into the brain parenchyma. Once in the 
brain, activated leukocytes and microglia produce a variety of inflammatory 
mediators such as iNOS, MMPs, cytokines and ROS which lead to brain 
edema, hemorrhage and ultimately, cell death. The microvascular injury 
provides a positive feedback loop which will amplify the inflammatory 
cascade. AP-1, activator protein-1; MAPK, mitogenactivated protein kinase; 
RAGE, receptor for advanced glycosylation end-product; MMP, matrix 
metalloproteinase; NFκB, nuclear factor kappa-B; RAGE, receptor for 
advanced glycosylation end-products; TLR, toll-like receptor. Adapted from 
Wang et al (2007) and Kleinig et al’s (2009) publications with modification. 
 
            Adhesion molecules are proteins located on the cell surface; they are 
involved in the binding with other cells or with the extracellular matrix in the 
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process called cell adhesion. These proteins are typically transmembrane 
receptors and are composed of three domains: an intracellular domain that 
interacts with the cytoskeleton, a transmembrane domain, and an extracellular 
domain that interacts either with other adhesion molecules or the extracellular 
matrix (Mousa, 2008; Yilmaz et al., 2008). Adhesion molecules play a pivotal 
role in the infiltration of leukocytes into the brain parenchyma after stroke. 
Three main groups of cell adhesion molecules: (1) selectins (P-selectin, E-
selectin, and L-selectin), (2) the immunoglobulin superfamily of intercellular 
adhesion molecules (e.g. ICAM-1, 2) and vascular cell adhesion molecule-1 
(VCAM-1), and (3) integrins (CD11a-c) are involved in the interaction 
between leukocytes and the vascular endothelium (DeGraba, 1998; Emsley et 
al., 2002). Targeting on these adhesion molecules to inhibit leukocyte 
adhesion has been reported to prevent leukocytes from entering the ischemic 
brain, thus resulting in reduced neurologic injury (Wang et al., 2007). 
Furthermore, reduced infarct volumes have been observed in animals deficient 
in adhesion molecules after transient focal cerebral ischemia (Soriano et al., 
1999).  
             Cytokines are non-antibody proteins secreted not only by cells of the 
immune system, but also by resident brain cells, including the glial cells and 
neurons (Wang et al., 2007). They generally act locally as intercellular 
mediators in a paracrine or autocrine manner. Cytokines are upregulated in the 
brain after stroke attack. The most studied cytokines related to inflammation in 
stroke are interleukin-1 (IL-1), TNF-α, interleukin-6 (IL-6), interleukin-10 
(IL-10) and transforming growth factor-β (TGF-β) (Han et al., 2003; Zheng et 
al., 2003). Among the cytokines, while IL-1 and TNF-α exacerbate cerebral 
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injury, IL-6, IL-10 and TGF-β appear to be neuroprotective (Allan et al., 
2001). In this chapter, the LPS-enhanced IL-1β mRNA level was inhibited 
when the cells were pre-treated with compounds 1 to 4 at 10 µM. Pre-
treatment of the LPS-stimulated cells with 10 µM of compound 2 luteolin 
brought about suppression of TNF-α mRNA expression to a level lower than 
that of the untreated cells. In addition, The LPS-reduced mRNA expression of 
IL-10 was restored by pre-treatment of the cells with 2 µM of compounds 1, 2 
and 3. Considering that IL-10 blocks NF-κB activity, down-regulates the 
expression of Th1 cytokines, MHC class II antigens and is involved in the 
regulation of the JAK-STAT signaling pathway (Schottelius et al., 1999; 
Murray, 2005), through promoting IL-10 expression, flavonoid compounds 1, 
2 and 3 isolated from Ixeris sonchifolia Hance might exert important 
cytoprotective effects in the inflammatory reactions after a stroke event. 
            The arachidonic acid (AA) cascade lies downstream of immune cell 
activation and is initiated via the release of phospholipase A2 (PLA2). PLA2s 
are from several unrelated protein families sharing common enzymatic 
activities. Among which, secreted and cytosolic phospholipase A2 (sPLA2 and 
cPLA2) are the two most notable families. High concentration of calcium due 
to energy failure after a stroke event activates PLA2 to hydrolyze 
glycerophospholipids to release AA (Kudo et al., 2002; Murakami et al., 
2002). AA is next metabolized through the cyclooxygenase (Cox)  (Soriano et 
al.) or lipoxygenase (Lox) pathways (Saeed et al., 1997; Funk, 2006; 
Gonzalez-Periz et al., 2007). There are two isoforms of cyclooxygenase, 
namely Cox-1 and Cox-2. Cox-1 is constitutively expressed in many cells 
types, whereas Cox-2 is upregulated in regions of ischemic injury, as well as 
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in regions remote from the infarct area (Sairanen et al., 1998; Iadecola et al., 
1999; Toti et al., 2001; Schwab et al., 2002). While Cox-1 exacerbates or 
attenuates the inflammatory reaction depending on the differences in the 
immune response, upregulation of Cox-2 is deleterious. Treatment with Cox-2 
inhibitors has been reported to improve neurological outcome after stroke 
(Iadecola et al., 2001). In this chapter, investigative work on the effects of 
flavonoids on the LPS-stimulated microglial BV-2 cells had revealed that 
while the protein level of cPLA2 was not regulated by LPS stimulation and 
pretreatment with the flavonoid compounds, lower concentration (2 µM) of 
compound 1 apigenin attenuated the LPS-elevated expression of Cox-2 
mRNA and Cox-2 protein, suggesting this compound might exert anti-
inflammatory activity via inhibiting Cox-2 expression and subsequent 
removing downstream effector of PGE2. 
            Nitric oxide (NO), an important signaling molecule involved in 
physiological processes such as neuronal communication, host defense, and 
regulation of vascular tone, is a relatively stable gas that is water-soluble and 
can readily diffuse into cells and cell membranes where it reacts with 
molecular targets (Wang et al., 2007). The molecule is synthesized from L-
arginine (L-Arg) by the enzyme nitric oxide synthase (Yamagata et al.). Three 
distinct isoforms of NOS have been isolated, namely neuronal NOS (nNOS, 
NOS I, NOS1), endothelial NOS (eNOS, NOS III, NOS3) and inducible NOS 
(iNOS, NOS II, NOS2). The first two isoforms, which are constitutively 
expressed under “basal” conditions, are calcium-dependent. In contrast, iNOS 
is a calcium-independent enzyme that is only produced by many cell types in 
response to endotoxins or cytokines. The main physiological effects of NO are 
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mediated through activation of soluble guanylate cyclase (SGC) in smooth 
muscle cells, platelets, leucocytes, neurons and other cells to increase the 
secondary messenger cyclic GMP (cGMP) levels (Schmidt et al., 1993; 
Denninger et al., 1999). In the cardiovascular system, NO acts as a mediator 
of vascular tone and blood flow. In addition, NO acts to protect the vascular 
endothelium against atherosclerosis through suppression of leukocyte 
migration and adhesion to endothelium (Bath, 1993), exerting antiproliferative 
effects on vascular smooth muscle cells (Garg et al., 1989), and reducing 
lipoprotein oxidation and absorption into blood vessels (Cardona-Sanclemente 
et al., 1995). Moreover, NO has antiplatelet properties, and protects against 
thrombosis by inhibiting platelet adhesion and aggregation. When released in 
controlled amounts, NO also plays a fundamental role in many biological 
processes outside of the cardiovascular system. However, when high 
concentrations of NO are secreted, in particular as derived from iNOS, it can 
react with ROS such as superoxide anion radical to produce reactive nitrogen 
species (RNS) like peroxynitrite. This can disrupt many cellular processes 
through direct oxidative effects and/or alteration of protein conformation via a 
process termed nitration (Landino et al., 1996; Packer et al., 1996; Xia et al., 
1996). Interestingly, NO release in stroke appears to be able to either promote 
or prevent cellular inflammation and death. It has been revealed that NO can 
be anti-inflammatory through (1) inhibition of the maturation of cytokines  
such as IL-1β and IL-18, (2) blockade of interferon γ, and (3) prevention of the 
expression of cellular adhesion molecules by acting on NF-κB pathway 
(Murphy, 2000; Liu et al., 2002; Eynott et al., 2003; Zeidler et al., 2004). 
Alternatively, NO can be pro-inflammatory by ptomoting the expression of 
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certain cytokines like TNF-α and IL-6 (Liu et al., 2002; Eynott et al., 2003; 
Zeidler et al., 2004). While transgenic mice which do not express eNOS 
develop larger infarcts after middle cerebral artery (MCA) occlusion and show 
decreased blood flow at the periphery of the ischemic lesion (Huang et al., 
1996; Huang, 1999), transgenic mice that are deficient in iNOS (Zhao et al., 
2000) or nNOS (Huang et al., 1994) have smaller infarcts and better outcomes 
than control mice when subjected to MCA occlusion. The protective effect of 
hypothermia in stroke management is associated with reduced generation of 
both NO and iNOS by microglial cells (Han et al., 2002), and ischemic brain 
protection by estrogen and progesterone is proven to be mediated through 
modulation of iNOS expression (Park et al., 2006). In this chapter, it had been 
revealed that the concentration of NO released into the culture medium and the 
iNOS expression was significantly enhanced when the cells were treated with 
1 µg/ml of LPS, whereas pre-treatment of the cells with 1 to 10 µM of 
compounds 1 to 5, in particular compound 1 apigenin at 10 µM, resulted in a 
reduction in NO release and iNOS expression, thus indicating the potential 
anti-inflammatory activities of these flavonoid compounds.  
            In conclusion, compounds 1 to 4 at concentration of 10 µM inhibited 
LPS-enhanced IL-1β mRNA level, and compound 2 luteolin at 10 µM 
depressed TNF-α mRNA expression. The LPS-inhibited mRNA expression of 
IL-10 was restored by pre-treatment of the cells with 2 µM of compounds 1, 2 
and 3. In addition, compound 1 apigenin at 2 µM attenuated the LPS-elevated 
gene and protein expression of Cox-2. Finally, 1 to 10 µM of compounds 1 to 
5 at concentration of 10 µM reduced the NO release and iNOS expression. 
The results suggest that flavonoid compounds 1 to 5 isolated from Ixeris 
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sonchifolia Hance extract, in particular compound 1, might exert anti-
inflammatory activities by regulating cytokine secretion, inhibiting Cox-2 













Possible protective effects of luteolin in rats suffering from 





            In the previous studies, flavonoid compounds 1 to 5 isolated from 
Ixeris sonchifolia Hance extract, in particular compounds 2, 4 and 5, were 
found to protect cells from H2O2-induced cytotoxiciy by scavenging free 
radical directly and inducing phase Ⅱdetoxifying enzymes (see Chapter 4). In 
addition, compounds 1 to 5 were revealed to regulate cytokine secretion and 
reduce NO release and iNOS expression (see Chapter 5). These results 
suggested that flavonoid compounds 1 to 5, namely Apigenin (1), Luteolin (2), 
Apigenin-7-O-β-glucopyranoside (3), Luteolin-7-O-β-glucopyranoside (4), 
Luteolin-7-O-β-glucruonopyranoside (5), might exert neuroprotective effects 
during the early response to stroke occurrence (characterized by excitotoxicity 
and oxidative damage) and the second wave of cell death (characterized by 
neuroinflammation). To study the potential in vivo anti-stroke effects of these 
compounds, this chapter investigated the possible protective effects of a 
selected compound luteolin on rats suffering from cerebral ischemia induced 
by middle cerebral artery (MCA) occlusion. The mortality rates for each 
treatment group and the infarct area in the brain slices were analyzed. In 
addition, the expression of cleaved caspase-3 and Cox-2 in samples of brain 
slices was also assessed. 
 
6.2 Materials and methods 
6.2.1. Experimental animals  
            The animal experimentation described in this study was approved by 
the Institutional Animal Care and Use Committee (IACUC, Singapore) 
(Protocol number 110/06). Male Sprague-Dawley rats weighing 280 to 320 g 
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were purchased from the Animal Holding Unit, National University of 
Singapore. They were provided with a standard diet and water ad libitum. The 
room was kept on a 12/12 h light/dark cycle at a temperature of 23 ± 1 °C and 
relative humidity of 50 ± 10%. An acclimatization period of at least 1 week 
was allowed for the rats prior to drug administration.  
 
6.2.2 Surgical procedures 
            Following 12 h fasting of food, animals were neurologically evaluated 
before anesthesia to confirm normal neurological function. Anesthesia was 
induced with 12% chloral hydrate (350 mg/kg; intraperitoneal injection). The 
right common carotid artery was carefully exposed, the occipital branches of 
the external carotid artery were coagulated, and the internal carotid artery was 
isolated. A 4 cm length of φ0.24 mm monofilament, poly-L-lysine-coated 
nylon suture was inserted through the proximal external carotid artery into the 
internal carotid artery, and was advanced a distance of 18 to 20 mm to occlude 
the MCA (Fig 6.2.2.1). Incisions were closed, and rats were returned to their 
cages. After 2 h of MCA occlusion, animals were anesthetized again and the 
suture was withdrawn to achieve reperfusion injury (Ley et al., 2005). Sham 
occlusion animals underwent the same surgical procedures without inserting 
the MCA occlusion suture. 
            At time points 0, 24 and 48 h post MCA occlusion, luteolin dissolved 
in 0.5% NaHCO3 solution, sterile-filtered, was injected to the animals via the 
tail vein (4 mg/kg). For sham occlusion animals and vehicle control animals, 





















Fig 6.2.2.1 Schematic drawing of the suture placed into ECA and ICA of rat 
brains to induce middle cerebral artery occlusion (MCAO). ACA: anterior 
cerebral artery; MCA: middle cerebral artery; PCA: posterior cerebral artery; 
ICA: internal carotid artery; ECA: external carotid artery; CCA: common 
carotid artery; SCA: superior cerebellar artery 
    
6.2.3 Evaluation of neurobehavior 
            Neurological examinations were performed at 1 h prior to, as well as 
24, 48 and 72 h post MCA occlusion. The neurological findings were scored 
on a 5- points scale as described by Longa et al with modifications (Longa et 
al., 1989; Zhang et al., 1997; Wei et al., 2005):  
0 = no neurologic deficit 
1 = failure to extend left forepaw fully 
2 = circling to the left 
3 = falling to the left 




6.2.4 Measurement of infarct area 
            Following 72 h of MCA occlusion, the rats were neurologically 
assessed and killed by carbon dioxide euthanasia. The brains were removed 
and washed with cold PBS, and then cut using a vibrating-blade microtome 
(Leica VT1000S; Leica microsystems, Germany) into 7 coronal sections each 
of 2 mm thick. The fourth slice (~2 to 4 mm posterior to the bregma) for each 
rat brain was quickly immersed in freshly prepared 1% 2,3,5-
triphenyltetrazolium chloride (TTC; purchased from Sigma-Aldrich Pte Ltd, 
USA) solution in PBS for 20 min at room temperature. The area of damaged 
parenchyma (unstained tissue) was measured on the posterior surface of each 
slice using Image-Pro® Analyzer software (Media Cybernetics, USA). The 
percentage of infarct area, corrected for edema, was expressed as {Infarct area 
× [1 - (ipsilateral hemispheric area - contralateral hemispheric 
area)/contralateral hemispheric area]}/brain slice area × 100% (Swanson et al., 
1990; Lee et al., 2005). After measurement of infarct area, the brain slices 
were stored in 10% formaldehyde (Fluka BioChemika, Switzerland) solution 
in PBS at 4 ℃ before immunohistological analysis.  
 
6.2.5 Immunohistological analysis 
            The formaldehyde-fixed brain slices were sent to Self Service 
Histology Laboratory, Institute of Molecular and Cell Biology (IMCB, 
Singapore) for embedding and sectioning. Hematoxylin-Eosin staining on the 
deparaffinized brain slices (5 µm) was performed according to the reported 
protocol (Kiernan, 2008). Immunohistological analysis on the brain slices was 
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carried out by Dr. Keith Rogers (IMCB, Singapore). Briefly, antigen retrieval 
was performed on the deparaffinized coronal brain sections (5 µm) with 0.01 
M sodium citrate buffer at 95 ℃  for 30 min. Following a rinse in PBS, 
endogenous peroxidase activity was blocked with 0.3% H2O2. Nonspecific 
binding sites were saturated with goat serum. The expression of cleaved 
caspase 3 and cyclooxygenase-2 (Cox-2) was detected by overnight incubation 
at 4  with ℃ the respective anti-cleaved caspase 3 (Cell Signaling Technology 
Inc., MA, USA) and anti-Cox-2 (Santa Cruz Biotechnology Inc., CA, USA) 
antibody, followed by 60 min incubation at room temperature with 
biotinylated anti-rabbit IgG (BD Biosciences, CA, USA), and finally the 
processing for immunoperoxidase staining using 3,3-diaminobenzidine 
tetrahydrochloride as the substrate (BD Biosciences, CA, USA).  
 
6.2.6 Statistical analysis 
            All results were presented as means ± S.D. and statistical analysis was 
performed using the software SPSS 13.0. Mortality comparisons between the 
sham occlusion group, vehicle control group and luteolin treatment group 
were analyzed one to one using the Chi-square test. The neurobehavioral 
scores, due to a lack of normality, were analyzed using the Mann-Whitney U 
test. The infarct area between vehicle control group and luteolin treatment 
group were compared with one-way ANOVA. Difference was considered 
significant at p < 0.05.  
 
6.3 Results 





            All the animals before MCA occlusion surgery, as well as sham 
occlusion animals at 72 h showed normal neurobehavior (neurobehavioral 
scores being 0). Three rats died during the surgery and 5 rats failed to show 
ischemic symptoms after MCA occlusion, thus these animals were excluded 
from statistical analysis. The 3-day survival rates for sham occlusion group, 
vehicle control group and luteolin treatment group were 100% (4/4), 59% 
(16/27) and 60% (18/30) respectively, suggesting that treatment with luteolin 
did not reduce mortality induced by MCA occlusion (p > 0.05 between vehicle 
control group and luteolin treatment group). Animals exhibited moderate to 
severe neurological deficit 72 h after MCA occlusion, with neurobehavioral 
scores being 2.0 ± 0.4 (p < 0.01 between sham occlusion group and vehicle 
control group). Treatment with luteolin was found not to improve 
neurobehavioral recovery with neurobehavioral scores being 1.9 ± 0.5 for rats 
receiving luteolin treatment (p > 0.05 between vehicle control group and 
luteolin treatment group).  
 
6.3.2 Effect of luteolin on infarct area in the brains of rats suffering from 
cerebral ischemia induced by MCA occlusion 
 
            For calculating of the infarct area, the rat brain slices were treated with 
TTC staining, which due to reaction of the tetrazolium salts with viable 
dehydrogenases would result in viable tissues being stained “brick-red” while 
infracted tissues were stained “pale-white”. As shown in Fig 6.3.2.1, MCA 
occlusion gave rise to an infarct area of 33% when the rats were killed 72 h 
after surgery (Fig 6.3.2.1B, D), while treatment with luteolin had significantly 
reduced the infarct area to 25% (p < 0.01; Fig 6.3.2.1C, D), suggesting a 







Fig 6.3.2.1 Analysis of the infarct area in rat brains by TTC staining. 
Representative images for brain slices of the sham occlusion rats (A), vehicle 
control rats (B) and luteolin treatment rats (C) are presented.  The luteolin 
treatment group exhibited significantly reduced infarct area as compared with 
the vehicle control group (D); results were obtained from brain slices of 8 rats 
from each group. ** p < 0.01 versus vehicle control. 
 
6.3.3 Immunohistochemistry staining of brain slices 
            MCA occlusion and the subsequent reperfusion injury resulted in 
obvious cell death and cell apoptosis in the rat brains, which were evidently 
characterized by eosinophilic neurons (red neurons, Fig 6.3.3.1A) and neurons 
with a loss of cellular integrity and affinity for hematoxylin staining (ghost 
neurons, Fig 6.3.3.1B), as well as an enhancement in the number of cells in the 
ischemic lesion that were positively stained with anti-cleaved caspase-3 
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antibody (Fig 6.3.3.2B). Luteolin treatment resulted in the inhibition of 
caspase-3 cleavage (Fig 6.3.3.2C), which suggested the potential 





Fig 6.3.3.1 Hematoxylin-Eosin staining of brain slices of rats subjected to 
MCA occlusion and reperfusion. The middle cerebral arteries of male 
Sprague-Dawley rats were occluded by inserting nylon suture and the suture 
was withdrawn 2 h after ischemia to achieve reperfusion injury. The animals 
were killed 72 h after MCA occlusion and the brains were removed, embedded 
and sectioned for Hematoxylin-Eosin staining. Eosinophilic neurons (red 
neurons, A) and neurons with a loss of cellular integrity and affinity for 
hematoxylin staining (ghost neurons, B) were evident in the ischemic lesion at 
72 h after MCA occlusion. 
 
 
            MCA occlusion and the subsequent reperfusion injury also resulted in 
enhanced expression of Cox-2 in the ischemic tissues (Fig 6.3.3.3B), 
indicating an activation of neuroinflammatory status in the rat brains following 
MCA occlusion. Treatment of the animals with luteolin was found to reduce 
the number of cells positively stained with anti-Cox-2 antibody (Fig 6.3.3.3C), 
implying that the compound might exert a certain extent of neuroprotective 





































Fig 6.3.3.2 Cleaved caspase-3 immunohistochemical staining of brain tissue 
sections of rats subjected to MCA occlusion and reperfusion. At time points 0, 
24 and 48 h post MCA occlusion, luteolin in 0.5% NaHCO3 solution, sterile-
filtered, was injected to animals via the tail vein (4 mg/kg). For sham 
occlusion animals and vehicle control animals, 0.5% NaHCO3 sterile solution 
was injected instead. The animals were killed 72 h after MCA occlusion and 
the brains were removed, embedded and sectioned for immunohistochemical 
staining. Representative images for ischemic parietal cortex of the sham 
occlusion rats (A), vehicle control rats (B) and luteolin treatment rats (C) are 
presented. MCA occlusion resulted in a significant elevation in the number of 
cells positively stained with cleaved caspase-3 antibody, while treatment with 
luteolin inhibited the induction (D). Results were obtained from brain slices of 
3 rats from each group. ## p < 0.01 versus sham occlusion control, ** p < 0.01 

































Fig 6.3.3.3 Cox-2 immunohistochemical staining of brain tissue sections of 
rats subjected to MCA occlusion and reperfusion. At time points 0, 24 and 48 
h post MCA occlusion, luteolin in 0.5% NaHCO3 solution, sterile-filtered, was 
injected to animals via the tail vein (4 mg/kg). For sham occlusion animals and 
vehicle control animals, 0.5% NaHCO3 sterile solution was injected instead. 
The animals were killed 72 h after MCA occlusion and the brains were 
removed, embedded and sectioned for immunohistochemical staining. 
Representative images for ischemic parietal cortex of the sham occlusion rats 
(A), vehicle control rats (B) and luteolin treatment rats (C) are presented. 
MCA occlusion resulted in a significant elevation in the ratio of anti-Cox-2 
positive stained cells, while treatment with luteolin inhibited the induction (D). 
Results were obtained from brain slices of 3 rats from each group. ## p < 0.01 
versus sham occlusion control, * p < 0.05 versus vehicle control.   
  
6.4 Discussion and conclusions 
            Ranked after coronary heart disease (CHD) and cancers of all types, 
stroke is the third leading cause of death. The principles in stroke therapy 
involve the restoration of blood supply to the affected brain area in the shortest 
possible time from the onset of stroke, as well as to reduce ischemia-caused 
tissue damage (see Chapter 2). Being different from strategies targeted to 
restore the blood supply, which can be achieved by delivering thrombolytic 
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reagents to the thrombus, strategies to reduce ischemia-caused tissue damage 
such as through scavenging of free radicals and through inhibition of 
inflammatory reactions can only be attained when the involved reagents can 
be transported to the ischemic tissues. Unfortunately, a physiological barrier, 
the blood-brain barrier (BBB), exists between the cerebral capillaries and the 
brain tissue. The BBB consists of specialized non-fenestrated tightly-joined 
endothelial cells around the capillaries and separates the circulatory blood 
system from the cerebrospinal fluid in the CNS; it restricts the diffusion of 
microscopic objects (e.g. bacteria) and large or hydrophilic molecules into the 
cerebrospinal fluid, while allowing the free diffusion of a restricted class of 
small molecules which have a molecular mass less than 400 Da and are lipid 
soluble (O2, hormones, CO2). Less than 2% of all small molecules falls under 
this category. All large molecules with molecular mass higher than 400 Da 
either do not cross the BBB, or are transported across the BBB via certain 
transport systems (Pardridge, 2005). Under such a situation, among all the 
flavonoid compounds isolated from Ixeris sonchifolia Hance, only compound 
1 (apigenin, with a molecular mass 270) and compound 2 (luteolin, with a 
molecular mass 286) possess the possibilities to pass through BBB via free 
diffusion. As presented in the findings in Chapter 4, compound 2 showed more 
potential than compound 1 in protecting cells from H2O2-induced cytotoxiciy 
by scavenging free radicals directly and inducing phase Ⅱ detoxifying 
enzymes. Furthermore, in anti-inflammatory studies, compound 1 showed 
almost the same effects with compound 2 in inhibiting cytokine secretion, NO 
release and iNOS expression (see Chapter 5). Taken together, in this chapter, 
compound 2 luteolin was selected as the representative compound to 
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investigate the potential anti-stroke effects of flavonoids isolated from Ixeris 
sonchifolia Hance. 
            Animal models play pivotal roles in screening and developing of 
pharmacological agents for stroke treatment. Several animal models in 
different species are currently used to produce cerebral ischemia, while 
hemorrhagic animal models are less appropriate and less studied due to the 
relative low occurrence (~15% of all stroke occurrences; see Chapter 1).  
Ischemic stroke animal models can be divided into global ischemic and focal 
ischemic models. Global models, both complete and incomplete, results in 
ischemia over a large area of the brain. Obvious advantage for global models 
is that it can be easily performed. However, they are of less immediate 
relevance to human stroke than the focal stroke models,  and are now 
generally considered to model the cerebral consequences of cardiac arrest 
rather than stroke (Green et al., 1997). Focal models occlude a specific vessel, 
usually the middle cerebral artery (MCA) because the majority of human 
ischemic strokes result from an occlusion in the region of the MCA (Millikan, 
1992; Richard Green et al., 2003; Traystman, 2003). MCA occlusion models, 
either permanent or transient (based on the removal of the blockade to allow 
reperfusion), can be achieved by (1) injection of particles like blood clots or 
artificial spheres into the carotid artery (to achieve thromboembolic MCAO), 
(2) surgical occlusion (e.g. by electrocautery or ligation) of MCA (Millikan, 
1992; Richard Green et al., 2003; Traystman, 2003), or by cerebrocortical 
photothrombosis (van Rossem et al., 1992). Another simple, relatively 
noninvasive method to produce either permanent or transient MCAO animal 
models is to insert a piece of surgical filament into the internal carotid artery 
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and push the filament forward until the tip occludes the origin of the middle 
cerebral artery. If the filament is left in place, the procedure is suitable as a 
model of permanent MCAO. Reperfusion can be easily obtained by 
withdrawing the thread, and the animals may survive for days, weeks, and 
months, which will enable functional outcome measures to be recorded 
(Longa et al., 1989). The experiment employed in this Ph.D study had used 
transient focal ischemic rats to study the potential anti-stroke effects of 
compound 2 luteolin. Ischemia was achieved by inserting a nylon suture 17 to 
20 mm from the origin of the internal carotid artery to occlude collateral 
circulation from the anterior communicating arteries; reperfusion was 
performed 2 h after the occlusion by withdrawing the thread. The suture was 
coated with poly-L-lysine to afford a tighter adherence to the surrounding 
endothelium and a more consistent infarction. Previous observational studies 
had suggested a protective effect of estrogens on stroke risk among women 
who received postmenopausal hormone replacement therapy (Mendelsohn et 
al., 1999; Mendelsohn, 2002; Cho et al., 2003). Therefore, to avoid the 
possible influence of estrogens on ischemic outcomes, only male rats were 
used in this experiment to minimize individual variation.  
            In view that excitotoxicity and free radicals attack occurs in minutes 
after ischemia with a “burst” upon reperfusion, and neuroinflammation occurs 
after several hours, to investigate the neuroprotective effects of luteolin on 
MCA-occluded rats, the compound, dissolved in 0.5% NaHCO3 sterile 
solution, was intravenously administrated immediately after the ischemia (4 
mg/kg). The dose selection was as referenced from the study by Li et al (2006). 
In their study, flavonoid glycoside nicotiflorin, at a concentration of 5 to 10 
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mg/kg, was demonstrated to reduce the size of infarction and improve the 
behavioral deficits observed in permanent MCAO rats (Li et al., 2006). Upon 
normalization to molar concentration, 4 mg/kg of luteolin fell under the same 
concentration range (8.4 to 16.8 µM). In consideration that the maximum 
infarct size would have been established 24 to 36 h after stroke onset (Pantano 
et al., 1999), in this study, the ischemic rats were killed 72 h after MCA 
occlusion for infarct area calculation and immunohistological staining.  
            The 3-day survival rates for sham occlusion group, vehicle control 
group and luteolin treatment group were 100% (4/4), 59% (16/27) and 60% 
(18/30) respectively. The high mortality rates for the latter two groups might 
be due to surgery-related complications, such as bleeding and infections 
during surgery, extended surgery duration or body temperature loss after 
ischemia induction. Another reason could be that severe ischemic rats had 
failed to consume food and water. In rats that survived 72 h post MCA 
occlusion had neurobehavioral scores less than 2; animals with scores higher 
than 2 (3: falling to the left; 4: no spontaneous walking with a depressed level 
of consciousness), though might be surviving at 24 h after MCA occlusion, 
had indeed lost their ability to ingest food and water and thus hardly survived 
at 72 h. Treatment of the MCA-occluded rats with intravenous injection of 4 
mg/kg luteolin had reduced the infarct area,  decreased the cell number 
positively stained with anti-cleaved caspase-3 antibody and anti-Cox-2 
antibody. Taken together, the results obtained in this chapter suggest that 
luteolin might exert neuroprotective effects by inhibiting cell apoptosis and by 















General discussion and conclusions 
138 
 
            Based on the therapeutic outcomes of Diemailing Injection, which 
contains a raw extract of Ixeris sonchifolia Hance, this Ph.D project had 
hypothesized that Ixeris sonchifolia Hance contained phytochemical 
constituents that possessed anti-stroke potential with anticoagulation, 
antioxidant and anti-inflammatory activities, and by conducting bioassay-
guided isolation and purification would indentify the constituents. Therefore, 
the primary objective of this Ph.D study was to isolate and identify 
constituents from Ixeris sonchifolia Hance that display anti-stroke activities 
and to elucidate the possible mechanism(s) through which the identified 
compound(s) exerted the neuroprotective effects.   
            To accomplish this objective, the aerial part of Ixeris sonchifolia Hance 
was extracted and the crude extract was partitioned into fractions using 
different solvents. The fractions were then subjected to screening using both 
cell-based in vitro bioassays and biochemical reactions. Taking into 
consideration that the principles in stroke treatment would involve (1) the 
restoration of blood supply to the affected brain area in the shortest possible 
time from the onset of stroke, as well as (2) to reduce ischemia-caused tissue 
damage, this study had employed an in vitro assay to evaluate the 
anticoagulation activities and two in vitro approaches to evaluate the 
antioxidant activities of these fractions. The cytoprotective effect of these 
fractions on H2O2-exposed cells was also evaluated using the MTT cell 
viability assay. Based on what has been reported so far, this was the first time 
that fractions isolated from Ixeris sonchifolia Hance extract were 
systematically screened with the objective to identify fraction(s) possessing 
desired neuroprotective bioactivities. The results had revealed that the ethyl 
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acetate fraction (Fr. 3) isolated from Ixeris sonchifolia Hance extract protected 
cells dose-dependently from H2O2-induced cytotoxicity, scavenged DPPH free 
radicals, induced ARE-dependent transcriptional activity and caused 
upregulation of Nrf2 protein levels. However, it failed to exhibit anticoagulant 
activities. In vitro bioassays are adopted in drug discovery screening programs 
as they possess the advantages of high throughput, low cost, and operational 
convenience. Although they may successfully model one or two aspects of the 
interactions between the investigated agents and the pathological response, 
there exist significant differences between the physiological response and the 
in vitro experimental set-up. As such, as demonstrated in this study, although 
the fractions failed to exert direct and immediate inhibitory effects on clotting 
factors in the in vitro anti-coagulation assay, they might yield different 
outcome under physiological conditions. Possibilities that these fractions 
isolated from Ixeris sonchifolia Hance might exert anti-coagulation activity in 
an in vivo setting therefore could not be excluded. Similarly, possibilities that 
these fractions might exert beneficial effects in the treatment of stroke via 
pathways other than restoration of redox homeostasis also could not be 
excluded. Based on what had been obtained from the preliminary assays, the 
ethyl acetate fraction (Fr. 3) was identified as the fraction possessing potential 
neuroprotective properties and was subjected to further fractionation and 
purification experimental work with the ultimate goal of identifying 
components that could play key roles in the prevention and treatment of 
ischemia-related diseases. 
            The follow-up isolation work focused on the ethyl acetate fraction (Fr. 
3) of Ixeris sonchifolia Hance revealed the presence of two classes of 
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compounds: flavonoids and sesquiterpene lactones. Among all the purified 
compounds, compound 8, 11,13-Dihydroixerinoside, is a new sesquiterpene 
lactone which has not been reported previously. Sesquiterpene lactones 
demonstrate a variety of biological activities such as cytotoxicity (Kim et al., 
2007; Suzuki et al., 2007; Tabopda et al., 2007; Yang et al., 2007; Yang et al., 
2007), antimalarial (Bischoff et al., 2004; Pedersen et al., 2009), antibacterial 
(Theodori et al., 2006) and herbicidal (Macias et al., 2000) effects. The 
isolation of this new compound and characterization of its structure and 
physical and chemical properties has enabled new information about the Ixeris 
genus to be generated. Given that thousands of compounds exist in a single 
herb, and that the chemical properties of these compounds may vary greatly, 
the efficiency of isolating natural pure components from the herb by 
traditional strategies is heavily challenged. In most cases, an optimized 
isolation method is only suited for the purification of one or one group of 
components with similar chemical properties. Therefore, compounds that 
possess distinct physical and chemical properties from these components of 
interest will be missed out. Such loss of compounds in the isolation procedures, 
especially those possessing desirable bioactivities, is one obvious shortcoming 
in the traditional approach in natural product research. In this thesis, HPLC 
analysis of the ethyl acetate fraction from Ixeris sonchifolia Hance extract had 
revealed the presence of more than twenty compounds with conjugated 
structure (compounds that gave signals when the detector wavelength was set 
at 350 nm with 410 nm as reference; Fig 3.3.2.1B). However, only six 
flavonoid compounds had been isolated and identified from this fraction, 
suggesting that the majority (at least in quantity) of compounds were lost 
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during the isolation and purification process. In addition, the purity of samples 
isolated from natural products was directly related to the rigor of bioassay and 
the intensity of side effect reactions. In order to achieve a highly purified 
compound on column chromatography, the tails on both sides of the peak for 
the compound of interest, which might overlap partially with that of 
compounds of non-interest, would have to be discarded. The exclusion of the 
overlaping parts of the compound of interest would result in poor yield or poor 
recovery, which made up another obvious shortcoming in the traditional 
natural product isolation techniques. Fortunately,  outstanding developments 
in the areas of separation science and spectroscopic techniques (e.g. GC-MS, 
LC-PDA, LC-MS, LC-FTIR, LC-NMR, LC-NMR-MS, CE-MS) over the last 
decade have allowed higher sensitivity and efficiency in the isolation analysis 
of crude extracts or fractions from different natural sources (Sarker et al., 
2005). Even so, to obtain adequate and highly purified compounds from 
natural products for bioactivity studies remains to be challenging.  
            Flavonoids are found ubiquitously in plants and possess multiple 
health-modulating effects, such as anti-allergic (Muthian et al., 2004), anti-
inflammatory (Kao et al., 2005; Lim et al., 2006; Zhou et al., 2009), anti-
microbial (Cushnie et al., 2005; Alvarez et al., 2008; Pistelli et al., 2009) and 
anti-cancer (Choi et al., 2009; Guo et al., 2009; Jung et al., 2009; Rajkapoor et 
al., 2009) activities. In this thesis, the in vitro bioassays conducted on the 
flavonoids isolated from the ethyl acetate fraction of Ixeris sonchifolia Hance 
extract had revealed that these compounds could protect cells from H2O2-
induced cytotoxiciy by scavenging free radical directly and inducing phase Ⅱ
detoxifying enzymes. This has suggested that the purified flavonoid 
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compounds might exert neuroprotective effects during the early response to 
stroke occurrence. To our knowledge so far, this is the first time to attribute 
the chemical components being responsible for the neuroprotective effects of 
Ixeris sonchifolia Hance. The findings provide important experimental data for 
developing potential anti-stroke agents derived from Ixeris sonchifolia Hance. 
Although flavonoid compounds isolated from the ethyl acetate fraction of 
Ixeris sonchifolia Hance extract showed considerable bioactivities in 
protecting cells from H2O2-induced cytotoxiciy through induction of phase Ⅱ
detoxifying enzymes, the greatest fold of induction of ARE-dependent 
transcriptional activity effected by the isolated flavonoid compounds was not 
as high as the induction fold registered by the ethyl acetate fraction (the 
induction fold being around 5 and 20 respectively; see Section 2.3.3 and 4.3.2). 
Components in the fraction might exert synergistic effects with one another, 
which could account for the higher phase Ⅱ enzymes inducing ability of the 
fraction over that of each purified flavonoid compound. The isolation and 
identification of compounds with higher phase Ⅱ enzymes induction abilities 
from the ethyl acetate fraction, or to elucidate the possible synergistic 
interactions between these compounds should be one of the research directions 
in future studies.  
            Considering that the second wave of cell death after a stroke incident 
stems from the neuroinflammatory response, the anti-inflammatory effects of 
these isolated flavonoid compounds on the LPS-stimulated cells were next 
determined. The results suggested that flavonoid compounds isolated from 
Ixeris sonchifolia Hance extract might exert anti-inflammatory activities by 
regulating cytokine secretion, inhibiting Cox-2 expression, as well as reducing 
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NO release and iNOS expression. Inflammatory processes are initiated by 
cytokines, adhesion molecules, prostanoid mediators of inflammation and NO 
and may progress for days and weeks. The wide therapeutic window and the 
multiple targets have rendered inflammatory intervention an attractive 
therapeutic strategy in stroke treatment (Michael et al., 2004; Sacco et al., 
2007). The findings presented in this thesis had indicated that the isolated 
flavonoid compounds showed potential neuroprotective activities by inhibiting 
the inflammatory reactions. However, the biological signaling pathways in 
inflammatory reactions are extremely complicated and certain cytokines can 
have different effects depending on the context (Rothwell, 1997; Allan et al., 
2001). The investigation of the intricate interactions between the compounds 
and the inflammatory response, and the detailed relationship between the 
inflammatory response and the stroke injury, will be another arduous task in 
the future studies. 
            As validation, the potential anti-stroke effects of luteolin, a 
representative of these isolated flavonoid compounds, were investigated in 
vivo using rats suffering from cerebral ischemia induced by MCA occlusion. 
This MCAO animal model closely resembles a clinical stroke incident caused 
by focal ischemic attack and has been shown to be sensitive to treatment with 
neuroprotective compounds that function via a number of mechanisms. The 
results presented in this study revealed that while treatment with luteolin failed 
to neither reduce MCAO-induced mortality nor improve neurobehavioral 
recovery in the treated rats, it significantly reduced the infarct area, decreased 
the number of cells positively stained with anti-cleaved caspase-3 and anti-
Cox-2 antibody, suggesting that luteolin might exert neuroprotective effects in 
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an in vivo stroke model. Unfortunately, the development of neuroprotective 
therapies for acute ischemic stroke has proven to be a difficult and challenging 
endeavor. To date, more than 700 compounds of potential neuroprotective 
effects have been studied, but none of them has been accepted by regulatory 
authorities to be used for treatment of patients with acute stroke (Kaste, 2005). 
The failure in developing neuroprotective agents into clinical application may 
be attributed to several factors. For example, it must be recognized that no 
animal stroke model will precisely mimick humans’ heterogeneous 
physiological reactions. In a laboratory study, the investigator can modify all 
known confounding factors. The age, body weight, body temperature, blood 
pressure, blood glucose, and acid-base balance of animals can be kept 
consistent and within normal physiological ranges, whereas in a hospital 
emergency room, stroke patients may be admitted with several severe 
concomitant diseases, e.g. fragile diabetes, untreated hypertension and recent 
myocardial infarction; their physiological parameters can hardly be unified. In 
addition, inappropriate time points to administer the experimental drug may be 
another reason contributing to the failure in developing neuroprotective agents. 
Once the necrotic core has been formed in the brain tissue, which accounts for 
the largest proportion (~70%) of the final infarct volume, even if 
neuroprotectants can prevent the maturation of the ischemic penumbra to an 
infarct by half, it would only reduce the size of the final area of infarction by 
15%, which implies a minor neuro-function recovery. Therefore, careful 
constitution of patient enrolment criterion and optimization of drug dose and 
administration timepoints play a crucial role in the successful development of 
neuroprotectants for the treatment of ischemic stroke. 
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            In conclusion, extraction and isolation works on Ixeris sonchifolia 
Hance revealed the presence of two categories of compounds in the ethyl 
acetate fractions of its raw extract: flavonoids and sesquiterpene lactones. The 
isolated bioactive flavonoids were found to possess potential anti-stroke 
effects, which at least in part were attributed to their antioxidant and anti-
inflammatory activities. These findings have provided important experimental 
data for developing potential anti-stroke agents from Ixeris sonchifolia Hance. 
Considering that the ethyl acetate fraction of Ixersi sonchifolia Hance extract 
is also a rich source of sesquentepene lactones, screening of the bioactivities 
of this category of compounds are to be performed in the future. In view of the 
fact that the majority of components were discarded during the isolation 
procedure, this traditional natural product research strategy had only 
successfully isolated and identified a small percentage of all the compounds 
contained in the herb. For the future work, the use of tandem techniques (e.g. 
GC-MS, LC-NMR-MS, CE-MS) should be employed in order to 
systematically draw a comprehensive  “component mapping” of Ixeris 
sonchifolia Hance. Following “component mapping”, the bioactivities of these 
components need be studied, the quantity of active components present in the 
herb be determined and the possible interactions between the components are 
to be elucidated. Another research direction in the future work can be focused 
on the screening strategies. Since ischemia in stroke leads to the activation of 
several pathways such as excitotoxic cell death, apoptosis, complex cascades 
of local inflammatory response, and remodeling of neuronal function, anti-
stroke effects exerted via pathway(s) other than anticoagulation activities and 
antioxidant activities may be missed. Thus, more bioassays that model 
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different aspects of the pathophysiological responses following stroke can be 
adopted in the future screening studies. At last, with the aim to optimize 
dosing regimen, pharmacokinetics studies conducted on animals or human 
body are to be carried out. After which a “modern” herb preparation that 
consists of all the beneficial components with optimized ratios of each desired 
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